

CITATION REPORT

List of articles citing

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group

DOI: 10.1016/0092-8674(93)90585-e
Cell, 1993, 72, 971-83.

Source: <https://exaly.com/paper-pdf/24190741/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2245	Huntington's Disease and related disorders and their association with schizophrenia-like psychosis. 348-357		
2244	Genetics and Schizophrenia. 2002 , 371-402		
2243	Neurochemical dissociation of memory systems. 1987 , 37, 789-94		286
2242	The Solution of the Sherman Paradox or the Successful Search for the Huntington Gene. 1993 , 32, 1415-1418		
2241	Parental origin of chromosome 4p deletion in Wolf-Hirschhorn syndrome. 1993 , 47, 921-4		55
2240	The polymerase chain reaction: application to nervous system disease. 1993 , 34, 513-23		19
2239	Molecular genetics in neurology. 1993 , 34, 757-73		43
2238	Die Lösung des Sherman-Paradoxons oder die erfolgreiche Suche nach dem Huntington-Gen. 1993 , 105, 1479-1481		
2237	Simple repetitive (GAA) _n loci in the human genome. 1993 , 14, 973-7		8
2236	Gene mapping of the mammalian genome: the CEPH and Genethon initiative. 1993 , 4, 665-71		
2235	Identification of new genes by systematic analysis of cDNAs and database construction. 1993 , 4, 672-7		24
2234	Opa-like repeats in the genome of the Medfly <i>Ceratitis capitata</i> . 1993 , 92, 43-53		3
2233	Allele frequencies and linkage disequilibrium of polymorphic DNA markers of the Huntington disease region in the German population. 1993 , 92, 593-7		
2232	Characterizations of candidate genes for IDD susceptibility from the diabetes-prone NOD mouse strain. 1993 , 4, 549-54		28
2231	Lasermikrosonden und Laserspektroskopie. 1993 , 24, 170-175		1
2230	Molecular cloning of BRCA1: a gene for early onset familial breast and ovarian cancer. 1993 , 28, 121-35		16
2229	Offering predictive testing for Huntington disease in a medical genetics clinic: Practical applications. 1993 , 2, 123-37		10

2228	Triplet repeats on the rise. 1993 , 364, 88-88	9
2227	Rapid evolution of the sex determining locus in Old World mice and rats. 1993 , 364, 715-7	192
2226	Huntington's is still holding out. 1993 , 366, 90-90	1
2225	Trinucleotide repeat instability: when and where?. 1993 , 4, 107-8	51
2224	Direct detection of novel expanded trinucleotide repeats in the human genome. 1993 , 4, 135-9	251
2223	A cosmid contig and high resolution restriction map of the 2 megabase region containing the Huntington's disease gene. 1993 , 4, 181-6	93
2222	Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1. 1993 , 4, 221-6	1453
2221	Effect of the myotonic dystrophy (DM) mutation on mRNA levels of the DM gene. 1993 , 4, 233-8	143
2220	Human and murine FMR-1: alternative splicing and translational initiation downstream of the CCG-repeat. 1993 , 4, 244-51	223
2219	Chromosomal distribution of 320 genes from a brain cDNA library. 1993 , 4, 381-6	70
2218	Trinucleotide repeat length instability and age of onset in Huntington's disease. 1993 , 4, 387-92	875
2217	Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. 1993 , 4, 393-7	606
2216	The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. 1993 , 4, 398-403	868
2215	Polygenic control of autoimmune diabetes in nonobese diabetic mice. 1993 , 4, 404-9	286
2214	Anticipation in spinocerebellar ataxia type 2. 1993 , 5, 8-10	63
2213	Identification of the genetic locus for keratosis palmaris et plantaris on chromosome 17 near the RARA and keratin type I genes. 1993 , 5, 158-62	38
2212	De novo expansion of a (CAG) _n repeat in sporadic Huntington's disease. 1993 , 5, 168-73	226
2211	Molecular analysis of new mutations for Huntington's disease: intermediate alleles and sex of origin effects. 1993 , 5, 174-9	224

2210	Reduced transcriptional regulatory competence of the androgen receptor in X-linked spinal and bulbar muscular atrophy. 1993 , 5, 184-8	322
2209	Site of (CCG) polymorphism in the HD gene. 1993 , 5, 214-5	32
2208	A complex mutable polymorphism located within the fragile X gene. 1993 , 5, 248-53	59
2207	Evidence for a mechanism predisposing to intergenerational CAG repeat instability in spinocerebellar ataxia type I. 1993 , 5, 254-8	436
2206	Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues. 1993 , 5, 259-65	338
2205	Huntington's disease. The end of the beginning. 1993 , 362, 408-9	2
2204	Neuronal transplantation in rat models of Parkinson's and Huntington's diseases. 1993 , 5, 413-421	5
2203	Neurotrophic factors and neural grafts: a growing field. 1993 , 5, 431-441	8
2202	An expanding enigma. 1993 , 3, 456-9	5
2201	Generation of high-density DNA markers from yeast artificial chromosome DNA by single unique primer-polymerase chain reaction. 1993 , 10, 105-8	
2200	Construction and characterization of partial digest DNA libraries made from flow-sorted human chromosome 16. 1993 , 10, 69-76	30
2199	Methods for finding genes. A major rate-limiting step in positional cloning. 1993 , 10, 29-41	11
2198	Transgenic animals as models for human disease--report of an EC Study Group. 1993 , 2, 286-99	13
2197	Genes with triplet repeats: candidate mediators of neuropsychiatric disorders. 1993 , 16, 254-60	143
2196	Erratum. 1993 , 16, 260	3
2195	Microsatellite instability in cancer of the proximal colon. 1993 , 260, 816-9	2587
2194	Rapid Fragile X Carrier Screening and Prenatal Diagnosis Using a Nonradioactive PCR Test. 1993 , 270, 1569	164
2193	Molecular analysis of juvenile Huntington disease: the major influence on (CAG) _n repeat length is the sex of the affected parent. 1993 , 2, 1535-40	170

2192	Patterns in genome evolution. 1993 , 3, 911-4	60
2191	A simple non-radioactive method for diagnosis of Huntington's disease. 1993 , 2, 633-4	23
2190	Oxidative stress, glutamate, and neurodegenerative disorders. 1993 , 262, 689-95	3346
2189	Strategies for the molecular genetic analysis of obesity in humans. 1993 , 33, 351-8	12
2188	Larger expansions of the CTG repeat in muscle compared to lymphocytes from patients with myotonic dystrophy. 1993 , 2, 1397-400	166
2187	An association between the risk of cancer and mutations in the HRAS1 minisatellite locus. 1993 , 329, 517-23	261
2186	FSHD associated DNA rearrangements are due to deletions of integral copies of a 3.2 kb tandemly repeated unit. 1993 , 2, 2037-42	448
2185	Trinucleotide repeats and genome variation. 1993 , 3, 404-7	41
2184	Myotonic dystrophy: over-expression or/and under-expression? A critical review on a controversial point. 1993 , 3, 497-501	13
2183	Huntington's disease gene (IT15) is widely expressed in human and rat tissues. 1993 , 11, 985-93	275
2182	Huntington's disease: animal models and transplantation repair. 1993 , 3, 790-6	32
2181	The dynamic genomics of myotonic dystrophy and its clinical relevance: an overview. 1993 , 47, 321-30	4
2180	'Cold SSCP': a simple, rapid and non-radioactive method for optimized single-strand conformation polymorphism analyses. 1993 , 21, 3637-42	318
2179	Huntingdon's disease gene. 1993 , 341, 822	
2178	Polymorphism in the multi-phosphorylation domain of the human neurofilament heavy-subunit-encoding gene. 1993 , 132, 297-300	26
2177	Trinucleotide repeat expansions in neurological disease. 1993 , 3, 752-9	55
2176	Trinucleotide repeat amplification and hypermethylation of a CpG island in FRAXE mental retardation. <i>Cell</i> , 1993 , 74, 127-34	56.2 487
2175	Human genetic diseases due to codon reiteration: relationship to an evolutionary mechanism. <i>Cell</i> , 1993 , 74, 955-6	56.2 209

2174	Molecular analysis and clinical correlations of the Huntington's disease mutation. 1993 , 342, 954-8	91
2173	Borderline repeat expansion in Huntington's disease. 1993 , 342, 1491-2	5
2172	Widespread distribution of cells containing human DNA in embryos derived from mouse eggs injected with human chromosome fragments. 1993 , 4, 597-607	
2171	Dynamic mutation in Dutch Huntington's disease patients: increased paternal repeat instability extending to within the normal size range. 1993 , 30, 996-1002	41
2170	A single trinucleotide, 5'AGC3'/5'GCT3', of the triplet-repeat disease genes confers metal ion-induced non-B DNA structure. 1993 , 21, 5651-5	22
2169	A zinc-finger gene ZNF141 mapping at 4p16.3/D4S90 is a candidate gene for the Wolf-Hirschhorn (4p-) syndrome. 1993 , 2, 1571-5	44
2168	Construction of cosmid contigs and high-resolution restriction mapping of the Huntington disease region of human chromosome 4. 1993 , 2, 889-99	25
2167	Predictive testing for Huntington's disease: after the gene. The United Kingdom Huntington's Disease Prediction Consortium. 1993 , 30, 1036-8	22
2166	New human DNA polymorphisms submitted to the genome data base. 1993 , 2, 1985-7	
2165	High resolution methylation analysis of the FMR1 gene trinucleotide repeat region in fragile X syndrome. 1993 , 2, 1659-65	115
2164	Gene therapy for neurologic disease. 1993 , 50, 1252-68	102
2163	Molecular genetics of Huntington's disease. 1993 , 50, 1157-63	121
2162	Molecular genetics of neurological diseases. 1993 , 262, 674-6	37
2161	Elastic DNA elements--boon or blight?. 1993 , 329, 571-2	5
2160	Progress toward cloning of the gene responsible for childhood spinal muscular atrophy. 1993 , 13, 276-82	3
2159	Characterization and localization of the Huntington disease gene product. 1993 , 2, 2069-73	163
2158	Mitotic stability and meiotic variability of the (CAG) _n repeat in the Huntington disease gene. 1993 , 2, 2063-7	137
2157	The needle found!!! Trinucleotide repeat expansion in the Huntington's disease gene. 1993 , 2, 497-8	1

2156	Ethical and social issues in presymptomatic testing for Huntington's disease: a European Community collaborative study. European Community Huntington's Disease Collaborative Study Group. 1993 , 30, 1028-35	25
2155	An Alu element retroposition in two families with Huntington disease defines a new active Alu subfamily. 1993 , 21, 3379-83	44
2154	Identification of human chromosome 9 specific genes using exon amplification. 1993 , 2, 1915-20	27
2153	A specific mutation for Huntington's disease. 1993 , 30, 975-7	5
2152	The irregular chiasm C-roughest locus of Drosophila, which affects axonal projections and programmed cell death, encodes a novel immunoglobulin-like protein. 1993 , 7, 2533-47	146
2151	Analysis of DNA sequences. 1993 , 2, 225-39	1
2150	A clinico-genetic study of psychiatric disorder in Huntington's chorea. 1993 , Suppl 23, 1-46	14
2149	Mutation of human short tandem repeats. 1993 , 2, 1123-8	1255
2148	The Human Genome Project and the future of medicine. 1993 , 147, 1145-52	10
2147	Neurology. 1993 , 270, 228	
2146	Attitudes Toward Direct Predictive Testing for the Huntington Disease Gene. 1993 , 270, 2321	41
2145	Molecular analysis of late onset Huntington's disease. 1993 , 30, 991-5	46
2144	The myotonic dystrophy gene. 1993 , 50, 1173-9	31
2143	A role for the otolaryngologist in identification and discovery of genetic disorders and chromosomal abnormalities. 1993 , 119, 1074-81	1
2142	George Huntington: the man behind the eponym. 1993 , 30, 1042	
2141	Mutation size and age at onset in Huntington's disease. 1993 , 30, 1008-11	29
2140	Presymptomatic testing for Huntington's disease: a world wide survey. The World Federation of Neurology Research Group on Huntington's Disease. 1993 , 30, 1020-2	20
2139	The new genetics: some issues for social scientists.. 1993 , 15, 567-586	66

2138	Identification of an expanded CAG repeat in the Huntington's disease gene (IT15) in a family reported to have benign hereditary chorea. 1993 , 30, 1012-3	29
2137	Huntington's disease in Grampian region: correlation of the CAG repeat number and the age of onset of the disease. 1993 , 30, 1014-7	12
2136	A study of the Huntington's disease associated trinucleotide repeat in the Scottish population. 1993 , 30, 1003-7	44
2135	DNA storage and duplicate sampling: lessons learnt from testing for Huntington's disease. 1993 , 30, 1042	0
2134	Presymptomatic analysis of spinocerebellar ataxia type 1 (SCA1) via the expansion of the SCA1 CAG-repeat in a large pedigree displaying anticipation and parental male bias. 1993 , 2, 2123-8	81
2133	Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. 1993 , 43, 2689-95	419
2132	Cell-specific action and mutable structure of a transcription factor effector domain. 1993 , 90, 9978-82	30
2131	Identification of a human achaete-scute homolog highly expressed in neuroendocrine tumors. 1993 , 90, 5648-52	153
2130	Searching for human epilepsy genes: a progress report. 1993 , 3, 357-69	14
2129	Phenotypic variability in autosomal dominant cerebellar ataxia type I is unrelated to genetic heterogeneity. 1993 , 116 (Pt 6), 1497-508	44
2128	Clinical consequences of isolating the gene for Huntington's disease. 1993 , 307, 397-8	7
2127	Genetic Anticipation. 1994 , 12, 683-697	14
2126	Atypical Inheritance. 1994 , 12, 663-681	1
2125	Improving diagnosis of Huntington's disease by analysis of an intragenic trinucleotide repeat expansion. 1994 , 161, 356-60	4
2124	Genetic Predisposition for Breast Cancer: From Epidemiologic Studies to Molecular Genetics. 1994 , 17, 470-477	
2123	Characterization of a human chromosome 4 flow-sorted cosmid library. 1994 , 65, 238-42	12
2122	Benefits and risks of emerging genetic technologies: the need for regulation. 1994 , 40, 1652-1657	10
2121	Linkage of a new locus for autosomal dominant familial spastic paraplegia to chromosome 2p. 1994 , 3, 1569-73	135

2120	Advances in Molecular Analysis of Fragile X Syndrome. 1994 , 271, 536	89
2119	Inducible cyclooxygenase (COX-2): a safer therapeutic target?. 1994 , 33, 410-2	15
2118	Tuberous Sclerosis. 1994 , 130, 348	85
2117	No Structural Mutation in the Dopamine D2 Receptor Gene in Alcoholism or Schizophrenia. 1994 , 271, 204	114
2116	The molecular basis of genetic dominance. 1994 , 31, 89-98	223
2115	Chemiluminescent detection of blotted PCR products (CB-PCR) of two CAG dynamic mutations (Huntington's disease and spinocerebellar ataxia type 1). 1994 , 31, 654-5	9
2114	Expanded CAG trinucleotide repeat of Huntington's disease gene in a patient with schizophrenia and normal striatal histology. 1994 , 31, 658-9	13
2113	Study of the Huntington's disease (HD) gene CAG repeats in schizophrenic patients shows overlap of the normal and HD affected ranges but absence of correlation with schizophrenia. 1994 , 31, 690-3	17
2112	Internal tracts of telomeric DNA act as silencers in <i>Saccharomyces cerevisiae</i> . 1994 , 8, 1411-22	70
2111	Multiple disease genes cause hypertrophic cardiomyopathy. 1994 , 72, S4-9	25
2110	Simple repetitive DNA sequences are transcribed in early embryonal stages of <i>Xenopus laevis</i> . 1994 , 5, 77-81	2
2109	Huntington's disease: update and review of neuropsychiatric aspects. 1994 , 24, 189-208	86
2108	GENETIC INSTABILITY IN MICROSATELLITE SEQUENCES IN PROSTATE-CANCER. 1994 , 5, 921	
2107	A single allele from the polymorphic CCG rich sequence immediately 3' to the unstable CAG trinucleotide in the IT15 cDNA shows almost complete disequilibrium with Huntington's disease chromosomes in the Scottish population. 1994 , 3, 173-5	26
2106	A P1-based physical map of the region from D17S776 to D17S78 containing the breast cancer susceptibility gene BRCA1. 1994 , 3, 1919-26	55
2105	Molecular genetic approaches to the study of human cardiovascular disease. 1994 , 56, 763-96	16
2104	Precursor arrays for triplet repeat expansion at the fragile X locus. 1994 , 3, 1553-60	120
2103	Instability of CAG repeats in Huntington's disease: relation to parental transmission and age of onset. 1994 , 31, 377-82	135

2102	Hypothesis II: Tourette's syndrome is part of a clinical spectrum that includes normal brain development. 1994 , 51, 1145-50	69
2101	The cloning of FRAXF: trinucleotide repeat expansion and methylation at a third fragile site in distal Xqter. 1994 , 3, 2115-21	65
2100	Specific isolation of 3'-terminal exons of human genes by exon trapping. 1994 , 22, 4148-53	11
2099	Genetic modelling in rheumatoid arthritis: cat walk or tight rope?. 1994 , 33, 409-10	1
2098	Anticipation in Swedish families with bipolar affective disorder. 1994 , 31, 686-9	72
2097	Distribution of trinucleotide repeat sequences across a 2 Mbp region containing the Huntington's disease gene. 1994 , 3, 73-8	5
2096	Analysis of the trinucleotide repeat expansion in Italian families affected with Huntington disease. 1994 , 3, 93-8	54
2095	Polymorphism analysis of the huntingtin gene in Italian families affected with Huntington disease. 1994 , 3, 1129-32	29
2094	Improvement of abnormal saccadic eye movements in Huntington's disease by sulpiride: a case study. 1994 , 8, 262-5	11
2093	Therapeutische Ansätze zur neurodegenerativen Protektion. 1994 , 21, 151-161	0
2092	Molecular basis of the common electrophoretic polymorphism (Fu1/Fu2) in human alpha-L-fucosidase. 1994 , 31, 659-60	4
2091	Huntington's disease and repeating trinucleotides. 1994 , 330, 1450-1	15
2090	Loss of mutation at the FMR1 locus through multiple exchanges between maternal X chromosomes. 1994 , 3, 1823-7	39
2089	The zebrafish egr1 gene encodes a highly conserved, zinc-finger transcriptional regulator. 1994 , 13, 1047-55	13
2088	Absence of myotonic dystrophy in southern African Negroids is associated with a significantly lower number of CTG trinucleotide repeats. 1994 , 31, 37-40	49
2087	Heritable trinucleotide repeats and neurological disorders. 1994 , 50, 1099-105	3
2086	Dopamine D1 receptor number--a sensitive PET marker for early brain degeneration in Huntington's disease. 1994 , 243, 249-55	64
2085	Genetic factors in the etiology of idiopathic Parkinson's disease. 1994 , 8, 1-37	27

2084	Toward the complete genomic map and molecular pathology of human chromosome 4. 1994 , 94, 1-18	15
2083	Synteny conservation of the Huntington's disease gene and surrounding loci on mouse Chromosome 5. 1994 , 5, 424-8	12
2082	Drive-selection equilibrium: homopolymer evolution in the Drosophila gene mastermind. 1994 , 38, 637-41	13
2081	The dichotomous size variation of human complement C4 genes is mediated by a novel family of endogenous retroviruses, which also establishes species-specific genomic patterns among Old World primates. 1994 , 40, 425-36	111
2080	Chromosomal localization of three human genes coding for A15, L6, and S5.7 (TAPA1): all members of the transmembrane 4 superfamily of proteins. 1994 , 39, 329-34	12
2079	Anticipation in hereditary dentatorubral-pallidoluysian atrophy. 1994 , 93, 699-702	22
2078	A Sau3A polymorphism in the 5' end of the IT15 gene that nonrandomly segregates with the Huntington disease trinucleotide expansion. 1994 , 93, 457-9	
2077	Geographical distribution of haplotypes in Swedish families with Huntington's disease. 1994 , 94, 124-8	8
2076	Trinucleotide (CAG) repeat expansion in chromosomes of Spanish patients with Huntington's disease. 1994 , 94, 563-4	17
2075	Expression of (cac) _n /(gtg) _n simple repetitive sequences in mRNA of human lymphocytes. 1994 , 93, 35-41	13
2074	Platelet-derived growth factor exerts trophic effects on rat striatal DARPP-32-containing neurons in culture. 1994 , 101, 291-6	20
2073	Use of neuropathological tissue for molecular genetic studies: parameters affecting DNA extraction and polymerase chain reaction. 1994 , 88, 19-25	63
2072	DNA analysis in forensics, disease and animal/plant identification. 1994 , 5, 29-33	18
2071	Polar zippers: their role in human disease. 1994 , 3, 1629-37	121
2070	Brain repair: an overview. 1994 , 242, S1-4	5
2069	Autosomal-dominant dentatorubropallidoluysian atrophy in the United Kingdom. 1994 , 9, 289-96	46
2068	Cortical myoclonus in Huntington's disease. 1994 , 9, 633-41	49
2067	Enzymatic amplification of synthetic oligodeoxyribonucleotides: implications for triplet repeat expansions in the human genome. 1994 , 3, 19-24	30

2066	Detection of point mutations by solid-phase methods. 1994 , 3, 172-9	28
2065	A complex composed of at least two HeLa nuclear proteins protects preferentially one DNA strand of the simple (gt)n(ga)m containing region of intron 2 in HLA-DRB genes. 1994 , 56, 74-85	18
2064	Trinucleotide repeat expansions and human genetic disease. 1994 , 16, 277-84	107
2063	Growth of recombinant fibroblasts in alginate microcapsules. 1994 , 43, 925-33	51
2062	Psychological aspects of genetic counseling: a legal perspective. 1994 , 50, 234-8	18
2061	Informed consent and Huntington disease: a model for communication. 1994 , 50, 239-46	36
2060	Fragile X founder chromosome effects: linkage disequilibrium or microsatellite heterogeneity?. 1994 , 51, 405-11	41
2059	Distribution of FMR-1 and associated microsatellite alleles in a normal Chinese population. 1994 , 51, 417-22	58
2058	Predictive testing for Huntington disease: a psychologist's view. 1994 , 54, 161-6	64
2057	Self-selection in predictive testing for Huntington's disease. 1994 , 54, 167-73	114
2056	Psychological costs and benefits of predictive testing for Huntington's disease. 1994 , 54, 174-84	138
2055	Genetic studies in alcohol research. 1994 , 54, 304-8	10
2054	Research on neuropsychiatric genetics: interests of the National Institute of Neurological Disorders and Stroke. 1994 , 54, 309-10	1
2053	Schizophrenia and mental retardation associated in a pedigree with retinitis pigmentosa and sensorineural deafness. 1994 , 54, 354-60	10
2052	Myotonic dystrophy patients have larger CTG expansions in skeletal muscle than in leukocytes. 1994 , 35, 104-7	225
2051	Autosomal-dominant cerebellar ataxia with retinal degeneration (ADCA type II) is genetically different from ADCA type I. 1994 , 35, 439-44	46
2050	Selective vulnerability in Huntington's disease: preferential loss of cannabinoid receptors in lateral globus pallidus. 1994 , 36, 577-84	160
2049	Trinucleotide repeat length and rate of progression of Huntington's disease. 1994 , 36, 630-5	89

2048	Trinucleotide repeat expansion in neurological disease. 1994 , 36, 814-22	165
2047	Diagnosis and the new genetics. 1994 , 5, 654-62	
2046	Pharmaceutical biotechnology. 1994 , 5, 706-35	
2045	Fishing for complements: finding genes by direct selection. 1994 , 10, 352-7	58
2044	Genes for normal and diseased mental states. 1994 , 10, 37-9	4
2043	Application of hybridization techniques to genome mapping and sequencing. 1994 , 10, 79-83	21
2042	International Commission for Protection Against Environmental Mutagens and Carcinogens. Working paper no. 6. Estimation of genetic risks of exposure to chemical mutagens: relevance of data on spontaneous mutations and of experience with ionizing radiation. 1994 , 304, 139-58	15
2041	Ionizing radiation and genetic risks. V. Multifactorial diseases: A review of epidemiological and genetic aspects of congenital abnormalities in man and of models on maintenance of quantitative traits in populations. 1994 , 317, 1-23	5
2040	The human genome project Genetic and physical mapping. 1994 , 4, 201-6	2
2039	Screening cosmid libraries with oligonucleotides corresponding to splice-site consensus sequences. 1994 , 11, 39-42	2
2038	Dopamine receptors: molecular biology, biochemistry and behavioural aspects. 1994 , 64, 291-370	348
2037	Serum iron, total iron binding capacity and ferritin in early Huntington disease patients. 1994 , 163, 236-7	12
2036	IT15 gene expression in fetal human brain. 1994 , 659, 33-41	19
2035	Identification and characterization of transcribed sequences on human chromosome 9q32-34. 1994 , 5, 165-79	
2034	Structure and expression of the Huntington's disease gene: evidence against simple inactivation due to an expanded CAG repeat. 1994 , 20, 27-38	210
2033	Mouse Huntington's disease gene homolog (Hdh). 1994 , 20, 87-97	56
2032	Dentatorubral and pallidolusian atrophy expansion of an unstable CAG trinucleotide on chromosome 12p. 1994 , 6, 14-8	689
2031	Triplet repeats strike again. 1994 , 6, 3-4	53

2030	Unstable expansion of CAG repeat in hereditary dentatorubral-pallidoluysian atrophy (DRPLA). 1994, 6, 9-13	1033
2029	Isolation of genes from complex sources of mammalian genomic DNA using exon amplification. 1994, 6, 98-105	267
2028	Simple repeat DNA is not replicated simply. 1994, 6, 114-6	298
2027	Complex gene conversion events in germline mutation at human minisatellites. 1994, 6, 136-45	470
2026	Instability of short tandem repeats (microsatellites) in human cancers. 1994, 6, 152-6	362
2025	Polymorphism of a CAG trinucleotide repeat within Sry correlates with B6.YDom sex reversal. 1994, 6, 245-50	100
2024	Long-range mapping of gaps and telomeres with RecA-assisted restriction endonuclease (RARE) cleavage. 1994, 6, 379-83	29
2023	Somatic and gonadal mosaicism of the Huntington disease gene CAG repeat in brain and sperm. 1994, 6, 409-14	331
2022	Identification and characterization of the gene causing type 1 spinocerebellar ataxia. 1994, 7, 513-20	310
2021	Mutational bias provides a model for the evolution of Huntington's disease and predicts a general increase in disease prevalence. 1994, 7, 525-30	127
2020	Studying human mutations by sperm typing: instability of CAG trinucleotide repeats in the human androgen receptor gene. 1994, 7, 531-5	99
2019	Minisatellite mutation rate variation associated with a flanking DNA sequence polymorphism. 1994, 8, 162-70	116
2018	Structure and expression of the gene responsible for the triplet repeat disorder, dentatorubral and pallidoluysian atrophy (DRPLA). 1994, 8, 177-82	195
2017	Dynamic mutations hit double figures. 1994, 8, 213-5	136
2016	CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. 1994, 8, 221-8	1526
2015	Spinocerebellar ataxia type 5 in a family descended from the grandparents of President Lincoln maps to chromosome 11. 1994, 8, 280-4	294
2014	Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer. 1994, 8, 387-91	350
2013	Is there evidence for anticipation in autosomal-dominant polycystic kidney disease?. 1994, 45, 1153-62	40

2012	Hereditary and acquired cystic disease of the kidney. 1994 , 46, 951-64		97
2011	Morphological and molecular characterization of the response of differentiated PC12 cells to calcium stress. 1994 , 6, 577-86		27
2010	Neurotrophin-4/5 promotes survival and differentiation of rat striatal neurons developing in culture. 1994 , 6, 1669-79		85
2009	The fragile X syndrome: implications of molecular genetics for the clinical syndrome. 1994 , 24, 1-10		14
2008	Analysing brain function and dysfunction in transgenic animals. 1994 , 20, 350-8		11
2007	Cloning and structural characterization of the human endothelial nitric-oxide-synthase gene. 1994 , 223, 719-26		115
2006	Disease caused by expanding genes. 1994 , 236, 1-2		
2005	Isolation of exons from cloned DNA by exon trapping. 2001 , Chapter 6, Unit 6.1		
2004	Programmed cell death: implications for neuropsychiatric disorders. 1994 , 35, 946-56		116
2003	Huntington's disease: the neuroexcitotoxin aspartate is increased in platelets and decreased in plasma. 1994 , 127, 48-53		13
2002	Deficit of [3H]L-689,560 binding to the glycine site of the glutamate/NMDA receptor in the brain in Huntington's disease. 1994 , 125, 46-9		11
2001	Molecular basis and diagnosis of neurogenetic disorders. 1994 , 124, 119-40		17
2000	Breakpoint break for consortium studying adult polycystic kidney disease. <i>Cell</i> , 1994 , 77, 785-6	56.2	3
1999	The diastrophic dysplasia gene encodes a novel sulfate transporter: positional cloning by fine-structure linkage disequilibrium mapping. <i>Cell</i> , 1994 , 78, 1073-87	56.2	650
1998	The future of Alzheimer's disease research: a molecular genetic perspective. 1994 , 15 Suppl 2, S161-4		22
1997	Major patterns of human inheritance: relevance to the epilepsies. 1994 , 35 Suppl 1, S2-6		9
1996	The human genome project: genetic and physical mapping. 1994 , 5, 359-64		
1995	Isolation of genes from cloned DNA. 1994 , 4, 360-5		6

1994	Androgen insensitivity syndrome. 1994 , 8, 379-404		29
1993	A worldwide study of the Huntington's disease mutation. The sensitivity and specificity of measuring CAG repeats. 1994 , 330, 1401-6		485
1992	Preferential nucleosome assembly at DNA triplet repeats from the myotonic dystrophy gene. 1994 , 265, 669-71		211
1991	Huntington's disease CAG trinucleotide repeats in pathologically confirmed post-mortem brains. 1994 , 1, 159-66		70
1990	Analysis of CAG trinucleotide repeats from mouse cDNA sequences. 1994 , 58, 87-94		12
1989	Positron emission tomography and central neurotransmitter systems in movement disorders. 1994 , 8, 503-17		6
1988	Molecular biology techniques in the diagnosis of monogenic diseases. 1994 , 225, S35-50		5
1987	IQ and variation in the number of fragile X CGG repeats: No association in a normal sample. 1994 , 19, 45-50		10
1986	Polymerase chain reaction-based methods for the detection of mutations in oncogenes and tumor suppressor genes. 1994 , 25, 564-71		31
1985	Unstable trinucleotide repeats and the diagnosis of neurodegenerative disease. 1994 , 25, 598-601		9
1984	Mutation analysis in patients with possible but apparently sporadic Huntington's disease. 1994 , 344, 714-7		45
1983	False-negative result for Huntington's disease mutation. 1994 , 343, 1232		5
1982	Cryptic and polar variation of the fragile X repeat could result in predisposing normal alleles. <i>Cell</i> , 1994 , 77, 853-61	56.2	339
1981	Trinucleotide repeats in neurologic diseases: an hypothesis concerning the pathogenesis of Huntington's disease, Kennedy's disease, and spinocerebellar ataxia type I. 1994 , 54, 1459-64		25
1980	Simple sequences. 1994 , 4, 832-7		252
1979	The DNA diagnosis for bulbospinal muscular atrophy. 1994 , 96, 20-3		3
1978	Genes with triplet repeats: a new class of mutations causing neurological diseases. 1994 , 48, 191-7		11
1977	Differential expression of a Distal-less homeobox gene Xdll-2 in ectodermal cell lineages. 1994 , 46, 63-70		67

1976	Isolation of human simple repeat loci by hybridization selection. 1994 , 3, 599-65	426
1975	Intrastriatal infusion of nerve growth factor after quinolinic acid prevents reduction of cellular expression of choline acetyltransferase messenger RNA and trkA messenger RNA, but not glutamate decarboxylase messenger RNA. 1994 , 61, 257-68	46
1974	Imprinting and anticipation. Are they relevant to genetic studies of schizophrenia?. 1994 , 164, 619-24	80
1973	The zebrafish <i>egr1</i> gene encodes a highly conserved, zinc-finger transcriptional regulator. 1994 , 13, 953-61	5
1972	Transcriptional activation modulated by homopolymeric glutamine and proline stretches. 1994 , 263, 808-11	549
1971	The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. 1994 , 22, 3181-6	934
1970	Late-onset Huntington's disease: a clinical and molecular study. 1994 , 23, 445-8	49
1969	DNA haplotype analysis of Huntington disease reveals clues to the origins and mechanisms of CAG expansion and reasons for geographic variations of prevalence. 1994 , 3, 2103-14	154
1968	Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. 1994 , 3, 1757-61	398
1967	Basalganglienerkrankungen - Bersicht 1992-1993. 1994 , 21, 141-148	3
1966	The trinucleotide repeat expansion on chromosome 6p (SCA1) in autosomal dominant cerebellar ataxias. 1994 , 117 (Pt 4), 645-9	55
1965	The relations between neuroscience and human behavioral science. 1994 , 61, 307-17	3
1964	F. 371-386	
1963	Genetic clues to glaucoma's secrets. The L Edward Jackson Memorial Lecture. Part 2. 1994 , 117, 706-27	56
1962	Positron emission tomography: applications to the investigation of movement disorders. 1994 , 24, 433-40	
1961	Mutations in the phenylalanine hydroxylase gene: methods for their characterization. 1994 , 407, 27-33	19
1960	Magnetic resonance imaging of neurodegenerative diseases. 1994 , 4, 146-58	11
1959	Schizophrenia epigenesis: past, present, and future. 1994 , 384, 26-33	48

1958	Homologous recombination of monkey alpha-satellite repeats in an in vitro simian virus 40 replication system: possible association of recombination with DNA replication. 1994 , 14, 4173-82	14
1957	Psychological effects of presymptomatic DNA testing for Huntington's disease in the Dutch program. 1994 , 56, 526-32	47
1956	Transcription of the Huntington disease gene during the quinolinic acid excitotoxic cascade. 1995 , 6, 1121-4	17
1955	Effects of striatal excitotoxicity on huntingtin-like immunoreactivity. 1995 , 6, 1125-9	26
1954	Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodies. 1995 , 92, 8710-4	256
1953	Fatal familial insomnia and familial Creutzfeldt-Jakob disease: clinical, pathological and molecular features. 1995 , 5, 43-51	167
1952	Huntington's disease: recent advances in diagnosis and management. 1995 , 22, 5-12	25
1951	Sensory- and memory-mediated olfactory dysfunction in Huntington's disease. 1995 , 1, 281-90	65
1950	Hereditary late-onset chorea without significant dementia: genetic evidence for substantial phenotypic variation in Huntington's disease. 1995 , 45, 443-7	48
1949	Analysis of spinocerebellar ataxia type 1 (SCA1)-related CAG trinucleotide expansion in Japan. 1995 , 45, 1587-94	47
1948	Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models. 1995 , 15, 3775-87	558
1947	Mapping of the human TATA-binding protein gene (TBP) to chromosome 6qter. 1995 , 69, 279-80	1
1946	Compact structures of d(CNG) _n oligonucleotides in solution and their possible relevance to fragile X and related human genetic diseases. 1995 , 23, 1876-81	42
1945	Gene Defects & Therapies: An Update on the Expanding Nature of Science. 1995 , 57, 70-75	
1944	Clinical, neuropathologic, and genetic studies of a large spinocerebellar ataxia type 1 (SCA1) kindred: (CAG) _n expansion and early premonitory signs and symptoms. 1995 , 45, 24-30	115
1943	How is the Human Genome Project doing, and what have we learned so far?. 1995 , 92, 10841-8	56
1942	Functional caudate imaging in symptomatic Huntington's disease: positron emission tomography versus single-photon emission computed tomography. 1995 , 5, 227-32	2
1941	Gene therapy and pharmacological treatment of inherited neurological disorders. 1995 , 13, 28-35	17

1940	Huntington's disease. Their loss is our gain?. 1995 , 5, 1229-31	2
1939	Long-term survival in the Wolf-Hirschhorn (4p-) syndrome. 1995 , 39 (Pt 1), 83-6	7
1938	Brain repair. 1995 , 237, 127-34	13
1937	Huntington's disease: a multidisciplinary study. 1995 , 2, 185-91	2
1936	A family with mild clinical manifestations of spinocerebellar ataxia type 1 (SCA1): correlation with smaller CAG repeats. 1995 , 2, 349-55	1
1935	A Japanese family with Machado-Joseph disease characterized by initial emaciation and myoclonus. 1995 , 2, 477-82	1
1934	The cortical neuritic pathology of Huntington's disease. 1995 , 21, 18-26	73
1933	Androgen receptor gene (CAG) _n repeat analysis in the differential diagnosis between Kennedy disease and other motoneuron disorders. 1995 , 55, 105-11	40
1932	Exploration of the effects of predictive testing for Huntington disease on intimate relationships. 1995 , 57, 46-51	66
1931	Isolation of genes from the Batten candidate region using exon amplification. Batten Disease Consortium. 1995 , 57, 320-3	5
1930	Normal CAG and CCG repeats in the Huntington's disease genes of Parkinson's disease patients. 1995 , 60, 109-10	3
1929	Towards the finer mapping of facioscapulohumeral muscular dystrophy at 4q35: construction of a laser microdissection library. 1995 , 60, 244-51	5
1928	Analysis of the SCA1 CAG repeat in a large number of families with dominant ataxia: clinical and molecular correlations. 1995 , 37, 176-80	62
1927	Huntington's disease gene: regional and cellular expression in brain of normal and affected individuals. 1995 , 37, 218-30	178
1926	Reduced expression of preproenkephalin in striatal neurons from Huntington's disease patients. 1995 , 37, 335-43	72
1925	Cognitive scores in carriers of Huntington's disease gene compared to noncarriers. 1995 , 37, 657-64	110
1924	Dentatorubral-pallidoluysian atrophy: clinical features are closely related to unstable expansions of trinucleotide (CAG) repeat. 1995 , 37, 769-75	125
1923	Molecular and clinical correlations in spinocerebellar ataxia type 3 and Machado-Joseph disease. 1995 , 38, 68-72	94

1922	A Greek-American kindred with autosomal dominant, levodopa-responsive parkinsonism and anticipation. 1995 , 38, 373-8	104
1921	Preferential loss of preproenkephalin versus preprotachykinin neurons from the striatum of Huntington's disease patients. 1995 , 38, 852-61	134
1920	Tourettism associated with Huntington's disease. 1995 , 10, 103-5	106
1919	Automobile driving in Huntington's disease. 1995 , 10, 778-87	37
1918	A fragile gene. 1995 , 17, 941-7	37
1917	X-linked recessive bulbospinal neuronopathy: clinical phenotypes and CAG repeat size in androgen receptor gene. 1995 , 18, 1378-84	46
1916	Phenotypic/genotypic correlation will assist genetic counseling in 4q35-facioscapulohumeral muscular dystrophy. 1995 , 18, S103-S109	42
1915	Indirect DNA/gene diagnoses via electrophoresis--an obsolete principle?. 1995 , 16, 683-90	10
1914	Biological significance of minisatellites. 1995 , 16, 1586-95	22
1913	Trinucleotide repeat expansion and human disease. 1995 , 16, 1698-704	16
1912	Theoretical basis of one-dimensional genome scanning: a direct method to identify the site of a mutation. 1995 , 16, 174-8	4
1911	Somatic cell heterogeneity between DNA extracted from lymphocytes and skeletal muscle in congenital myotonic dystrophy. 1995 , 40, 319-26	4
1910	Spinocerebellar ataxia 1 (SCA1) in the Japanese: analysis of CAG trinucleotide repeat expansion and instability of the repeat for paternal transmission. 1995 , 40, 131-43	11
1909	Huntington disease: a case study describing the complexities and nuances of predictive testing of monozygotic twins. 1995 , 4, 125-37	12
1908	Recent observations in human DNA-minisatellite mutations. 1995 , 107, 204-8	14
1907	Preclinical stages in subjects at risk for neurological disorders: can PET-FDG tell us more?. 1995 , 242, 112-4	2
1906	Transcript identification in the BRCA1 candidate region. 1995 , 33, 115-24	2
1905	Frequent in-frame length variations are found in the diverged simple repeat sequences of the protein-coding regions of two putative protein kinase genes of <i>Brassica napus</i> . 1995 , 27, 829-33	4

1904	Fundulus heteroclitus vitellogenin: the deduced primary structure of a piscine precursor to noncrystalline, liquid-phase yolk protein. 1995 , 41, 505-21	95
1903	Simple repetitive DNA sequences from primates: compilation and analysis. 1995 , 40, 120-6	183
1902	Somatic stability in chorionic villi samples and other Huntington fetal tissues. 1995 , 96, 229-32	14
1901	Confidence intervals for predicted age of onset, given the size of (CAG) _n repeat, in Huntington's disease. 1995 , 95, 231-2	30
1900	Somatic expansion of the (CAG) _n repeat in Huntington disease brains. 1995 , 95, 270-4	51
1899	Elongated CAG repeats of the B37 gene in a Danish family with dentato-rubro-pallido-luysian atrophy. 1995 , 95, 313-8	29
1898	Genetic mapping of adrenergic receptor genes in humans. 1995 , 73, 299-306	19
1897	Length variation of CAG repeats in Sry across populations of <i>Mus domesticus</i> . 1995 , 6, 206-8	8
1896	Recent advances in reproductive genetic technologies. 1995 , 13, 968-73	1
1895	Stability of an expanded trinucleotide repeat in the androgen receptor gene in transgenic mice. 1995 , 9, 191-6	126
1894	Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form. 1995 , 10, 104-10	394
1893	Gain of glutamines, gain of function?. 1995 , 10, 3-4	77
1892	Comparative sequence analysis of the human and pufferfish Huntington's disease genes. 1995 , 10, 67-76	135
1891	The gene for autosomal dominant cerebellar ataxia with pigmentary macular dystrophy maps to chromosome 3p12-p21.1. 1995 , 10, 84-8	134
1890	Retinal degeneration characterizes a spinocerebellar ataxia mapping to chromosome 3p. 1995 , 10, 89-93	125
1889	Expression analysis of the ataxin-1 protein in tissues from normal and spinocerebellar ataxia type 1 individuals. 1995 , 10, 94-8	265
1888	Abnormal gene product identified in hereditary dentatorubral-pallidoluysian atrophy (DRPLA) brain. 1995 , 10, 99-103	151
1887	Expansion and deletion of CTG repeats from human disease genes are determined by the direction of replication in <i>E. coli</i> . 1995 , 10, 213-8	324

1886	Gametic and somatic tissue-specific heterogeneity of the expanded SCA1 CAG repeat in spinocerebellar ataxia type 1. 1995 , 10, 344-50	163
1885	HEAT repeats in the Huntington's disease protein. 1995 , 11, 115-6	461
1884	Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. 1995 , 11, 155-63	625
1883	Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. 1995 , 375, 754-60	3425
1882	A huntingtin-associated protein enriched in brain with implications for pathology. 1995 , 378, 398-402	534
1881	Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias. 1995 , 378, 403-6	582
1880	Analysis of CAG/CTG triplet repeats in the human genome: Implication in transcription factor gene regulation. 1995 , 20, 613-627	10
1879	Impact of the human genome project on medical practice. 1995 , 2, 14-25	2
1878	Introduction: Unstable repeat diseases. 1995 , 6, 1-3	
1877	Huntington's disease. 1995 , 6, 21-8	69
1876	Spinocerebellar ataxia type 1. 1995 , 6, 29-35	88
1875	Dentatorubral-pallidoluysian atrophy (DRPLA): close correlation of CAG repeat expansions with the wide spectrum of clinical presentations and prominent anticipation. 1995 , 6, 37-44	41
1874	Twin studies in insulin dependent diabetes and other autoimmune diseases. 1995 , 11, 121-35	9
1873	Unstable triplet repeat sequences: a source of cancer mutations?. 1995 , 13, 146-57	28
1872	The Human Genome Project and Biology Education. 1995 , 45, 786-791	9
1871	Diagnosis of human heritable diseases—laboratory approaches and outcomes. 1995 , 41, 785-794	4
1870	Embryonic Striatal Grafting: Progress and Future Directions for Therapeutic Approaches to Neurodegenerative Diseases of the Basal Ganglia. 1995 , 14, 225-234	
1869	Molecular Genetic Advances in Neurodegenerative Disorders. 1995 , 15, 915-926	2

1868	Correlations between molecular and clinical data in Huntington's disease and implications for predictive testing. 1995 , 7, 7-12	
1867	The new genetics in psychiatry. 1995 , 1, 109-115	
1866	Spontaneous mutations in <i>pcaH</i> and <i>-G</i> , structural genes for protocatechuate 3,4-dioxygenase in <i>Acinetobacter calcoaceticus</i> . 1995 , 177, 1336-47	53
1865	Differential effects of simple repeating DNA sequences on gene expression from the SV40 early promoter. 1995 , 270, 3313-9	8
1864	Construction of human embryonic cDNA libraries: HD, PKD1 and BRCA1 are transcribed widely during embryogenesis. 1995 , 71, 197-202	14
1863	Normal and Expanded Huntington's Disease Gene Alleles Produce Distinguishable Proteins Due to Translation Across the CAG Repeat. 1995 , 1, 374-383	90
1862	Perspectives and Molecular Diagnosis of the Fragile X Syndrome. 1995 , 15, 859-876	4
1861	Glutamine Repeats as Polar Zippers: Their Role in Inherited Neurodegenerative Disease. 1995 , 1, 718-721	30
1860	Haplotype analysis of the delta 2642 and (CAG) <i>n</i> polymorphisms in the Huntington's disease (HD) gene provides an explanation for an apparent 'founder' HD haplotype. 1995 , 4, 203-6	41
1859	An intramolecular triplex in the human gamma-globin 5'-flanking region is altered by point mutations associated with hereditary persistence of fetal hemoglobin. 1995 , 270, 24556-63	38
1858	Population genetics of trinucleotide repeat polymorphisms. 1995 , 4, 1485-91	75
1857	Alterations of intermediate filaments in various histopathological conditions. 1995 , 73, 627-34	8
1856	Ancestral differences in the distribution of the delta 2642 glutamic acid polymorphism is associated with varying CAG repeat lengths on normal chromosomes: insights into the genetic evolution of Huntington disease. 1995 , 4, 207-14	67
1855	Inherited Creutzfeldt-Jakob disease in a British family associated with a novel 144 base pair insertion of the prion protein gene. 1995 , 58, 65-9	28
1854	The epidemiology of Huntington's disease in Northern Ireland. 1995 , 32, 524-30	46
1853	Sequence analysis of the CCG polymorphic region adjacent to the CAG triplet repeat of the HD gene in normal and HD chromosomes. 1995 , 32, 399-400	20
1852	Emotional and functional impact of DNA testing on patients with symptoms of Huntington's disease. 1995 , 32, 516-8	13
1851	Molecular diagnostic analysis for Huntington's disease: a prospective evaluation. 1995 , 58, 496-8	9

1850	A promoter within intron 35 of the human C4A gene initiates abundant adrenal-specific transcription of a 1 kb RNA: location of a cryptic CYP21 promoter element?. 1995 , 4, 2109-16	40
1849	Evidence from antibody studies that the CAG repeat in the Huntington disease gene is expressed in the protein. 1995 , 4, 465-9	63
1848	Simple tandem DNA repeats and human genetic disease. 1995 , 92, 3636-41	294
1847	Triplet repeat expansion mutations: the example of fragile X syndrome. 1995 , 18, 77-99	73
1846	Correlation between fragment size at D4F104S1 and age at onset or at wheelchair use, with a possible generational effect, accounts for much phenotypic variation in 4q35-facioscapulohumeral muscular dystrophy (FSHD). 1995 , 4, 951-8	170
1845	Trinucleotide repeat expansion and human disease. 1995 , 29, 703-28	343
1844	Increased instability of intermediate alleles in families with sporadic Huntington disease compared to similar sized intermediate alleles in the general population. 1995 , 4, 1911-8	117
1843	Localization of autosomal dominant cerebellar ataxia associated with retinal degeneration and anticipation to chromosome 3p12-p21.1. 1995 , 4, 1441-5	52
1842	Applications of molecular biology to biomedicine and toxicology. 1995 , 13, 1-51	8
1841	Expression of the mutant allele of IT-15 (the HD gene) in striatum and cortex of Huntington's disease patients. 1995 , 4, 15-8	27
1840	Somatic mosaicism in sperm is associated with intergenerational (CAG) _n changes in Huntington disease. 1995 , 4, 189-95	64
1839	Model for a transcript map of human chromosome 21: isolation of new coding sequences from exon and enriched cDNA libraries. 1995 , 4, 1291-304	68
1838	Cognitive performance in UK sample of presymptomatic people carrying the gene for Huntington's disease. 1995 , 32, 358-62	26
1837	Correlations between triplet repeat expansion and clinical features in Huntington's disease. 1995 , 52, 749-53	68
1836	Review : Glial Boundaries and Scars: Programs for Normal Development and Wound Healing in the Brain. 1995 , 1, 142-154	21
1835	An expression-independent catalog of genes from human chromosome 22. 1995 , 5, 214-24	20
1834	Mental health law and dangerousness. 1995 , 29, 154-5	
1833	Allele distribution of a highly polymorphic repeat on chromosome 12 in patients with symptoms of chorea and ataxia. 1995 , 32, 577-8	

1832	Neuropsychological characteristics of Huntington's disease carriers: a double blind study. 1995 , 32, 600-4	42
1831	Molecular genetic approaches to the study of human craniofacial dysmorphologies. 1995 , 158, 215-77	6
1830	Some speech disorders. 1995 , 58, 191, 200	
1829	DNA analysis in hereditary dentatorubral-pallidoluysian atrophy: correlation between CAG repeat length and phenotypic variation and the molecular basis of anticipation. 1995 , 45, 143-9	126
1828	Survey of trinucleotide repeats in the human genome: assessment of their utility as genetic markers. 1995 , 4, 1829-36	72
1827	Rapid cDNA sequencing in combination with RNA expression studies in mice identifies a large number of male germ cell-specific sequence tags. 1995 , 52, 131-8	38
1826	Neurotrophic Factor Protection against Excitotoxic Neuronal Death. 1995 , 1, 286-297	18
1825	Stability of the Huntington disease (CAG) _n repeat in a late onset form occurring on the Island of Crete. 1995 , 4, 2239-43	13
1824	Expression of the Huntington's disease (IT15) protein product in HD patients. 1995 , 4, 1365-71	95
1823	Longitudinal neuropsychological and genetic linkage analysis of persons at risk for Huntington's disease. 1995 , 52, 59-64	67
1822	Marked increase in mitochondrial DNA deletion levels in the cerebral cortex of Huntington's disease patients. 1995 , 45, 1879-83	94
1821	A gene for autosomal dominant nonsyndromic hereditary hearing impairment maps to 4p16.3. 1995 , 4, 1967-72	74
1820	The prevention of neurogenetic disease. 1995 , 52, 356-62	8
1819	A comparison of the Huntington's disease associated trinucleotide repeat between Chinese and white populations. 1995 , 32, 404-5	11
1818	Analysis of triplet repeats in the huntingtin gene in Japanese families affected with Huntington's disease. 1995 , 32, 701-5	37
1817	Characterisation of the unstable expanded CAG repeat in the MJD1 gene in four Brazilian families of Portuguese descent with Machado-Joseph disease. 1995 , 32, 827-30	15
1816	CAG repeat length variation in sperm from a patient with Kennedy's disease. 1995 , 4, 303-5	50
1815	Genetic anticipation in Parkinson's disease. 1995 , 45, 135-8	71

1814	Pausing of DNA synthesis in vitro at specific loci in CTG and CGG triplet repeats from human hereditary disease genes. 1995 , 270, 27014-21	145
1813	Single-stranded DNA binding proteins isolated from mouse brain recognize specific trinucleotide repeat sequences in vitro. 1995 , 23, 2654-60	18
1812	Human chromosome-specific cDNA libraries: new tools for gene identification and genome annotation. 1995 , 5, 185-94	15
1811	Impaired prepulse inhibition of acoustic and tactile startle response in patients with Huntington's disease. 1995 , 58, 192-200	334
1810	Huntington's disease in Saudi Arabia. 1995 , 32, 325	2
1809	DNA analysis of Huntington's disease in southern Chinese. 1995 , 32, 120-4	2
1808	Huntington's Disease: Lessons from and for Molecular Neuroscience. 1995 , 1, 51-58	4
1807	Imaging the head: functional imaging. 1995 , 58, 132-44	10
1806	Impaired source memory in Huntington's disease and its relation to basal ganglia atrophy. 1995 , 17, 868-77	32
1805	CAG repeat expansions and schizophrenia: association with disease in females and with early age-at-onset. 1995 , 4, 1957-61	125
1804	Somatic mosaicism of CAG repeat in dentatorubral-pallidoluysian atrophy (DRPLA). 1995 , 4, 663-6	67
1803	Inactivation of the mouse Huntington's disease gene homolog Hdh. 1995 , 269, 407-10	582
1802	CAG expansion affects the expression of mutant Huntingtin in the Huntington's disease brain. 1995 , 15, 1193-201	161
1801	When more is less: pathogenesis of glutamine repeat neurodegenerative diseases. 1995 , 15, 493-6	240
1800	Widespread expression of Huntington's disease gene (IT15) protein product. 1995 , 14, 1065-74	435
1799	Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. 1995 , 14, 1075-81	623
1798	The fragile X syndrome. 1995 , 1271, 293-303	6
1797	Positional cloning reaches maturity. 1995 , 5, 298-303	11

1796	Novel approaches to linkage mapping. 1995 , 5, 335-41	53
1795	YAC transgenics and the study of genetics and human disease. 1995 , 5, 342-8	40
1794	Finding genes involved in human developmental disorders. 1995 , 5, 354-61	10
1793	Huntington's disease: CAG genetics expands neurobiology. 1995 , 5, 656-62	55
1792	Origins and evolution of Huntington disease chromosomes. 1995 , 4, 239-44	21
1791	Is there a genetic susceptibility to idiopathic parkinsonism?. 1995 , 1, 73-84	6
1790	Trophic and protective actions of brain-derived neurotrophic factor on striatal DARPP-32-containing neurons in vitro. 1995 , 90, 92-101	67
1789	Genetics and molecular biology of Huntington's disease. 1995 , 18, 11-4	124
1788	Trinucleotide-repeat expansions and neurodegenerative diseases. 1995 , 18, 440	1
1787	Spinal and bulbar muscular atrophy: a trinucleotide-repeat expansion neurodegenerative disease. 1995 , 18, 459-61	73
1786	The identification of a functional nuclear localization signal in the Huntington disease protein. 1995 , 33, 165-73	30
1785	Allelic instability in the mitosis model and the inheritance of psoriasis. 1995 , 32, 44-52	14
1784	Defects of androgen receptor function: from sex reversal to motor neurone disease. 1995 , 112, 133-41	44
1783	Effect of riluzole on quinolinate-induced neuronal damage in rats: comparison with blockers of glutamatergic neurotransmission. 1995 , 201, 92-6	51
1782	A molecular model for bipolar affective disorder. 1995 , 45, 255-64	5
1781	Random rapid amplification of cDNA ends (RRACE) allows for cloning of multiple novel human cDNA fragments containing (CAG) _n repeats. 1995 , 155, 289-92	10
1780	Expanded CTG triplet blocks from the myotonic dystrophy gene create the strongest known natural nucleosome positioning elements. 1995 , 25, 570-3	120
1779	Nonrandom patterns of simple and cryptic triplet repeats in coding and noncoding sequences. 1995 , 26, 510-20	17

1778	Isolation of the human genomic brain-2/N-Oct 3 gene (POUF3) and assignment to chromosome 6q16. 1995 , 26, 272-80		30
1777	SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat. <i>Cell</i> , 1995 , 82, 937-48	56.2	505
1776	Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. <i>Cell</i> , 1995 , 81, 811-23	56.2	671
1775	Analysis of the 5' end of the rat plasma membrane Ca(2+)-ATPase isoform 3 gene and identification of extensive trinucleotide repeat sequences in the 5' untranslated region. 1995 , 1240, 119-24		5
1774	Consecutive low-usage leucine codons block translation only when near the 5' end of a message in <i>Escherichia coli</i> . 1995 , 245, 467-73		144
1773	Cloning and expression of the rat atrophin-I (DRPLA disease gene) homologue. 1995 , 2, 129-38		15
1772	Neuroprotective therapeutic strategies. Comparison of experimental and clinical results. 1995 , 50, 1-16		39
1771	Polar zippers: their role in human disease. 1995 , 69, 213-24		17
1770	No association between length of the (CAG) _n repeat of the Huntington's disease gene and Tourette's syndrome. 1995 , 37, 209-11		3
1769	Carrier diagnosis of the fragile X syndrome--a challenge in antenatal clinics. 1995 , 172, 1236-9		13
1768	Diagnosis of "sporadic" Huntington's disease. 1995 , 129, 51-5		28
1767	Dysfunction of brain kynurenic acid metabolism in Huntington's disease: focus on kynurenine aminotransferases. 1995 , 130, 39-47		100
1766	Parents do matter: genomic imprinting and parental sex effects in neurological disorders. 1995 , 130, 1-10		13
1765	CAG repeat expansion of Machado-Joseph disease in the Japanese: analysis of the repeat instability for parental transmission, and correlation with disease phenotype. 1995 , 133, 128-33		20
1764	Further evidence for anticipation in schizophrenia. 1995 , 59, 25-33		45
1763	Somatic mosaicism, germline expansions, germline reversions and intergenerational reductions in myotonic dystrophy males: small pool PCR analyses. 1995 , 4, 1-8		262
1762	Mechanisms of DNA expansion. 1995 , 104, 2-13		108
1761	Quinolinic acid-induced increases in calbindin D28k immunoreactivity in rat striatal neurons in vivo and in vitro mimic the pattern seen in Huntington's disease. 1995 , 65, 397-407		64

1760	The molecular basis of hereditary skeletal disorders. 1995 , 27, 433-4	0
1759	Type II diabetes: clinical aspects of molecular biological studies. 1995 , 44, 1-10	66
1758	The neuroscience perspective and the changing role of the psychiatrist : the challenge for psychiatric educators. 1995 , 19, 202-12	5
1757	Presymptomatic testing for genetic diseases of later life. Pharmacoepidemiological considerations. 1995 , 7, 117-30	3
1756	Aetiology of Schizophrenia. 1995 , 3, 126-144	6
1755	Evidence for a preferential loss of enkephalin immunoreactivity in the external globus pallidus in low grade Huntington's disease using high resolution image analysis. 1995 , 64, 397-404	139
1754	GABA and GABAA receptor changes in the substantia nigra of the rat following quinolinic acid lesions in the striatum closely resemble Huntington's disease. 1995 , 66, 507-21	36
1753	Single sperm analysis of the trinucleotide repeats in the Huntington's disease gene: quantification of the mutation frequency spectrum. 1995 , 4, 1519-26	171
1752	Diagnostic testing in movement disorders. 1996 , 14, 169-82	5
1751	Strategies for amplification of trinucleotide repeats: Optimization of fragile X and androgen receptor PCR. 1996 , 1, 59-64	5
1750	Muscle morphology and mitochondrial investigations of a family with autosomal dominant cerebellar ataxia and retinal degeneration mapped to chromosome 3p12-p21.1. 1996 , 144, 91-8	20
1749	A Dutch family with benign hereditary chorea of early onset: differentiation from Huntington's disease. 1996 , 98, 165-70	12
1748	Gene analysis of human skin and skin diseases. 1996 , 11, 169-76	1
1747	Differential pattern in tissue-specific somatic mosaicism of expanded CAG trinucleotide repeats in dentatorubral-pallidoluysian atrophy, Machado-Joseph disease, and X-linked recessive spinal and bulbar muscular atrophy. 1996 , 135, 43-50	50
1746	Spinal and bulbar muscular atrophy: androgen receptor dysfunction caused by a trinucleotide repeat expansion. 1996 , 135, 149-57	38
1745	Analysis of CAG trinucleotide expansion associated with Machado-Joseph disease. 1996 , 136, 101-7	26
1744	The relationship between trinucleotide repeat length and phenotypic variation in Machado-Joseph disease. 1996 , 139, 52-57	25
1743	Familial psychiatric presentation of Huntington's disease. 1996 , 33, 128-31	31

1742	Huntington disease: new insights into the relationship between CAG expansion and disease. 1996 , 5 Spec No, 1431-5	56
1741	Dynamic mutation loci: allele distributions in different populations. 1996 , 60, 391-400	21
1740	Genetic fitness in Huntington's Disease and Spinocerebellar Ataxia 1: a population genetics model for CAG repeat expansions. 1996 , 60, 423-35	20
1739	Ethnicity and myotonic dystrophy: a possible explanation for its absence in sub-Saharan Africa. 1996 , 60, 57-65	18
1738	Intrastriatal implants of polymer encapsulated cells genetically modified to secrete human nerve growth factor: trophic effects upon cholinergic and noncholinergic striatal neurons. 1996 , 72, 63-77	52
1737	Reduction in enkephalin and substance P messenger RNA in the striatum of early grade Huntington's disease: a detailed cellular in situ hybridization study. 1996 , 72, 1023-36	133
1736	Decreased neuronal nitric oxide synthase messenger RNA and somatostatin messenger RNA in the striatum of Huntington's disease. 1996 , 72, 1037-47	87
1735	Phenotypic development of the human embryonic striatal primordium: a study of cultured and grafted neurons from the lateral and medial ganglionic eminences. 1996 , 73, 171-83	40
1734	Distribution and variability of trinucleotide repeats in the genome of the yeast <i>Saccharomyces cerevisiae</i> . 1996 , 174, 165-74	31
1733	Postexcitatory inhibition after transcranial magnetic single and double brain stimulation in Huntington's disease. 1996 , 101, 298-303	39
1732	[Molecular biology of fragile X syndrome: recent data and diagnostic applications]. 1996 , 3, 814-21	1
1731	Triplet repeats and human disease. 1996 , 2, 65-9	5
1730	DRPLA gene (atrophin-1) sequence and mRNA expression in human brain. 1996 , 36, 219-26	35
1729	Zygotic expression of the zebrafish Sox-19, an HMG box-containing gene, suggests an involvement in central nervous system development. 1996 , 40, 221-8	26
1728	Differential trophic effects of basic fibroblast growth factor, insulin-like growth factor-1, and neurotrophin-3 on striatal neurons in culture. 1996 , 138, 144-57	59
1727	CTG triplet repeats from the myotonic dystrophy gene are expanded in <i>Escherichia coli</i> distal to the replication origin as a single large event. 1996 , 258, 543-7	55
1726	Neurobiology of Huntington's disease. 1996 , 3, 3-15	118
1725	NADPH diaphorase-containing striatal or cortical neurons are resistant to apoptosis. 1996 , 3, 72-5	28

1724	cDNA cloning and characterization of an atrophin-1 (DRPLA disease gene)-related protein. 1996 , 3, 121-8		8
1723	Differential expression of normal and mutant Huntington's disease gene alleles. 1996 , 3, 183-90		68
1722	Neurogenetic diseases: molecular diagnosis and therapeutic approaches. 1996 , 74, 71-84		13
1721	Molecular re-investigation of patients with Huntington's disease in Wessex reveals a family with dentatorubral and pallidolusian atrophy. 1996 , 97, 76-8		19
1720	Linkage disequilibrium and extended haplotypes in the HLA-A to D6S105 region: implications for mapping the hemochromatosis gene (HFE). 1996 , 97, 103-13		33
1719	Toxicity of expanded polyglutamine-domain proteins in <i>Escherichia coli</i> . 1996 , 399, 135-9		40
1718	Prospects for development of genetic markers for resistance to gastrointestinal parasite infection in sheep. 1996 , 26, 879-97		31
1717	Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. <i>Cell</i> , 1996 , 87, 493-506	56.2	2587
1716	Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca ²⁺ channel gene CACNL1A4. <i>Cell</i> , 1996 , 87, 543-52	56.2	2021
1715	Variable subcellular localization of a neuron-specific protein during NTera 2 differentiation into post-mitotic human neurons. 1996 , 42, 202-12		9
1714	Cloning and sequencing of a copper-containing, topa quinone-containing monoamine oxidase from human placenta. 1996 , 179, 279-86		66
1713	Effects of alpha-phenyl-tert-butyl nitron on neuronal survival and motor function following intrastriatal injections of quinolinate or 3-nitropropionic acid. 1997 , 76, 749-61		81
1712	The placement of a striatal ibotenic acid lesion affects skilled forelimb use and the direction of drug-induced rotation. 1996 , 41, 409-16		66
1711	A general method for the detection of large CAG repeat expansions by fluorescent PCR. 1996 , 33, 1022-6		195
1710	Huntington's disease: translating a CAG repeat into a pathogenic mechanism. 1996 , 6, 638-43		85
1709	Glutamine repeats and inherited neurodegenerative diseases: molecular aspects. 1996 , 6, 848-58		179
1708	TRANSPLANTATION OF FETAL TISSUES. 1996 , 16, 333-359		
1707	Monoclonal antibodies directed against the amino-terminal domain of human TBP cross-react with TBP from other species. 1996 , 15, 55-68		34

1706	Cloning and sequence analysis of the human MG160, a fibroblast growth factor and E-selectin binding membrane sialoglycoprotein of the Golgi apparatus. 1996 , 15, 1121-8	32
1705	Myotonic dystrophy: will the real gene please step forward!. 1996 , 5 Spec No, 1417-23	67
1704	Dynamic mutations pose unique challenges for the molecular diagnostics laboratory. 1996 , 42, 1582-1588	6
1703	Huntingtin-associated protein (HAP1): discrete neuronal localizations in the brain resemble those of neuronal nitric oxide synthase. 1996 , 93, 4839-44	118
1702	Nonisotopic method for accurate detection of (CAG) _n repeats causing Huntington disease. 1996 , 42, 1601-1603	18
1701	Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's disease. 1996 , 16, 3019-25	220
1700	Gene conversion plays the major role in controlling the stability of large tandem repeats in yeast.. 1996 , 15, 1715-1725	86
1699	Ciliary neurotrophic factor protects striatal output neurons in an animal model of Huntington disease. 1996 , 93, 7346-51	130
1698	Expression of normal and mutant huntingtin in the developing brain. 1996 , 16, 5523-35	148
1697	Multiplex sets for the amplification of polymorphic short tandem repeat loci--silver stain and fluorescence detection. 1996 , 20, 882-9	56
1696	Neural Transplantation for Huntington's Disease: Experimental Rationale and Recommendations for Clinical Trials. 1996 , 5, 339-352	24
1695	In vitro synthesis and cloning of long CAG repeats. 1996 , 21, 609-10, 612	29
1694	Synaptic transmission and modulation in the neostriatum. 1996 , 39, 77-111	30
1693	Modern molecular genetic approaches to psychiatric disease. 1996 , 52, 434-52	37
1692	Dynamic mutations and psychiatric genetics. 1996 , 26, 1-6	24
1691	Confirmation of association between expanded CAG/CTG repeats and both schizophrenia and bipolar disorder. 1996 , 26, 1145-53	119
1690	Familial dementia due to a frameshift mutation in the caeruloplasmin gene. 1996 , 89, 355-360	38
1689	The relevance of genetic testing in late-onset Huntington's disease. 1996 , 44, 609-11	1

1688	Orientation dependence of trinucleotide CAG repeat instability in <i>Saccharomyces cerevisiae</i> . 1996 , 16, 6617-22	109
1687	Molecular genetics and craniofacial surgery. 1996 , 97, 666-75	19
1686	Codon repeats in genes associated with human diseases: fewer repeats in the genes of nonhuman primates and nucleotide substitutions concentrated at the sites of reiteration. 1996 , 93, 417-21	64
1685	Purification of nuclear proteins from human HeLa cells that bind specifically to the unstable tandem repeat (CGG) _n in the human FMR1 gene. 1996 , 271, 4327-34	37
1684	Chapter 15 DNA probes in human diseases. 1996 , 307-329	1
1683	A reproducible assay of polymerase chain reaction to detect trinucleotide repeat expansion of Huntington's disease and senile chorea. 1996 , 18, 16-8	20
1682	On the trail of the genetics and pathophysiology of schizophrenia. 1996 , 59, 117-27	6
1681	Expanded CAG/CTG repeats in schizophrenia. A study of clinical correlates. 1996 , 169, 766-71	14
1680	Expansion of polyglutamine repeat in huntingtin leads to abnormal protein interactions involving calmodulin. 1996 , 93, 5037-42	129
1679	Mutation and mutagenesis in inherited and acquired human disease. The first EEMS Frits Sobels Prize Lecture, Noordwijkerhout, The Netherlands, June 1995. 1996 , 351, 89-103	11
1678	Somatostatin 1-12 immunoreactivity is decreased in the hypothalamic lateral tuberal nucleus of Huntington's disease patients. 1996 , 728, 141-8	47
1677	Expression of the rat S100A1 gene in neurons, glia, and skeletal muscle. 1996 , 721, 204-16	16
1676	Characterization of dentatorubral-pallidolusian atrophy proteins using two-dimensional electrophoretic analysis. 1996 , 732, 154-8	5
1675	Coexistence of Huntington's disease and familial amyotrophic lateral sclerosis: case presentation. 1996 , 92, 421-7	23
1674	Fragile site and interstitial telomere repeat sequences at the fusion point of a de novo (Y;13) translocation. 1996 , 98, 323-7	23
1673	Mosaicism of a microdeletion of 486 bp involving the CGG repeat of the FMR1 gene due to misalignment of GTT tandem repeats at chi-like elements flanking both breakpoints and a full mutation. 1996 , 98, 409-14	38
1672	Molecular basis governing primary sex in mammals. 1996 , 41, 363-79	4
1671	Unstable expansion of triplet repeats as a new disease mechanism for neurodegenerative diseases. 1996 , 41, 279-90	17

1670	Update on genetics of Huntington's disease: availability of direct and accurate predictive test. 1996 , 17, 185-7	3
1669	Phylogenetic analysis of DNA length mutations in a repetitive region of the Hawaiian <i>Drosophila</i> yolk protein gene Yp2. 1996 , 43, 116-24	13
1668	Identification of a long huntingtin mRNA transcript in mouse brain. 1996 , 743, 320-3	6
1667	Linkage and cytogenetic mapping of a CAG repeat containing human cDNA to 3p24.2-p22. 1996 , 92, 46-9	
1666	Clinical implications of unstable DNA repeat sequences. 1996 , 85, 265-71	11
1665	Issues in genetic testing for susceptibility to alcoholism: lessons from Alzheimer's disease and Huntington's disease. 1996 , 20, 1430-7	14
1664	Basal ganglia: new therapeutic approaches to Parkinson's disease. 1996 , 6, 368-71	20
1663	Glutamine and tetrapeptide repeat variations affect the biological activity of different mouse interleukin-2 alleles. 1996 , 26, 1675-82	19
1662	Modern genome research and DNA diagnostics in domestic animals in the light of classical breeding techniques. 1996 , 17, 1-11	18
1661	Core Assessment Program for Intracerebral Transplantation in Huntington's Disease (CAPIT-HD). 1996 , 11, 143-50	99
1660	Proton magnetic resonance spectroscopy in Huntington's disease: evidence in favour of the glutamate excitotoxic theory. 1996 , 11, 167-73	94
1659	Assessment of coenzyme Q10 tolerability in Huntington's disease. 1996 , 11, 321-3	92
1658	Dentatorubral-pallidolusian atrophy. Clinical features of a five-generation Danish family. 1996 , 11, 533-41	13
1657	A controlled trial of idebenone in Huntington's disease. 1996 , 11, 549-54	76
1656	Evidence of cortical metabolic dysfunction in early Huntington's disease by single-photon-emission computed tomography. 1996 , 11, 671-7	53
1655	Relationship between trinucleotide repeats and neuropathological changes in Huntington's disease. 1996 , 39, 132-6	122
1654	Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. 1996 , 40, 49-54	184
1653	Somatic mosaicism in the central nervous system in spinocerebellar ataxia type 1 and Machado-Joseph disease. 1996 , 40, 199-206	55

1652	Regional and cellular expression of the Machado-Joseph disease gene in brains of normal and affected individuals. 1996 , 40, 776-81	42
1651	Psychiatric symptoms and CAG expansion in Huntington's disease. 1996 , 67, 53-7	44
1650	Direct detection of expanded trinucleotide repeats using PCR and DNA hybridization techniques. 1996 , 67, 85-91	15
1649	Cataracts, motor system disorder, short stature, learning difficulties, and skeletal abnormalities: a new syndrome?. 1996 , 62, 42-7	18
1648	Patients' rights to laboratory data: trinucleotide repeat length in Huntington disease. 1996 , 62, 6-9	10
1647	High phenotypic correlations among siblings with autism and pervasive developmental disorders. 1996 , 67, 354-60	39
1646	Strong linkage disequilibrium and haplotype analysis in Japanese pedigrees with Machado-Joseph disease. 1996 , 67, 437-44	9
1645	Additional support for schizophrenia linkage on chromosomes 6 and 8: a multicenter study. Schizophrenia Linkage Collaborative Group for Chromosomes 3, 6 and 8. 1996 , 67, 580-94	147
1644	Inability to induce fragile sites at CTG repeats in congenital myotonic dystrophy. 1996 , 66, 60-3	10
1643	Molecular detection of new mutations, resolution of ambiguous results and complex genetic counseling issues in Huntington disease. 1996 , 66, 281-6	11
1642	Microsatellites and PCR genomic analysis. 1996 , 178, 239-48	63
1641	Huntington's disease. 1996 , 16, 1237-45	8
1640	(CTG) _n expansions in various tissues from a myotonic dystrophy patient. 1996 , 19, 240-2	23
1639	Genetic alterations as clonal markers for bladder cancer detection in urine. 1996 , 63, 191-196	5
1638	Somatic stability of the expanded CAG trinucleotide repeat in X-linked spinal and bulbar muscular atrophy. 1996 , 8, 32-7	16
1637	Highly rugged kinetic method for the enzymatic determination of DNA in agarose gel with array detection using a charge coupled device. 1996 , 329, 285-295	1
1636	Expanded glutamines and neurodegeneration--a gain of insight. 1996 , 18, 175-8	23
1635	CAC--the neglected repeat. 1996 , 18, 237-42	5

1634	Visual processing disorders in patients with Huntington's disease and asymptomatic carriers. 1996 , 243, 286-92	52
1633	Evolution of simple sequence repeats. 1996 , 20, 41-8	23
1632	Identification of a novel protein, DMAP, which interacts with the myotonic dystrophy protein kinase and shows strong homology to D1 snRNP. 1996 , 97, 117-25	8
1631	John Jacob Wasmuth (1946-1995). 1996 , 12, 119-20	
1630	Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo. 1996 , 13, 196-202	492
1629	Mice lacking the myotonic dystrophy protein kinase develop a late onset progressive myopathy. 1996 , 13, 325-35	311
1628	Huntingtin: new marker along the road to death?. 1996 , 13, 380-2	8
1627	Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. 1996 , 13, 442-9	501
1626	Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. 1996 , 14, 269-76	963
1625	Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT. 1996 , 14, 277-84	679
1624	Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH. 1996 , 2, 347-50	401
1623	Human genetics. Woman's meat, a man's poison. 1996 , 382, 494-5	5
1622	Trinucleotide-repeat expansions and neurodegenerative disease: a mechanism of pathogenesis. 1996 , 23, 1015-20	3
1621	The search for molecular defects in genetic disease. 1996 , 45, 43-52	
1620	Fragile X syndrome in humans and mice. 1996 , 45, 93-108	6
1619	Molecular cloning and characterization of a novel mouse macrophage gene that encodes a nuclear protein comprising polyglutamine repeats and interspersing histidines. 1996 , 271, 25515-23	8
1618	CTG triplet repeats from human hereditary diseases are dominant genetic expansion products in Escherichia coli. 1996 , 271, 1853-6	37
1617	Subcellular localization of the Huntington's disease gene product in cell lines by immunofluorescence and biochemical subcellular fractionation. 1996 , 5, 1093-9	83

1616	Huntington's disease: confirmation of diagnosis and presymptomatic testing in Spanish families by genetic analysis. 1996 , 61, 625-7	6
1615	Solution structures of the individual single strands of the fragile X DNA triplets (GCC) _n .(GGC) _n . 1996 , 24, 784-92	71
1614	Relations between genotype and phenotype in German patients with the Machado-Joseph disease mutation. 1996 , 61, 466-70	56
1613	Huntington's disease predictive testing: the case for an assessment approach to requests from adolescents. 1996 , 33, 912-8	26
1612	Absence of disease phenotype and intergenerational stability of the CAG repeat in transgenic mice expressing the human Huntington disease transcript. 1996 , 5, 177-85	100
1611	Brain tissue banks in psychiatric and neurological research. 1996 , 49, 870-3	4
1610	Neuropsychological stability over two years in asymptomatic carriers of the Huntington's disease mutation. 1996 , 61, 621-4	49
1609	Interactions between wild-type and mutant prion proteins modulate neurodegeneration in transgenic mice. 1996 , 10, 1736-50	203
1608	Generation of a transcriptional map for a 700-kb region surrounding the polycystic kidney disease type 1 (PKD1) and tuberous sclerosis type 2 (TSC2) disease genes on human chromosome 16p3.3. 1996 , 6, 525-37	17
1607	Novel proteins with binding specificity for DNA CTG repeats and RNA CUG repeats: implications for myotonic dystrophy. 1996 , 5, 115-21	177
1606	Molecular Diagnosis of Genetic Diseases. 1996 ,	2
1605	Linkage of scapulo-peroneal spinal muscular atrophy to chromosome 12q24.1-q24.31. 1996 , 5, 1377-82	54
1604	Basal ganglia volume and proximity to onset in presymptomatic Huntington disease. 1996 , 53, 1293-6	177
1603	Intergenerational instability of the CAG repeat of the gene for Machado-Joseph disease (MJD1) is affected by the genotype of the normal chromosome: implications for the molecular mechanisms of the instability of the CAG repeat. 1996 , 5, 923-32	60
1602	Tourette's syndrome in the year 2000. 1996 , 30, 749-59	1
1601	Huntingtin is ubiquitinated and interacts with a specific ubiquitin-conjugating enzyme. 1996 , 271, 19385-94	263
1600	Sequence Analysis by Numbers: Proteins. 1996 , 35, 697-726	1
1599	Molecular basis of genetic instability of triplet repeats. 1996 , 271, 2875-8	241

1598	Characterization of the G protein-coupled receptor kinase GRK4. Identification of four splice variants. 1996 , 271, 6403-10	151
1597	Identification of trinucleotide repeat-containing genes in human pancreatic islets. 1996 , 45, 157-64	11
1596	Nucleosome assembly on CTG triplet repeats. 1996 , 271, 15222-9	82
1595	Motor changes in presymptomatic Huntington disease gene carriers. 1996 , 53, 487-92	69
1594	Neuropathological diagnosis and CAG repeat expansion in Huntington's disease. 1996 , 60, 78-81	26
1593	Trinucleotide repeat length and clinical progression in Huntington's disease. 1996 , 46, 527-31	131
1592	Human huntingtin derived from YAC transgenes compensates for loss of murine huntingtin by rescue of the embryonic lethal phenotype. 1996 , 5, 1875-85	77
1591	In vitro expansion of GGC:GCC repeats: identification of the preferred strand of expansion. 1996 , 24, 2835-40	37
1590	Late-onset Huntington's disease: a geriatric psychiatry perspective. 1996 , 9, 26-9	5
1589	Apoptosis in the heart. 1996 , 335, 1224-6	111
1588	ICD-9 code for palliative or terminal care. 1996 , 335, 1232-4	68
1587	DNA triplet repeats and neurologic disease. 1996 , 335, 1222-4	31
1586	Detection of unstable trinucleotide repeats. 1996 , 5, 37-62	2
1585	Aberrant processing of the Fugu HD (FrHD) mRNA in mouse cells and in transgenic mice. 1997 , 6, 2141-9	19
1584	A high-resolution physical and transcript map of the Cri du chat region of human chromosome 5p. 1997 , 7, 787-801	39
1583	[Genetic diagnosis, classification and clinical hereditary ataxia disease entities]. 1997 , 65, 79-89	1
1582	Structure of human chromosome 21--for an understanding of genetic diseases including Down's syndrome. 1997 , 61, 403-9	2
1581	Contribution of DNA sequence and CAG size to mutation frequencies of intermediate alleles for Huntington disease: evidence from single sperm analyses. 1997 , 6, 301-9	98

1580	Huntingtin-associated protein 1 (HAP1) interacts with the p150Glued subunit of dynactin. 1997 , 6, 2205-12	255
1579	Instability of normal (CTG) _n alleles in the DM kinase gene. 1997 , 34, 871-3	3
1578	Reduced penetrance of the Huntington's disease mutation. 1997 , 6, 775-9	122
1577	Analysis of the 5' upstream sequence of the Huntington's disease (HD) gene shows six new rare alleles which are unrelated to the age at onset of HD. 1997 , 34, 371-4	16
1576	Maternal transmission in sporadic Huntington's disease. 1997 , 62, 535-7	10
1575	Huntingtin-associated protein 1 (HAP1) binds to a Trio-like polypeptide, with a rac1 guanine nucleotide exchange factor domain. 1997 , 6, 1519-25	96
1574	CAG repeat expansion in autosomal dominant pure spastic paraplegia linked to chromosome 2p21-p24. 1997 , 6, 1811-6	64
1573	Decreased N-acetyl-aspartate/choline ratio and increased lactate in the frontal lobe of patients with Huntington's disease: a proton magnetic resonance spectroscopy study. 1997 , 62, 27-30	69
1572	Increased trinucleotide repeat instability with advanced maternal age. 1997 , 6, 2135-9	87
1571	Psychological distress in applicants for predictive DNA testing for autosomal dominant, heritable, late onset disorders. The Rotterdam/Leiden Genetics Workgroup. 1997 , 34, 382-90	60
1570	Trinucleotide repeats associated with human disease. 1997 , 25, 2245-54	260
1569	The preference for GT-rich DNA by the yeast Rad51 protein defines a set of universal pairing sequences. 1997 , 11, 3423-31	54
1568	Avoiding errors in the diagnosis of (CAG) _n expansion in the huntingtin gene. 1997 , 34, 264	7
1567	Spinocerebellar ataxia type 2. Genotype and phenotype in German kindreds. 1997 , 54, 1073-80	154
1566	Ocular changes in patients with spinocerebellar degeneration and repeated trinucleotide expansion of spinocerebellar ataxia type 1 gene. 1997 , 115, 231-6	47
1565	Clinical rationale of genetic testing in dementia. 1997 , 62, 217-21	8
1564	Preparing for presymptomatic DNA testing for early onset Alzheimer's disease/cerebral haemorrhage and hereditary Pick disease. 1997 , 34, 63-72	30
1563	HIP-I: a huntingtin interacting protein isolated by the yeast two-hybrid system. 1997 , 6, 487-95	298

1562	Sequence alignment with tandem duplication. 1997 , 4, 351-67	45
1561	Transgenic models of Huntington's disease. 1997 , 6, 1633-7	72
1560	Rethinking genotype and phenotype correlations in polyglutamine expansion disorders. 1997 , 6, 2005-10	116
1559	SH3 domain-dependent association of huntingtin with epidermal growth factor receptor signaling complexes. 1997 , 272, 8121-4	80
1558	Large intergenerational variation in age of onset in two young patients with Huntington's disease presenting as dyskinesia. 1997 , 100, 896-8	2
1557	Cognitive manifestations of Huntington disease in relation to genetic structure and clinical onset. 1997 , 54, 1081-8	55
1556	Biased mutations and microsatellite variation. 1997 , 14, 926-33	61
1555	Which diagnostic procedures in the elderly? The case of late-onset Huntington's disease. 1997 , 10, 39-46	7
1554	Genetic testing of children at risk for Huntington's disease. US Huntington Disease Genetic Testing Group. 1997 , 49, 1048-53	66
1553	Identification and chromosomal localization of human genes containing CAG/CTG repeats expressed in testis and brain. 1997 , 7, 705-15	15
1552	Finding disease genes. From cystic fibrosis to sarcoidosis. Thomas A. Neff Lecture. 1997 , 111, 70S-73S	3
1551	Trinucleotide Repeats in Transgenic Mice: New Insights. 1997 , 3, 273-275	1
1550	Huntington disease and the related disorder, dentatorubral-pallidoluysian atrophy (DRPLA). 1997 , 76, 305-38	80
1549	Temporal lobe magnetic resonance imaging can differentiate Alzheimer's disease from normal ageing, depression, vascular dementia and other causes of cognitive impairment. 1997 , 27, 1267-75	52
1548	Male infertility and the androgen receptor: molecular, clinical and therapeutic aspects. 1997 , 6, 113-131	6
1547	Fast transport and retrograde movement of huntingtin and HAP 1 in axons. 1997 , 8, 2247-51	124
1546	Biochemie und Molekulargenetik 1996. 1997 , 45, 166-178	
1545	Predictors of psychological adjustment to genetic testing for Huntington's disease.. 1997 , 16, 36-50	73

1544	Three-year follow-up after presymptomatic testing for Huntington's disease in tested individuals and partners.. 1997 , 16, 20-35	111
1543	Statistical issues in the search for genes affecting quantitative traits in experimental populations. 1997 , 12, 195	75
1542	Diagnostic molecular genetics. 1997 , 40, 103-17	
1541	Triplet repeat polymorphism in the transmembrane region of the MICA gene: a strong association of six GCT repetitions with Behçet disease. 1997 , 94, 1298-303	328
1540	BNaC1 and BNaC2 constitute a new family of human neuronal sodium channels related to degenerins and epithelial sodium channels. 1997 , 94, 1459-64	303
1539	Apoptosis in neurodegenerative diseases. 1997 , 41, 337-68	15
1538	Molecular methods in diagnostic pathology. 1997 , 169-195	
1537	Huntington's disease: psychiatric practice in molecular genetic prediction and diagnosis. 1997 , 170, 146-9	12
1536	Strategies to identify genes for complex diseases. 1997 , 29, 493-8	12
1535	A review of Huntington's disease. 1997 , 1, 135-40	3
1534	Social work and genetic testing: Ethical issues encountered in predictive testing for Huntington disease. 1997 , 50, 61-67	8
1533	Tourette syndrome. Secondary tic disorders. 1997 , 15, 309-31	55
1532	Modified method for the detection of the CAG repeat expansion in Huntington's disease and application to a predictive testing protocol. 1997 , 2, 53-59	1
1531	Psychological opportunities and hazards in predictive genetic testing for cancer risk. 1997 , 26, 19-39	15
1530	At physiological pH, d(CCG)15 forms a hairpin containing protonated cytosines and a distorted helix. 1997 , 36, 3687-99	72
1529	Huntington's disease. 1997 , 20, 791-807	36
1528	Few psychological consequences of presymptomatic testing for Huntington disease. 1997 , 349, 4	29
1527	The reduction of androgen receptor mRNA in motoneurons of X-linked spinal and bulbar muscular atrophy. 1997 , 150, 161-5	9

1526	Localization of dopamine receptors and associated mRNA in transplants of human fetal striatal tissue in rodents with experimental Huntington's disease. 1997 , 27, 305-15	12
1525	Genetic screening for Huntington's disease in Chinese patients with involuntary movements. 1997 , 99, 244-7	
1524	The number of triplet repeats in five brain-expressed loci with CAG repeats is not associated with schizophrenia. 1997 , 25, 111-6	8
1523	Machado-Joseph disease gene product identified in lymphocytes and brain. 1997 , 233, 476-9	37
1522	Cloning of novel trinucleotide-repeat (CAG) containing genes in mouse brain. 1997 , 240, 239-43	7
1521	Instability of regions containing expanded CAG repeats during replication in Escherichia coli probed by labeled oligonucleotides. 1997 , 240, 471-7	2
1520	Huntingtin immunoreactivity in the rat neostriatum: differential accumulation in projection and interneurons. 1997 , 144, 239-47	49
1519	Expression of NMDA receptor-1 (NR1) and huntingtin in striatal neurons which colocalize somatostatin, neuropeptide Y, and NADPH diaphorase: a double-label histochemical and immunohistochemical study. 1997 , 145, 412-24	19
1518	3-Nitropropionic acid neurotoxicity: visualization by silver staining and implications for use as an animal model of Huntington's disease. 1997 , 146, 212-29	37
1517	Effect of embryonic donor age and dissection on the DARPP-32 content of cell suspensions used for intrastriatal transplantation. 1997 , 148, 271-80	24
1516	Short tandem repeat typing by capillary array electrophoresis: comparison of sizing accuracy and precision using different buffer systems. 1997 , 41, 1-9	32
1515	A novel tandem repeat sequence located on human chromosome 4p: isolation and characterization. 1997 , 42, 278-83	41
1514	Identification and characterization of the human homologue of SH3BP2, an SH3 binding domain protein within a common region of deletion at 4p16.3 involved in bladder cancer. 1997 , 44, 163-70	31
1513	Cloning and characterization of a novel rho-type GTPase-activating protein gene (ARHGAP6) from the critical region for microphthalmia with linear skin defects. 1997 , 46, 268-77	41
1512	Mapping and characterization of novel (CAG) _n repeat cDNAs from adult human brain derived by the oligo capture method. 1997 , 46, 174-82	12
1511	Age at onset of ovarian cancer in women with a strong family history of ovarian cancer. 1997 , 66, 3-9	29
1510	Attenuation of gene expression by a trinucleotide repeat-rich tract from the terminal exon of the rat hepatic polymeric immunoglobulin receptor gene. 1997 , 267, 229-36	28
1509	Identification and characterization of genomic nucleosome-positioning sequences. 1997 , 267, 807-17	168

1508	Characterization of an expanded glutamine repeat androgen receptor in a neuronal cell culture system. 1997 , 3, 313-23		75
1507	Apolipoprotein E, a gene with complex biological interactions in the aging brain. 1997 , 4, 170-85		85
1506	The complex pathology of trinucleotide repeats. 1997 , 9, 364-72		160
1505	Juvenile Huntington disease in the Netherlands. 1997 , 17, 37-43		50
1504	Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. 1997 , 19, 333-44		747
1503	Improved polymerase chain reaction conditions for quick diagnostics of Huntington disease. 1997 , 2, 44-6		6
1502	The natural resistance-associated macrophage protein gene is associated with Crohn's disease. 1997 , 122, 173-8; discussion 178-9		69
1501	Ocular motor abnormalities in Huntington's disease. 1997 , 37, 3639-45		140
1500	Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. <i>Cell</i> , 1997 , 90, 537-48	56.2	1918
1499	Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. <i>Cell</i> , 1997 , 90, 549-58	56.2	1114
1498	Sodium/hydrogen exchanger gene defect in slow-wave epilepsy mutant mice. <i>Cell</i> , 1997 , 91, 139-48	56.2	234
1497	Conformational disease. 1997 , 350, 134-8		793
1496	Japanese families with autosomal dominant pure cerebellar ataxia map to chromosome 19p13.1-p13.2 and are strongly associated with mild CAG expansions in the spinocerebellar ataxia type 6 gene in chromosome 19p13.1. 1997 , 61, 336-46		127
1495	Risk reversals in predictive testing for Huntington disease. 1997 , 61, 945-52		28
1494	Fine-scale genetic mapping based on linkage disequilibrium: theory and applications. 1997 , 60, 1513-31		135
1493	Huntington's disease gene product, huntingtin, associates with microtubules in vitro. 1997 , 51, 8-14		49
1492	Differences and similarities between various tandem repeat sequences: minisatellites and microsatellites. 1997 , 79, 577-86		94
1491	Clinical presentation and patterns of regional cerebral atrophy related to the length of trinucleotide repeat expansion in patients with adult onset Huntington's disease. 1997 , 225, 45-8		12

1490	Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid. 1997 , 79, 45-56	133
1489	Glial cell line-derived neurotrophic factor attenuates the excitotoxin-induced behavioral and neurochemical deficits in a rodent model of Huntington's disease. 1997 , 81, 1099-110	74
1488	Glial cell line-derived neurotrophic factor attenuates the locomotor hypofunction and striatonigral neurochemical deficits induced by chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid. 1998 , 82, 117-27	29
1487	Protective effects of neurotrophin-4/5 and transforming growth factor-alpha on striatal neuronal phenotypic degeneration after excitotoxic lesioning with quinolinic acid. 1997 , 78, 73-86	45
1486	Cloning and characterization of the mouse tob gene. 1997 , 191, 109-13	21
1485	Human genetic diseases: a cross-talk between man and yeast. 1997 , 195, 1-10	155
1484	Complementary oligonucleotides and the origin of the mammalian involucrin gene. 1997 , 194, 87-95	
1483	Molecular cloning and expression of a novel human cDNA containing CAG repeats. 1997 , 204, 71-7	15
1482	Evolution of a homopurine-homopyrimidine pentanucleotide repeat sequence upstream of the human inducible nitric oxide synthase gene. 1997 , 204, 165-70	67
1481	Epilepsies with single gene inheritance. 1997 , 19, 13-8	37
1480	Improved electrophoretic separation of polymorphic short tandem repeats in agarose gels using bis-benzimide. 1997 , 23, 634-6	7
1479	Accurate Sizing of (CAG) _n Repeats Causing Huntington Disease by Fluorescent PCR. 1997 , 43, 2422-2423	13
1478	Analysis of a polyadenine tract of the transforming growth factor- β -type II receptor gene in colorectal cancers by non-gel-sieving capillary electrophoresis. 1997 , 43, 759-763	8
1477	The Genetic Defect Causing Huntington's Disease: Repeated in Other Contexts?. 1997 , 3, 238-246	54
1476	Purkinje cell expression of a mutant allele of SCA1 in transgenic mice leads to disparate effects on motor behaviors, followed by a progressive cerebellar dysfunction and histological alterations. 1997 , 17, 7385-95	233
1475	Screening for fragile X syndrome: information needs for health planners. 1997 , 4, 60-94	31
1474	Frequency of the different mutations causing spinocerebellar ataxia (SCA1, SCA2, MJD/SCA3 and DRPLA) in a large group of Brazilian patients. 1997 , 55, 519-29	29
1473	Huntington's disease: a challenge for our times. 1997 , 167, 463-464	

1472	Heterogeneous topographic and cellular distribution of huntingtin expression in the normal human neostriatum. 1997 , 17, 3052-63	131
1471	Cortical control of movement in Huntington's disease. A PET activation study. 1997 , 120 (Pt 9), 1569-78	61
1470	Detection of the mutation in facioscapulohumeral muscular dystrophy patients. 1997 , 39, 92-6	
1469	Psychological consequences of genetic testing for spinocerebellar ataxia in the Japanese. 1997 , 4, 593-600	9
1468	Senile chorea: a multicenter prospective study. 1997 , 95, 180-3	20
1467	Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel. 1997 , 15, 62-9	1440
1466	Hypermutable myotonic dystrophy CTG repeats in transgenic mice. 1997 , 15, 193-6	118
1465	Instability of highly expanded CAG repeats in mice transgenic for the Huntington's disease mutation. 1997 , 15, 197-200	275
1464	HIP1, a human homologue of <i>S. cerevisiae</i> Sla2p, interacts with membrane-associated huntingtin in the brain. 1997 , 16, 44-53	327
1463	Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion. 1997 , 17, 65-70	694
1462	Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion. 1997 , 17, 404-10	416
1461	Inherited neurodegenerative disorders caused by CAG/polyglutamine tract expansions: symposium introduction. 1997 , 7, 877-80	6
1460	The CAG/polyglutamine tract diseases: gene products and molecular pathogenesis. 1997 , 7, 927-42	101
1459	Trinucleotide repeat instability: genetic features and molecular mechanisms. 1997 , 7, 943-63	66
1458	Mouse models of human CAG repeat disorders. 1997 , 7, 965-77	19
1457	Toward understanding the molecular pathology of Huntington's disease. 1997 , 7, 979-1002	68
1456	Huntington's disease and dentatorubral-pallidoluysian atrophy: proteins, pathogenesis and pathology. 1997 , 7, 1003-16	57
1455	Gene table: adult and paediatric movement disorders. 1997 , 1, 189-90	3

1454	Conceptualizing genetic influences on early behavioral development. 1997 , 422, 54-9	4
1453	Transgenic animals as models of neurodegenerative diseases in humans. 1997 , 15, 320-5	13
1452	Neuropathology and Molecular Studies of a Patient with Tourette Syndrome and Huntington Disease. 1997 , 9, 255-263	
1451	Characterization of a cDNA containing trinucleotide repeat sequences that is highly enriched in spermatogenic cells. 1997 , 46, 476-81	3
1450	Huntington disease: advances in molecular and cell biology. 1997 , 20, 125-38	17
1449	Kennedy disease. 1997 , 20, 152-8	85
1448	Exon trapping and sequence-based methods of gene finding in transcript mapping of human 4p16.3. 1997 , 23, 413-27	3
1447	Rare microsatellite polymorphisms in the DNA repair genes XRCC1, XRCC3 and XRCC5 associated with cancer in patients of varying radiosensitivity. 1997 , 23, 237-47	61
1446	Identification of an HD patient with a (CAG)180 repeat expansion and the propagation of highly expanded CAG repeats in lambda phage. 1997 , 99, 692-5	52
1445	cDNAs with long CAG trinucleotide repeats from human brain. 1997 , 100, 114-22	78
1444	Studies of the CAG repeat in the Machado-Joseph disease gene in Taiwan. 1997 , 100, 155-62	18
1443	Advances in the genetics of movement disorders: implications for molecular diagnosis. 1997 , 244, 341-8	5
1442	Triplex DNA: fundamentals, advances, and potential applications for gene therapy. 1997 , 75, 267-82	215
1441	3-Nitropropionic acid animal model and Huntington's disease. 1997 , 21, 289-93	149
1440	Wolff Award 1997. Involvement of a Ca ²⁺ channel gene in familial hemiplegic migraine and migraine with and without aura. Dutch Migraine Genetics Research Group. 1997 , 37, 479-85	34
1439	Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. 1997 , 41, 160-5	371
1438	Machado-Joseph disease gene product is a cytoplasmic protein widely expressed in brain. 1997 , 41, 453-62	230
1437	Brain regional differences in the expansion of a CAG repeat in the spinocerebellar ataxias: dentatorubral-pallidoluysian atrophy, Machado-Joseph disease, and spinocerebellar ataxia type 1. 1997 , 41, 505-11	51

1436	Regional and cellular expression of the dentatorubral-pallidolusian atrophy gene in brains of normal and affected individuals. 1997 , 41, 599-605	13
1435	Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. 1997 , 41, 646-53	735
1434	Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease. 1997 , 42, 215-21	155
1433	Frataxin gene of Friedreich's ataxia is targeted to mitochondria. 1997 , 42, 265-9	109
1432	Huntingtin localization in brains of normal and Huntington's disease patients. 1997 , 42, 604-12	285
1431	Differential distribution of the normal and mutated forms of huntingtin in the human brain. 1997 , 42, 712-9	43
1430	Spinocerebellar ataxia type 6: CAG repeat expansion in alpha1A voltage-dependent calcium channel gene and clinical variations in Japanese population. 1997 , 42, 879-84	117
1429	Dentatorubral and pallidolusian atrophy (DRPLA). Clinical and neuropathological findings in genetically confirmed North American and European pedigrees. 1997 , 12, 519-30	87
1428	Concordance of common movement disorders among familial cases. 1997 , 12, 747-51	7
1427	Dominance and homozygosity. 1997 , 68, 412-6	41
1426	Analysis of the CAG repeats in the SCA1 and B37 genes in schizophrenic and bipolar I disorder patients: tentative association between B37 and schizophrenia. 1997 , 74, 324-30	8
1425	Long-term impact of Huntington disease linkage testing. 1997 , 70, 365-370	27
1424	Detection of CAG repeats using silver staining in patients with Huntington disease in Hungary. 1997 , 70, 448-9	5
1423	Evidence for genetic anticipation in the oculodentodigital syndrome. 1997 , 71, 36-41	28
1422	Questions and problems in direct predictive testing for Huntington's disease. 1997 , 71, 238-239	2
1421	Reactions to predictive testing in Huntington disease: case reports of coping with a new genetic status. 1997 , 73, 356-65	25
1420	Instability of the FMR2 trinucleotide repeat region associated with expanded FMR1 alleles. 1997 , 73, 447-55	10
1419	Grafts of EGF-responsive neural stem cells derived from GFAP-hNGF transgenic mice: trophic and tropic effects in a rodent model of Huntington's disease. 1997 , 387, 96-113	81

1418	The repeat expansion detection method in the analysis of diseases with CAG/CTG repeat expansion: usefulness and limitations. 1997 , 10, 486-8	9
1417	A new statistical test for age-of-onset anticipation: application to bipolar disorder. 1997 , 14, 1091-6	25
1416	Positional cloning: A review and perspective. 1997 , 41, 129-141	2
1415	The role of apoptosis in neurodegenerative diseases. 1998 , 13, 79-96	19
1414	Somatic mosaicism of the expanded CAG trinucleotide repeat in mRNAs for the responsible gene of Machado-Joseph disease (MJD), dentatorubral-pallidoluysian atrophy (DRPLA), and spinal and bulbar muscular atrophy (SBMA). 1998 , 23, 25-32	20
1413	Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins. 1998 , 24, 217-33	207
1412	An isoform of ataxin-3 accumulates in the nucleus of neuronal cells in affected brain regions of SCA3 patients. 1998 , 8, 669-79	157
1411	Transgenic models of neurodegeneration. Neurodegeneration: of (transgenic) mice and men. 1998 , 8, 695-7	11
1410	Transgenic mice in the study of polyglutamine repeat expansion diseases. 1998 , 8, 699-714	49
1409	Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. 1998 , 20, 198-202	360
1408	The characterization and sequence analysis of thirty CTG-repeat containing genomic cosmid clones. 1998 , 6, 89-94	11
1407	Transgenic models and subcellular pathology--do they tell us what goes wrong in Huntington's disease?. 1998 , 3, 192-5	3
1406	Applications of DNA chips for genomic analysis. 1998 , 3, 483-92	31
1405	DNA variation and the future of human genetics. 1998 , 16, 33-9	162
1404	Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch. 1998 , 18, 111-7	350
1403	Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. 1998 , 18, 150-4	423
1402	Predicting functions from protein sequences--where are the bottlenecks?. 1998 , 18, 313-8	277
1401	Neuronal grafts for Huntington's disease. 1998 , 4, 669-70	2

1400	Model of unequal chromosomal crossing over in DNA sequences. 1998 , 249, 594-599	17
1399	Protein precipitation: a common etiology in neurodegenerative disorders?. 1998 , 14, 396-402	134
1398	Striking changes in anxiety in Huntington's disease transgenic mice. 1998 , 805, 234-40	61
1397	Kinematic analysis of the reach to grasp movement in Parkinson's and Huntington's disease subjects. 1998 , 36, 1203-8	36
1396	Advances in the understanding of early Huntington's disease using the functional imaging techniques of PET and SPET. 1998 , 4, 532-9	33
1395	The androgen receptor CAG repeat polymorphism and its relationship to prostate cancer. 1998 , 1378, C1-5	8
1394	Huntington's disease. 1998 , 8, R672	
1393	Association of obsessive-compulsive disorder and pathological gambling with Huntington's disease in an Italian pedigree: possible association with Huntington's disease mutation. 1998 , 97, 62-5	30
1392	Comparison of expanded CAG repeat tracts in sperm and lymphocyte DNA from Machado Joseph disease and spinocerebellar ataxia type I patients. 1998 , Suppl 1, S74-7	1
1391	Progressive atrophy of cerebellum and brainstem as a function of age and the size of the expanded CAG repeats in the MJD1 gene in Machado-Joseph disease. 1998 , 43, 288-96	64
1390	Complex I defect in muscle from patients with Huntington's disease. 1998 , 43, 397-400	130
1389	Stiff-leg syndrome: a focal form of stiff-man syndrome. 1998 , 43, 400-3	44
1388	Nuclear inclusions of the androgen receptor protein in spinal and bulbar muscular atrophy. 1998 , 44, 249-54	308
1387	Relation between microsatellite instability and N-ras mutation and duration of disease free survival in patients with acute leukemia. 1998 , 83, 475-481	6
1386	Preimplantation diagnosis for Huntington's disease (HD): clinical application and analysis of the HD expansion in affected embryos. 1998 , 18, 1427-36	99
1385	Molecular aspects of Huntington's disease. 1998 , 54, 301-8	46
1384	Distress in individuals facing predictive DNA testing for autosomal dominant late-onset disorders: comparing questionnaire results with in-depth interviews. Rotterdam/Leiden Genetics Workgroup. 1998 , 75, 62-74	48
1383	Analysis of SCA1, DRPLA, MJD, SCA2, and SCA6 CAG repeats in 48 Portuguese ataxia families. 1998 , 81, 134-8	40

1382	Different behavior in the paternally vs. maternally inherited mutated allele in Brazilian Machado-Joseph (MJD1) Families. 1998 , 77, 246-248	11
1381	Somatic mosaicism of the CAG repeat expansion in spinocerebellar ataxia type 3/Machado-Joseph disease. 1998 , 11, 23-7	46
1380	Subtle involuntary movements are not reliable indicators of incipient Huntington's disease. 1998 , 13, 96-9	28
1379	Huntington's disease confirmed by genetic testing in five African families. 1998 , 13, 726-30	13
1378	Unified Huntington's disease rating scale: a follow up. 1998 , 13, 915-9	89
1377	Neurophysiological abnormalities in the Westphal variant of Huntington's disease. 1998 , 13, 920-8	14
1376	The genetics of Parkinson's disease and parkinsonian syndromes. 1998 , 245, 625-33	7
1375	Predictive testing for Huntington's disease: ten years' experience in two Italian centres. 1998 , 19, 68-74	20
1374	A general multilocus two-allele model for epistatic selection. 1998 , 77, 115-121	1
1373	Gene structure and map location of the murine homolog of the Huntington-associated protein, Hap1. 1998 , 9, 565-70	21
1372	[Clinical value of positron emission tomography in neuromedicine. Position paper on results of an interdisciplinary consensus conference]. 1998 , 69, 1045-60	31
1371	The expression of Huntingtin-associated protein (HAP1) mRNA in developing, adult and ageing rat CNS: implications for Huntington's disease neuropathology. 1998 , 10, 1835-45	35
1370	Long-term effect of a single dose of flunarizine in Huntington's disease. 1998 , 5, 249-253	1
1369	Spinocerebellar ataxia type 6: CAG trinucleotide expansion, clinical characteristics and sperm analysis. 1998 , 5, 381-387	9
1368	Six new cosmid derived and physically mapped equine dinucleotide repeat microsatellites. 1998 , 29, 236-8	1
1367	Approaches to meta analysis in genetic disorders. 1998 , 28 Suppl 1, 106-7; discussion 108-10	2
1366	Predictive testing for Huntington's disease: a challenge for persons at risk and for professionals. 1998 , 35, 15-26	88
1365	Characterization of the Huntington's disease (HD) gene homologue in the zebrafish <i>Danio rerio</i> . 1998 , 217, 117-25	67

1364	Molecular cloning and characterization of a human brain-specific gene implicated in neuronal differentiation. 1998 , 54, 113-23	8
1363	Reversible Huntington's disease?. 1998 , 352, 1520-1	6
1362	Are neuronal intranuclear inclusions the common neuropathology of triplet-repeat disorders with polyglutamine-repeat expansions?. 1998 , 351, 131-3	163
1361	Increased peripheral benzodiazepine binding sites in the brain of patients with Huntington's disease. 1998 , 241, 53-6	84
1360	Trinucleotide (CAG) repeat length is positively correlated with the degree of DNA fragmentation in Huntington's disease striatum. 1998 , 87, 49-53	82
1359	No change in striatal glutamate in Huntington's disease measured by proton magnetic resonance spectroscopy. 1998 , 4, 123-7	8
1358	Trinucleotide repeat length variation in the human ribosomal protein L14 gene (RPL14): localization to 3p21.3 and loss of heterozygosity in lung and oral cancers. 1998 , 406, 9-23	12
1357	Huntingtin: a single bait hooks many species. 1998 , 8, 425-30	64
1356	Filamentous nerve cell inclusions in neurodegenerative diseases. 1998 , 8, 619-32	233
1355	Transglutaminase action imitates Huntington's disease: selective polymerization of Huntingtin containing expanded polyglutamine. 1998 , 1, 595-601	174
1354	SH3GL3 associates with the Huntingtin exon 1 protein and promotes the formation of polyglu-containing protein aggregates. 1998 , 2, 427-36	189
1353	Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons. 1998 , 21, 633-42	429
1352	Molecular neurobiology and genetics: investigation of neural function and dysfunction. 1998 , 20, 427-44	30
1351	Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. <i>Cell</i> , 1998 , 95, 41-53	56.2 898
1350	Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. <i>Cell</i> , 1998 , 95, 55-66	56.2 1375
1349	Laboratory Guidelines for Huntington Disease Genetic Testing. 1998 , 62, 1243-1247	166
1348	Close associations between prevalences of dominantly inherited spinocerebellar ataxias with CAG-repeat expansions and frequencies of large normal CAG alleles in Japanese and Caucasian populations. 1998 , 63, 1060-6	187
1347	A Huntington disease-like neurodegenerative disorder maps to chromosome 20p. 1998 , 63, 1431-8	55

1346	Genetic classification of primary neurodegenerative disease. 1998 , 282, 1075-9	244
1345	De nouveaux outils pour façonner le gène de la souris. 1998 , 9, 337-343	
1344	Genomic features of human PKR: alternative splicing and a polymorphic CCG repeat in the 5'-untranslated region. 1998 , 18, 609-16	11
1343	Huntington disease: clinical, genetic, and social aspects. 1998 , 11, 61-70	30
1342	Understanding developmental psychopathology: how useful are evolutionary accounts?. 1998 , 37, 1011-21	65
1341	Ubiquitin and the Biology of the Cell. 1998 ,	32
1340	Solution structures of the Huntington's disease DNA triplets, (CAG) _n . 1998 , 15, 723-44	28
1339	An algorithm for finding tandem repeats of unspecified pattern size. 1998 ,	9
1338	Tissue transglutaminase-catalyzed formation of high-molecular-weight aggregates in vitro is favored with long polyglutamine domains: a possible mechanism contributing to CAG-triplet diseases. 1998 , 352, 314-21	100
1337	Caspase-3 cleaves the expanded androgen receptor protein of spinal and bulbar muscular atrophy in a polyglutamine repeat length-dependent manner. 1998 , 252, 145-50	65
1336	Huntingtin protein colocalizes with lesions of neurodegenerative diseases: An investigation in Huntington's, Alzheimer's, and Pick's diseases. 1998 , 150, 213-22	57
1335	Wild-type and mutant huntingtins function in vesicle trafficking in the secretory and endocytic pathways. 1998 , 152, 34-40	223
1334	Regional specificity of brain atrophy in Huntington's disease. 1998 , 154, 663-72	175
1333	Identification and characterization of a novel RING-finger gene (RNF4) mapping at 4p16.3. 1998 , 47, 258-65	24
1332	Genomic structure of the human gene for spinocerebellar ataxia type 2 (SCA2) on chromosome 12q24.1. 1998 , 47, 359-64	28
1331	A novel long and unstable CAG/CTG trinucleotide repeat on chromosome 17q. 1998 , 49, 321-6	39
1330	Transcript mapping of the human chromosome 11q12-q13.1 gene-rich region identifies several newly described conserved genes. 1998 , 49, 419-29	15
1329	Cloning, characterization, and the complete 56.8-kilobase DNA sequence of the human NOTCH4 gene. 1998 , 51, 45-58	44

1328	Transcript map of a 900-kb genomic region in Xp22.1-p22.2: identification of 12 novel genes. 1998 , 51, 59-67	8
1327	Cloning and mapping of ZNF231, a novel brain-specific gene encoding neuronal double zinc finger protein whose expression is enhanced in a neurodegenerative disorder, multiple system atrophy (MSA). 1998 , 54, 50-8	29
1326	Characterization of the mouse Src homology 3 domain gene Sh3d2c on Chr 7 demonstrates coexpression with huntingtin in the brain and identifies the processed pseudogene Sh3d2c-ps1 on Chr 2. 1998 , 54, 505-10	11
1325	Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length. 1998 , 4, 387-97	373
1324	Neuronal death in cultured murine cortical cells is induced by inhibition of GAPDH and triosephosphate isomerase. 1998 , 5, 47-54	41
1323	Heterogeneous intracellular localization and expression of ataxin-3. 1998 , 5, 335-47	84
1322	Nonneural nuclear inclusions of androgen receptor protein in spinal and bulbar muscular atrophy. 1998 , 153, 695-701	119
1321	SCA6 mutation analysis in a large cohort of the Japanese patients with late-onset pure cerebellar ataxia. 1998 , 156, 89-95	49
1320	Analysis of spinocerebellar ataxia type 2 in Gunma Prefecture in Japan: CAG trinucleotide expansion and clinical characteristics. 1998 , 156, 180-5	11
1319	Clinical and molecular genetic study in seven Japanese families with spinocerebellar ataxia type 6. 1998 , 157, 52-9	30
1318	A Japanese family with spinocerebellar ataxia type 6 which includes three individuals homozygous for an expanded CAG repeat in the SCA6/CACNL1A4 gene. 1998 , 158, 141-7	35
1317	Phenotype variation correlates with CAG repeat length in SCA2--a study of 28 Japanese patients. 1998 , 159, 202-8	38
1316	Genetic neurodegenerative diseases: the human illness and transgenic models. 1998 , 282, 1079-83	196
1315	Activated immune system in patients with Huntington's disease. 1998 , 36, 747-50	57
1314	CAG repeat expansion in autosomal dominant familial spastic paraparesis: novel expansion in a subset of patients. 1998 , 7, 1779-86	25
1313	Expression of polyglutamine-expanded Huntingtin activates the SEK1-JNK pathway and induces apoptosis in a hippocampal neuronal cell line. 1998 , 273, 28873-7	100
1312	Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. 1998 , 7, 783-90	269
1311	Predicting adaptation to presymptomatic DNA testing for late onset disorders: who will experience distress? Rotterdam Leiden Genetics Workgroup. 1998 , 35, 745-54	55

1310	Aggregation of N-terminal huntingtin is dependent on the length of its glutamine repeats. 1998 , 7, 777-82	121
1309	Expansions of CAG repeat tracts are frequent in a yeast mutant defective in Okazaki fragment maturation. 1998 , 7, 69-74	161
1308	Spinocerebellar ataxia type 7 (SCA7): a neurodegenerative disorder with neuronal intranuclear inclusions. 1998 , 7, 913-8	249
1307	Trinucleotide repeats and human diseases. 1998 , 5, 487-496	
1306	Comparative analysis of mammalian stanniocalcin genes. 1998 , 139, 4714-25	123
1305	Crime in Huntington's disease: a study of registered offences among patients, relatives, and controls. 1998 , 65, 467-71	43
1304	Xlandscape: the graphical display of word frequencies in sequences. 1998 , 14, 74-80	13
1303	On the distribution of k-tuple matches for sequence homology: a constant time exact calculation of the variance. 1998 , 5, 87-100	10
1302	The prion diseases: Creutzfeldt-Jakob, Gerstmann-Strüssler-Scheinker, and related disorders. 1998 , 11, 78-97	13
1301	A novel multiple PDZ domain-containing molecule interacting with N-methyl-D-aspartate receptors and neuronal cell adhesion proteins. 1998 , 273, 21105-10	243
1300	Genetic counseling: clinical and ethical challenges. 1998 , 32, 547-59	27
1299	Patients with features similar to Huntington's disease, without CAG expansion in huntingtin. 1998 , 51, 215-20	26
1298	Evidence for genetic anticipation in nodal osteoarthritis. 1998 , 57, 524-6	17
1297	Larger CAG expansions in skeletal muscle compared with lymphocytes in Kennedy disease but not in Huntington disease. 1998 , 51, 1442-4	16
1296	Genetic polymorphisms adjacent to the CAG repeat influence clinical features at onset in Huntington's disease. 1998 , 64, 758-62	36
1295	Abnormal properties of prion protein with insertional mutations in different cell types. 1998 , 273, 11980-5	71
1294	A human HAP1 homologue. Cloning, expression, and interaction with huntingtin. 1998 , 273, 19220-7	49
1293	Huntingtin interacts with cystathionine beta-synthase. 1998 , 7, 371-8	64

1292	Huntingtin interacts with a family of WW domain proteins. 1998 , 7, 1463-74	288
1291	Detection of polymorphic triplet repeats in the genomes of patients suffering from bipolar affective disorder. 1998 , 1, 989-93	
1290	Treatment of the psychiatric manifestations of Huntington's disease: a review of the literature. 1998 , 43, 933-40	24
1289	Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. 1998 , 95, 6480-5	45 ^o
1288	Simple nonisotopic assays for detection of (CAG) _n repeats expansions associated with seven neurodegenerative disorders. 1998 , 7, 174-9	7
1287	Anticipation of age at onset in panic disorder. 1998 , 155, 590-5	27
1286	Huntingtin aggregation monitored by dynamic light scattering. 1998 , 95, 6118-21	55
1285	Vitamin E Status and Neurodegenerative Disease. 1998 , 1, 327-51	7
1284	Androgen receptor polymorphisms (CAG repeat lengths) in androgenetic alopecia, hirsutism, and acne. 1998 , 3, 9-15	159
1283	Neuronal distribution of intranuclear inclusions in Huntington's disease with adult onset. 1998 , 9, 1823-6	54
1282	Neurodegeneration and glutamate induced oxidative stress. 1998 , 116, 245-63	21
1281	When does Huntington's disease begin?. 1998 , 4, 467-73	51
1280	Atypical rigid form of Huntington's disease: a case with peripheral amyotrophy and congenital defects of a lower limb. 1998 , 37, 978-81	1
1279	Interaction of huntingtin-associated protein with dynactin P150Glued. 1998 , 18, 1261-9	234
1278	Genetic Disorders. 1998 , 409-426	
1277	Positron Emission Tomography Studies in Movement Disorders. 1998 , 9, 263-282	12
1276	Divining and Altering the Future: Implications From the Human Genome Project. 1998 , 280, 1532	1
1275	Prescription for Prophecy: Confronting the Ambiguity of Susceptibility Testing. 1998 , 280, 1535	

1274 In the Same Boat. **1998**, 280, 1537

1273 MS/JAMA CoverDivining and Altering the Future: Implications From the Human Genome ProjectGenetics in the Context of Medical PracticePrescription for Prophecy: Confronting the Ambiguity of Susceptibility TestingIn the Same BoatIndecision. **1998**, 280, 1532

1272 Fusion of Huntingtin Interacting Protein 1 to Platelet-Derived Growth Factor [Receptor (PDGFR) in Chronic Myelomonocytic Leukemia With t(5;7)(q33;q11.2). **1998**, 91, 4419-4426 158

1271 The role of memory assessment in the preclinical detection of dementia. **1998**, 278-289 2

1270 Clinical differentiation of memory disorders in neurodegenerative disease. **1998**, 290-313 2

1269 Genetics in the Context of Medical Practice. **1998**, 280, 1533 8

1268 Multivariate analysis of factors influencing repeat expansion detection. **1998**, 8, 1085-94 9

1267 Indecision. **1998**, 280, 1538

1266 Molecular genetic characterisation of frontotemporal dementia on chromosome 3. **1999**, 10 Suppl 1, 93-101 34

1265 Mutant huntingtin expression in clonal striatal cells: dissociation of inclusion formation and neuronal survival by caspase inhibition. **1999**, 19, 964-73 263

1264 Molecular Genetics of von Willebrand Disease. **1999**, 82, 585-591 34

1263 Expression of the Huntington's disease gene is regulated in astrocytes in the arcuate nucleus of the hypothalamus of postpartum rats. **1999**, 13, 1099-106 28

1262 Linkage disequilibrium and haplotype analysis in German Friedreich ataxia families. **1999**, 49, 90-6 7

1261 Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. **1999**, 19, 3248-57 784

1260 Cellular localization of huntingtin in striatal and cortical neurons in rats: lack of correlation with neuronal vulnerability in Huntington's disease. **1999**, 19, 1189-202 153

1259 Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. **1999**, 19, 2522-34 697

1258 Introduction to Parkinson's and Huntington's Disease. **1999**, 295-298 2

1257 DNA Microarrays for Polymorphism Detection and Genotyping: Utility in the Understanding of Complex Neuropsychiatric Diseases. **1999**, 4, 59-74 1

- 1256 Huntingtin Localization In Rat Cortex And Striatum. **1999**, 5, 1298-1299
- 1255 References. **1999**, 345-385
- 1254 Structural basis for triplet repeat disorders: a computational analysis. **1999**, 15, 918-29 23
- 1253 Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease. **1999**, 122 (Pt 9), 1667-78 121
- 1252 Huntington's disease progression. PET and clinical observations. **1999**, 122 (Pt 12), 2353-63 181
- 1251 Demenz bei neurodegenerativen Erkrankungen. **1999**, 26, 243-249
- 1250 Androgen receptor-mediated hypersensitivity to androgens in women with nonhyperandrogenic hirsutism: skewing of X-chromosome inactivation. **1999**, 84, 1091-5 71
- 1249 Detection of microsatellite instability in cancers by means of nongel-sieving capillary electrophoresis. **1999**, 27, 139-52
- 1248 Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial. **1999**, 53, 1000-11 134
- 1247 Recent insights into the molecular pathogenesis of Huntington disease. **1999**, 19, 385-95 40
- 1246 Expanded repeat sequences and disease. **1999**, 19, 289-99 21
- 1245 Preliminary evidence for anticipation in genetic E200K Creutzfeldt-Jakob disease. **1999**, 53, 1328-9 15
- 1244 Chapter 2 The Biology of Trinucleotide Repeat Disorders. **1999**, 33-79
- 1243 DNA analysis of Huntington's disease: five years of experience in Germany, Austria, and Switzerland. **1999**, 53, 801-6 64
- 1242 Impairments of attention after cingulotomy. **1999**, 53, 819-24 150
- 1241 Abundant expression and cytoplasmic aggregations of [alpha]1A voltage-dependent calcium channel protein associated with neurodegeneration in spinocerebellar ataxia type 6. **1999**, 8, 1185-93 140
- 1240 Differences in duration of Huntington's disease based on age at onset. **1999**, 66, 52-6 144
- 1239 Arteriovenous malformation of the cervical cord. **1999**, 53, 812-812 0

1238	A putative <i>Drosophila</i> homolog of the Huntington's disease gene. 1999 , 8, 1807-15	59
1237	Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse. 1999 , 8, 115-22	277
1236	Cleavage of atrophin-1 at caspase site aspartic acid 109 modulates cytotoxicity. 1999 , 274, 8730-6	90
1235	Nuclear localization of the spinocerebellar ataxia type 7 protein, ataxin-7. 1999 , 8, 1657-64	88
1234	Chemical architecture of the basal ganglia. 1999 , 227-284	13
1233	Sympathetic skin response and heart rate variability in patients with Huntington disease. 1999 , 56, 1248-52	48
1232	Trinucleotide Repeats, Genetic Instability and Variation in the Human Genome. 1999 , 53-64	1
1231	Transgenic mice harboring a full-length human mutant DRPLA gene exhibit age-dependent intergenerational and somatic instabilities of CAG repeats comparable with those in DRPLA patients. 1999 , 8, 99-106	86
1230	Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin. 1999 , 8, 1647-55	242
1229	Clinical correlation of striatal 1H MRS changes in Huntington's disease. 1999 , 53, 806-12	100
1228	How many patients with pseudoseizures receive antiepileptic drugs prior to diagnosis?. 1999 , 41, 114-5	47
1227	Extended hemorrhagic infarction following isolated cortical venous thrombosis. 1999 , 41, 115-6	11
1226	Prolonged coma after continuous sedation with propofol. 1999 , 41, 116-7	7
1225	Isolated episodic lingual myoclonus. 1999 , 41, 118-9	16
1224	A patient with Huntington's disease presenting with laryngeal chorea. 1999 , 41, 119-20	12
1223	A Huntington's disease CAG expansion at the murine <i>Hdh</i> locus is unstable and associated with behavioural abnormalities in mice. 1999 , 8, 763-74	232
1222	Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells. 1999 , 96, 11404-9	395
1221	Analysis of CAG repeat expansion in Huntington's disease gene (IT 15) in a Hungarian population. 1999 , 41, 107-10	9

1220	Trinucleotide repeat expansion and neuropsychiatric disease. 1999 , 56, 1019-31	74
1219	Clinical Applications of Capillary Electrophoresis. 1999 ,	3
1218	Clustering of identical oligomers in coding and noncoding DNA sequences. 1999 , 17, 79-87	7
1217	Psychological issues in genetic testing for breast cancer. 1999 , 28, 73-91	9
1216	Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology. 1999 , 96, 4604-9	584
1215	A neurological disease caused by an expanded CAG trinucleotide repeat in the TATA-binding protein gene: a new polyglutamine disease?. 1999 , 8, 2047-53	277
1214	Polyglutamine-mediated dysfunction and apoptotic death of a <i>Caenorhabditis elegans</i> sensory neuron. 1999 , 96, 179-84	257
1213	The education of a brain transplant. 1999 , 96, 9976-8	3
1212	Bioactive agents from natural sources: trends in discovery and application. 1999 , 64, 101-54	49
1211	Transforming properties of the Huntingtin interacting protein 1/ platelet-derived growth factor beta receptor fusion protein. 1999 , 274, 22328-36	53
1210	The GRK4 subfamily of G protein-coupled receptor kinases. Alternative splicing, gene organization, and sequence conservation. 1999 , 274, 29381-9	59
1209	Tandem repeats finder: a program to analyze DNA sequences. 1999 , 27, 573-80	4750
1208	Antiplatelet treatment does not reduce the severity of subsequent stroke. European Stroke Prevention Study 2 Working Group. 1999 , 53, 825-9	33
1207	Lens epithelial changes and mutated gene expression in patients with myotonic dystrophy. 1999 , 83, 452-7	15
1206	Accurate determination of the number of CAG repeats in the Huntington disease gene using a sequence-specific internal DNA standard. 1999 , 55, 198-202	24
1205	Distribution of histamine H3-receptor binding in the normal human basal ganglia: comparison with Huntington's and Parkinson's disease cases. 1999 , 11, 449-56	58
1204	Clinical and molecular analysis of 11 Sicilian SCA2 families: influence of gender on age at onset. 1999 , 6, 301-7	29
1203	Kennedy's disease: caspase cleavage of the androgen receptor is a crucial event in cytotoxicity. 1999 , 72, 185-95	173

1202	Life without huntingtin: normal differentiation into functional neurons. 1999 , 72, 1009-18	33
1201	3-Nitropropionic acid induces a spectrum of Huntington's disease-like neuropathology in rat striatum. 1999 , 25, 513-21	51
1200	The evaluation of the 'stages of change' model for use in counselling client's undergoing predictive testing for Huntington's disease. 1999 , 29, 1137-43	8
1199	Where's this thing in our family? predictive testing and the construction of risk for Huntington Disease. 1999 , 21, 622-646	109
1198	Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. 1999 , 399, 263-7	550
1197	In vivo cell sorting in complementary segmental domains mediated by Eph receptors and ephrins. 1999 , 399, 267-71	385
1196	A non-familial Huntington's disease patient with grumose degeneration in the dentate nucleus. 1999 , 99, 322-6	2
1195	Bioenergetics in Huntington's disease. 1999 , 893, 203-13	89
1194	Genetics session: the human genome. Prognostications and predispositions. 1999 , 882, 22-31; discussion 56-65	
1193	Adults seeking presymptomatic gene testing for Huntington disease. 1999 , 31, 109-14	25
1192	Resequencing and mutational analysis using oligonucleotide microarrays. 1999 , 21, 42-7	427
1191	Msh2 deficiency prevents in vivo somatic instability of the CAG repeat in Huntington disease transgenic mice. 1999 , 23, 471-3	313
1190	A European pilot quality assessment scheme for molecular diagnosis of Huntington's disease. 1999 , 7, 217-22	26
1189	No evidence to support the association of the potassium channel gene hSKCa3 CAG repeat with schizophrenia or bipolar disorder in the Irish population. 1999 , 4, 488-91	25
1188	Structure of the murine E-selectin ligand 1 (ESL-1) gene and assignment to Chromosome 8. 1999 , 10, 1085-8	5
1187	Clinical deficits in Huntington disease correlate with reduced striatal uptake on iodine-123 epidepride single-photon emission tomography. 1999 , 26, 1458-64	7
1186	Chorea Huntington Tiermodelle eröffnen neue Hypothesen zu Pathophysiologie und Therapie. 1999 , 70, 878-888	
1185	Crohn's disease-associated genetic marker is seen in medically unresponsive ulcerative colitis patients and may be associated with pouch-specific complications. 1999 , 42, 601-5; discussion 605-6	21

1184	The early cellular pathology of Huntington's disease. 1999 , 20, 111-24	32
1183	Acute and chronic changes in kynurenate formation following an intrastriatal quinolinate injection in rats. 1999 , 106, 229-42	31
1182	Correlation between triplet repeat expansion and computed tomography measures of caudate nuclei atrophy in Huntington's disease. 1999 , 246, 1090-3	11
1181	Isolation of CAG/CTG repeats from within the chromosome 2p21-p24 locus for autosomal dominant spastic paraplegia (SPG4) by YAC fragmentation. 1999 , 105, 217-25	3
1180	DGGE screening of PKD1 gene reveals novel mutations in a large cohort of 146 unrelated patients. 1999 , 105, 231-9	25
1179	The role of excitotoxicity in neurodegenerative disease: implications for therapy. 1999 , 81, 163-221	593
1178	Clinical characteristics of bipolar disorder subjects with large CAG/CTG repeat DNA. 1999 , 55, 221-4	3
1177	The genetics of complex diseases. 1999 , 15, M17-M20	9
1176	Predictive and prenatal diagnosis of Huntington's disease: attitudes of Mexican neurologists, psychiatrists, and psychologists. 1999 , 30, 320-4	4
1175	Neuronal degeneration in the basal ganglia and loss of pallido-subthalamic synapses in mice with targeted disruption of the Huntington's disease gene. 1999 , 818, 468-79	65
1174	Instability of the CAG repeat in immortalized fibroblast cell cultures from Huntington's disease transgenic mice. 1999 , 835, 74-9	31
1173	Cytoplasmic dynein and dynactin in cell division and intracellular transport. 1999 , 11, 45-53	392
1172	The genetics of complex diseases. 1999 , 9, M17-M20	12
1171	Glutamine repeats and neurodegenerative diseases: molecular aspects. 1999 , 24, 58-63	367
1170	The FF domain: a novel motif that often accompanies WW domains. 1999 , 24, 264-5	63
1169	The genetics of complex diseases. 1999 , 24, M17-M20	3
1168	Differential sequencing with mass spectrometry. 1999 , 14, 215-9	13
1167	Adult and paediatric movement disorders. 1999 , 3, 39-41	

1166	Expression of ataxin-2 in brains from normal individuals and patients with Alzheimer's disease and spinocerebellar ataxia 2. 1999 , 45, 232-41	147
1165	Sequence-specific cleavage of Huntingtin mRNA by catalytic DNA. 1999 , 46, 366-73	58
1164	Huntingtin aggregates may not predict neuronal death in Huntington's disease. 1999 , 46, 842-849	309
1163	Differential clinical and motor control function in a pair of monozygotic twins with Huntington's disease. 1999 , 14, 320-5	72
1162	Choreic movements and MRI abnormalities in the subthalamic nuclei reversible after administration of coenzyme Q10 and multiple vitamins in a patient with bilateral optic neuropathy. 1999 , 14, 855-9	12
1161	A novel PCR-based approach for the detection of the Huntington disease associated trinucleotide repeat expansion. 1999 , 13, 232-6	7
1160	Fieller's theorem and linkage disequilibrium mapping. 1999 , 17, 237-52	16
1159	Significantly lower incidence of cancer among patients with Huntington disease. 1999 , 86, 1342-1346	87
1158	Experience in prenatal testing for Huntington's disease in The Netherlands: procedures, results and guidelines (1987-1997). 1999 , 19, 450-457	33
1157	Accurate characterization of the tyrosine hydroxylase forensic allele 9.3 through development of electrospray ionization Fourier transform ion cyclotron resonance mass spectrometry. 1999 , 13, 954-62	36
1156	Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. 1999 , 58, 515-532	249
1155	Genetic anticipation in a large family with pure autosomal dominant hereditary spastic paraplegia. 1999 , 83, 392-396	6
1154	Trinucleotide repeat polymorphism at five disease loci in mixed Hungarian population. 1999 , 87, 245-250	7
1153	Predictive testing of 25 percent at-risk individuals for Huntington disease (1987-1997). 1999 , 88, 662-8	19
1152	Anticipation in schizophrenia: a review and reconsideration. 1999 , 88, 686-93	19
1151	Analysis of huntingtin-associated protein 1 in mouse brain and immortalized striatal neurons. 1999 , 403, 421-430	40
1150	The impact of genomics on mammalian neurobiology. 1999 , 21, 157-63	6
1149	Membrane filter assay for detection of amyloid-like polyglutamine-containing protein aggregates. 1999 , 309, 375-86	193

1148	Molecular basis of the neurodegenerative disorders. 1999 , 340, 1970-80	330
1147	Goals and objectives for molecular pathology education in residency programs. The Association for Molecular Pathology Training and Education Committee. 1999 , 1, 5-15	16
1146	Brain-derived neurotrophic factor-mediated protection of striatal neurons in an excitotoxic rat model of Huntington's disease, as demonstrated by adenoviral gene transfer. 1999 , 10, 2987-97	152
1145	Huntington's Disease. 1999 , 11, 105-123	6
1144	Disease Modifying Agents for Huntington's Disease. 1999 , 12, 383-389	
1143	Isolation and characterization of novel CAG repeat containing genes expressed in human brain. 1999 , 10, 1-6	5
1142	Synthesis of 2'-beta-Deoxy-[8-(13)C;amino,9-(15)N(2)]adenosine: Unusual Annulation Conditions To Assemble the Purine Core. 1999 , 64, 4685-4689	6
1141	Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. 1999 , 96, 8727-32	200
1140	Two novel single-base-pair substitutions adjacent to the CAG repeat in the huntington disease gene (IT15): implications for diagnostic testing. 1999 , 64, 323-6	19
1139	A worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric hospitalization after predictive testing for Huntington disease. 1999 , 64, 1293-304	214
1138	Patterns of instability of expanded CAG repeats at the ERDA1 locus in general populations. 1999 , 65, 192-8	17
1137	Tissue-specific somatic mosaicism in spinal and bulbar muscular atrophy is dependent on CAG-repeat length and androgen receptor--gene expression level. 1999 , 65, 966-73	61
1136	Mutation rates in humans. II. Sporadic mutation-specific rates and rate of detrimental human mutations inferred from hemophilia B. 1999 , 65, 1580-7	54
1135	Forskolin and dopamine D1 receptor activation increase huntingtin's association with endosomes in immortalized neuronal cells of striatal origin. 1999 , 89, 1159-67	43
1134	Coronary heart disease. At the interface of molecular genetics and preventive medicine. 1999 , 16, 122-33	28
1133	Chemical and anatomical changes in the striatum and substantia nigra following quinolinic acid lesions in the striatum of the rat: a detailed time course of the cellular and GABA(A) receptor changes. 1999 , 17, 75-97	27
1132	Localization of huntingtin-interacting protein-2 (Hip-2) mRNA in the developing mouse brain. 1999 , 17, 99-107	8
1131	Caspase-8 is required for cell death induced by expanded polyglutamine repeats. 1999 , 22, 623-33	367

1130	A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. 1999 , 23, 181-92	718
1129	Nuclear accumulation of truncated atrophin-1 fragments in a transgenic mouse model of DRPLA. 1999 , 24, 275-86	158
1128	Trinucleotide repeats and other microsatellites in yeasts. 1999 , 150, 589-602	28
1127	Administration of recombinant human Activin-A has powerful neurotrophic effects on select striatal phenotypes in the quinolinic acid lesion model of Huntington's disease. 1999 , 92, 197-209	76
1126	Recent advances in understanding the pathogenesis of Huntington's disease. 1999 , 22, 248-55	173
1125	The selective vulnerability of striatopallidal neurons. 1999 , 59, 691-719	152
1124	Localization of rabbit huntingtin using a new panel of monoclonal antibodies. 1999 , 69, 10-20	19
1123	Identification and localization of ataxin-7 in brain and retina of a patient with cerebellar ataxia type II using anti-peptide antibody. 1999 , 74, 35-43	40
1122	Linkage between male infertility and trinucleotide repeat expansion in the androgen-receptor gene. 1999 , 354, 640-3	221
1121	Risk of neurodegenerative diseases in children conceived by intracytoplasmic sperm injection?. 1999 , 354, 611-2	24
1120	Isolation of CAG/CTG repeats from within the chromosome 2p21-p24 locus for autosomal dominant spastic paraplegia (SPG4) by YAC fragmentation. 1999 , 105, 217-225	5
1119	DGGE screening of PKD1 gene reveals novel mutations in a large cohort of 146 unrelated patients. 1999 , 105, 231-239	29
1118	Linkage disequilibrium analysis in Australian haemochromatosis patients indicates bipartite association with clinical expression. 1999 , 31, 39-46	39
1117	Genetically modified mice in neuropharmacology. 1999 , 39, 405-19	17
1116	Cell transplantation in the central nervous system. 1999 , 52, 13-6	6
1115	Mvwf, a dominant modifier of murine von Willebrand factor, results from altered lineage-specific expression of a glycosyltransferase. <i>Cell</i> , 1999 , 96, 111-20	56.2 137
1114	Analysis of gait abnormalities in Huntington disease. 1999 , 80, 59-65	33
1113	Huntington's disease: a clinical, genetic and molecular model for polyglutamine repeat disorders. 1999 , 354, 957-61	17

1112	From neuronal inclusions to neurodegeneration: neuropathological investigation of a transgenic mouse model of Huntington's disease. 1999 , 354, 971-979	48
1111	Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. 1999 , 354, 981-9	185
1110	Aggregation of truncated GST-HD exon 1 fusion proteins containing normal range and expanded glutamine repeats. 1999 , 354, 991-4	31
1109	Are there multiple pathways in the pathogenesis of Huntington's disease?. 1999 , 354, 995-1003	48
1108	The localization and interactions of huntingtin. 1999 , 354, 1021-7	13
1107	Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease. 1999 , 354, 1035-45	66
1106	Analysis of the subcellular localization of huntingtin with a set of rabbit polyclonal antibodies in cultured mammalian cells of neuronal origin: comparison with the distribution of huntingtin in Huntington's disease autopsy brain. 1999 , 354, 1061-7	27
1105	Age at onset anticipation in familial schizophrenia. Does the phenomenon even exist?. 1999 , 40, 55-65	7
1104	Elimination of prions by branched polyamines and implications for therapeutics. 1999 , 96, 14529-34	224
1103	Recent advances on the pathogenesis of Huntington's disease. 1999 , 157, 1-18	110
1102	Cerebellar allografts survive and transiently alleviate ataxia in a transgenic model of spinocerebellar ataxia type-1. 1999 , 158, 301-11	36
1101	Cellular delivery of trophic factors for the treatment of Huntington's disease: is neuroprotection possible?. 1999 , 159, 4-20	59
1100	The IGF-I amino-terminal tripeptide glycine-proline-glutamate (GPE) is neuroprotective to striatum in the quinolinic acid lesion animal model of Huntington's disease. 1999 , 159, 84-97	40
1099	Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease. 1999 , 159, 362-76	229
1098	Effects of ciliary neurotrophic factor on excitotoxicity and calcium-ionophore A23187-induced cell death in cultured embryonic striatal neurons. 1999 , 160, 402-12	13
1097	A fine integrated map of the SPG4 locus excludes an expanded CAG repeat in chromosome 2p-linked autosomal dominant spastic paraplegia. 1999 , 60, 309-19	11
1096	Nuclear targeting of mutant Huntingtin increases toxicity. 1999 , 14, 121-8	166
1095	Comparative semi-automated analysis of (CAG) repeats in the Huntington disease gene: use of internal standards. 1999 , 13, 283-9	21

1094	Pathogenesis of polyglutamine-induced disease: A model for SCA1. 1999 , 66, 172-8	8
1093	CTG18.1 and ERDA-1 CAG/CTG repeat size in bipolar disorder. 1999 , 6, 302-7	17
1092	Mutant huntingtin forms in vivo complexes with distinct context-dependent conformations of the polyglutamine segment. 1999 , 6, 364-75	53
1091	Identification of the physiological promoter for spinocerebellar ataxia 2 gene reveals a CpG island for promoter activity situated into the exon 1 of this gene and provides data about the origin of the nonmethylated state of these types of islands. 1999 , 254, 315-8	13
1090	Abnormal dentatorubral-pallidoluysian atrophy (DRPLA) protein complex is pathologically ubiquitinated in DRPLA brains. 1999 , 260, 133-8	20
1089	Characterization of cybrid cell lines containing mtDNA from Huntington's disease patients. 1999 , 261, 701-4	32
1088	Meiotic contraction of CAG repeats in <i>Saccharomyces cerevisiae</i> . 1999 , 74, 159-67	6
1087	Familial risks and genetic counselling for common psychiatric disorders. 1999 , 5, 39-45	4
1086	Longitudinal analysis of phonemic clustering and switching during word-list generation in Huntington's disease.. 1999 , 13, 525-531	49
1085	Neural transplantation of hNT neurons for Huntington's disease. 1999 , 8, 143-51	59
1084	Bilineal transmission in Tourette syndrome. 1999 , 53, 813-8	64
1083	Chapter 5.3 Trinucleotide repeat disorders. 1999 , 13, 783-804	
1082	Chapter 3 The Genetic Basis and Molecular Pathogenesis of Huntington's Disease. 1999 , 3, 81-92	1
1081	Longitudinal cognitive and motor changes among presymptomatic Huntington disease gene carriers. 1999 , 56, 563-8	91
1080	Caspase activation during apoptotic cell death induced by expanded polyglutamine in N2a cells. 1999 , 10, 2435-8	84
1079	Intranuclear inclusions in subtypes of striatal neurons in Huntington's disease transgenic mice. 1999 , 10, 3891-6	24
1078	An overview of central nervous system transplantation in human disease. 1999 , 7, e1	1
1077	Analysis of the CAG repeat number in a patient with Huntington's disease. 1999 , 38, 407-11	10

1076 Presymptomatic testing for genetic diseases: new frontiers, new dilemmas. **2000**, 55, 244-8

1075 Characterization of autosomal dominant non-syndromic hearing loss loci: DFNA 4, 6, 10 and 13. **2000**, 56, 84-96 2

1074 Chapter 19 Cellular delivery of trophic factors for the treatment of Huntington's disease: is neuroprotection possible?. **2000**, 127, 413-430 1

1073 Striatal tissue transplantation in non-human primates. **2000**, 127, 381-404 28

1072 Components of Cell and Gene Therapy for Neurological Disorders. 203-233

1071 Neurotrophic factors NGF and FGF-2 alter levels of huntingtin (IT15) in striatal neuronal cell cultures. **2000**, 9, 623-7 18

1070 Confirmation of subtle motor changes among presymptomatic carriers of the Huntington disease gene. **2000**, 57, 1040-4 67

1069 N-arginine dibasic convertase (nardilysin) isoforms are soluble dibasic-specific metalloendopeptidases that localize in the cytoplasm and at the cell surface. **2000**, 349, 587-97 23

1068 Aberrant phosphorylation of dentatorubral-pallidoluysian atrophy (DRPLA) protein complex in brain tissue. **2000**, 351, 587 1

1067 N-arginine dibasic convertase (nardilysin) isoforms are soluble dibasic-specific metalloendopeptidases that localize in the cytoplasm and at the cell surface. **2000**, 349, 587-597 30

1066 Aberrant phosphorylation of dentatorubral-pallidoluysian atrophy (DRPLA) protein complex in brain tissue. **2000**, 351, 587-593 8

1065 Conceptual and perceptual implicit memory in Huntington's disease.. **2000**, 14, 331-340 5

1064 Gene Isolation by Exon Trapping. **2000**, 653-666

1063 HEAT repeats associated with condensins, cohesins, and other complexes involved in chromosome-related functions. **2000**, 10, 1445-52 220

1062 Demystified ... microsatellites. **2000**, 53, 177-83 51

1061 Towards a protocol for the preparation and delivery of striatal tissue for clinical trials of transplantation in Huntington's disease. **2000**, 9, 223-34 22

1060 Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. **2000**, 20, 4389-97 454

1059 N-Acetylaspartate and DARPP-32 levels decrease in the corpus striatum of Huntington's disease mice. **2000**, 11, 3751-7 91

1058	12-O-tetradecanoyl-phorbol-13-acetate down-regulates the Huntingtin promoter at Sp1 sites. 2000 , 11, 3157-61	3
1057	Recent advances in Huntington's disease. 2000 , 13, 445-50	22
1056	Distribution of ataxin-7 in normal human brain and retina. 2000 , 123 Pt 12, 2519-30	50
1055	The influence of excitotoxic basal ganglia lesions on motor performance in the common marmoset. 2000 , 123 (Pt 7), 1442-58	16
1054	What transgenic mice tell us about neurodegenerative disease. 2000 , 22, 297-304	27
1053	Anticipation in inflammatory bowel disease: a phenomenon caused by an accumulation of confounders. 2000 , 92, 178-83	23
1052	Triplet repeat expansion in neuromuscular disease. 2000 , 23, 843-50	53
1051	Human DNA sequence polymorphisms: New opportunities for drug discovery and customized patient care. 2000 , 49, 46-53	
1050	The expansion of the CAG repeat in exon 1 of the human androgen receptor gene is associated with uterine endometrial carcinoma. 2000 , 27, 237-244	26
1049	Family and molecular data for a fine analysis of age at onset in Huntington disease. 2000 , 95, 366-73	40
1048	Cyclosporin A protects striatal neurons in vitro and in vivo from 3-nitropropionic acid toxicity. 2000 , 425, 471-8	56
1047	Reduced expression of DMAHP/SIX5 gene in myotonic dystrophy muscle. 2000 , 23, 1421-6	16
1046	Detection of triplet repeat expansion in the human genome by use of hybridization signal intensity. 2000 , 286, 59-66	1
1045	Distributions of dimeric tandem repeats in non-coding and coding DNA sequences. 2000 , 202, 273-82	33
1044	Higher sedentary energy expenditure in patients with Huntington's disease. 2000 , 47, 64-70	125
1043	Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. 2000 , 47, 80-86	286
1042	Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidolusian atrophy. 2000 , 48, 72-76	220
1041	Severe off-period facial dystonia in Parkinson's disease. 2000 , 15, 163-4	1

1040	Broad bean (<i>Vicia faba</i>)--a natural source of L-dopa--prolongs "on" periods in patients with Parkinson's disease who have "on-off" fluctuations. 2000 , 15, 164-6	60
1039	Subcutaneous apomorphine injections as a treatment for intractable pain in Parkinson's disease. 2000 , 15, 167-9	42
1038	Extradural motor cortex stimulation for advanced Parkinson's disease: case report. 2000 , 15, 169-71	59
1037	Bruxism in Huntington's disease. 2000 , 15, 171-3	57
1036	Donepezil for Huntington's disease. 2000 , 15, 173-6	66
1035	An unusual cause of gait disturbance in an elite sprinter. 2000 , 15, 176-8	10
1034	Hemichoreoathetosis following posterior parietal watershed infarction: was striatal hypoperfusion really to blame?. 2000 , 15, 178-9	24
1033	Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease. 2000 , 15, 552-60	176
1032	Environmental stimulation increases survival in mice transgenic for exon 1 of the Huntington's disease gene. 2000 , 15, 925-37	90
1031	The first identified French family with dentatorubral-pallidoluysian atrophy. 2000 , 15, 996-9	12
1030	Fine scale association mapping of disease loci using simplex families. 2000 , 64, 223-237	3
1029	Fas and Fas-L expression in Huntington's disease and Parkinson's disease. 2000 , 26, 424-33	42
1028	Caspases and neurodegeneration: on the cutting edge of new therapeutic approaches. 2000 , 57, 1-10	106
1027	High suicidal ideation in persons testing for Huntington's disease. 2000 , 102, 150-61	54
1026	Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. 2000 , 6, 797-801	882
1025	Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity. 2000 , 25, 385-9	261
1024	Nuclear localization or inclusion body formation of ataxin-2 are not necessary for SCA2 pathogenesis in mouse or human. 2000 , 26, 44-50	264
1023	<i>Drosophila</i> models of human neurodegenerative disease. 2000 , 7, 1075-80	59

1022	Analysis of CAG and CCG repeats in Huntingtin gene among HD patients and normal populations of India. 2000 , 8, 678-82	36
1021	Evidence for a common Spinocerebellar ataxia type 7 (SCA7) founder mutation in Scandinavia. 2000 , 8, 918-22	42
1020	Motor disorder in Huntington's disease begins as a dysfunction in error feedback control. 2000 , 403, 544-9	324
1019	A neuronal analogue of state-dependent learning. 2000 , 403, 549-53	147
1018	Delaying the onset of Huntington's in mice. 2000 , 404, 721-2	406
1017	Huntington's disease. In reverse gear. 2000 , 404, 944-5	6
1016	Interaction of expanded polyglutamine stretches with nuclear transcription factors leads to aberrant transcriptional regulation in polyglutamine diseases. 2000 , 20, 326-333	36
1015	Functional Significance of the Androgen Receptor CAG Repeat Polymorphism. 2000 , 2, 14-21	
1014	Adult and paediatric movement disorders. 2000 , 4, 45-7	
1013	Protein aggregation in Huntington's and Parkinson's disease: implications for therapy. 2000 , 6, 387-91	42
1012	Making drug discovery a SN(i)P. 2000 , 5, 388-396	10
1011	The psychological complexity of predictive testing for late onset neurogenetic diseases and hereditary cancers: implications for multidisciplinary counselling and for genetic education. 2000 , 51, 831-41	92
1010	Huntington's disease: the challenge for cell biologists. 2000 , 10, 531-6	201
1009	Frontiers in chemical genetics. 2000 , 18, 449-55	85
1008	Striatal oxidative damage parallels the expression of a neurological phenotype in mice transgenic for the mutation of Huntington's disease. 2000 , 862, 234-7	113
1007	Brain-derived neurotrophic factor in Huntington disease. 2000 , 866, 257-61	269
1006	The problem of antipsychotic treatment for functional imaging in Huntington's disease: receptor binding, gene expression and locomotor activity after sub-chronic administration and wash-out of haloperidol in the rat. 2000 , 853, 125-35	9
1005	Oxidative stress, mitochondrial permeability transition and activation of caspases in calcium ionophore A23187-induced death of cultured striatal neurons. 2000 , 857, 20-9	81

1004	Neuroprotective role for the p50 subunit of NF-kappaB in an experimental model of Huntington's disease. 2000 , 15, 31-44	65
1003	Redefinition: coping with normal results from predictive gene testing for neurodegenerative disorders. 2000 , 23, 260-9	36
1002	Iron in the Brain: An Important Contributor in Normal and Diseased States. 2000 , 6, 435-453	80
1001	Age-dependence of malonate-induced striatal toxicity. 2000 , 134, 335-43	5
1000	Effects of systemic 3-nitropropionic acid-induced lesions of the dorsal striatum on cannabinoid and mu-opioid receptor binding in the basal ganglia. 2000 , 130, 142-50	39
999	Trinucleotide repeats and neuropsychiatric disorders. 2000 , 15, 136-44	1
998	Cell death in polyglutamine diseases. 2000 , 301, 189-204	59
997	Wild-type huntingtin protects from apoptosis upstream of caspase-3. 2000 , 20, 3705-13	310
996	Molecular diagnosis of Huntington disease in Brazilian patients. 2000 , 58, 11-7	14
995	The polyglutamine expansion in spinocerebellar ataxia type 6 causes a beta subunit-specific enhanced activation of P/Q-type calcium channels in <i>Xenopus</i> oocytes. 2000 , 20, 6394-403	110
994	Huntington disease: DNA analysis in Brazilian population. 2000 , 58, 977-85	16
993	Macular degeneration associated with aberrant expansion of trinucleotide repeat of the SCA7 gene in 2 Japanese families. 2000 , 118, 1415-21	35
992	. 2000 ,	0
991	Chaperones Hsp70 and Hsp40 suppress aggregate formation and apoptosis in cultured neuronal cells expressing truncated androgen receptor protein with expanded polyglutamine tract. 2000 , 275, 8772-8	252
990	. 2000 ,	3
989	Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. 2000 , 97, 7841-6	541
988	Restoration of cognitive and motor functions by ciliary neurotrophic factor in a primate model of Huntington's disease. 2000 , 11, 1177-87	127
987	Nadrin, a novel neuron-specific GTPase-activating protein involved in regulated exocytosis. 2000 , 275, 36885-91	51

- 986 Activation of MLK2-mediated signaling cascades by polyglutamine-expanded huntingtin. **2000**, 275, 19035-40 70
- 985 Aggregation of huntingtin in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins. **2000**, 97, 1589-94 462
- 984 Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. **2000**, 97, 6809-14 243
- 983 Transplanted fetal striatum in Huntington's disease: phenotypic development and lack of pathology. **2000**, 97, 13877-82 212
- 982 Null alleles at the Huntington disease locus: implications for diagnostics and CAG repeat instability. **2000**, 4, 55-60 15
- 981 Polymorphism of NACP-Rep1 in Parkinson's disease: an etiologic link with essential tremor?. **2000**, 54, 1195-8 109
- 980 Expansion of the (CTG)(n) repeat in the 5'-UTR of a reporter gene impedes translation. **2000**, 28, 3943-9 24
- 979 Paradox of a better test for Huntington's disease. **2000**, 69, 579-83 50
- 978 Activate your online subscription. **2000**, 54, 955-955
- 977 Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles. **2000**, 9, 2789-97 160
- 976 Molecular and clinical analyses of spinocerebellar ataxia type 8 in Japan. **2000**, 54, 950-5 78
- 975 Bradykinesia in early Huntington's disease. **2000**, 54, 119-25 68
- 974 The prion diseases. **2000**, 20, 337-52 22
- 973 Klinischer Nutzen genetischer Untersuchungen in der Neurologie. **2000**, 27, 365-375
- 972 Sequence analysis by additive scales: DNA structure for sequences and repeats of all lengths. **2000**, 16, 865-89 45
- 971 Gender of the embryo contributes to CAG instability in transgenic mice containing a Huntington's disease gene. **2000**, 9, 2767-75 48
- 970 Molecular Genetics and Inherited Ataxias: Redefining Phenotypes and Pathogenesis. **2000**, 6, 465-474
- 969 The status of SCA1, MJD/SCA3, FRDA, DRPLA and MD triplet containing genes in patients with Huntington disease and healthy controls. **2000**, 14, 257-63 9

968	The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. 2000 , 97, 6763-8	870
967	Spinocerebellar ataxia type 6 mutation alters P-type calcium channel function. 2000 , 275, 10893-8	86
966	Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. 2000 , 9, 1259-71	550
965	Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. 2000 , 9, 503-13	350
964	Huntingtin's WW domain partners in Huntington's disease post-mortem brain fulfill genetic criteria for direct involvement in Huntington's disease pathogenesis. 2000 , 9, 2175-82	73
963	Bacterial and yeast chaperones reduce both aggregate formation and cell death in mammalian cell models of Huntington's disease. 2000 , 97, 9701-5	185
962	Intranuclear huntingtin increases the expression of caspase-1 and induces apoptosis. 2000 , 9, 2859-67	94
961	Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. 2000 , 9, 2799-809	474
960	Subtle changes among presymptomatic carriers of the Huntington's disease gene. 2000 , 69, 773-9	96
959	Regulation of expanded polyglutamine protein aggregation and nuclear localization by the glucocorticoid receptor. 2000 , 97, 657-61	61
958	Family history and DNA analysis in patients with suspected Huntington's disease. 2000 , 69, 54-9	23
957	Psychological impact of genetic testing for Huntington's disease: an update of the literature. 2000 , 69, 574-8	146
956	Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease. 2000 , 59, 133-54	176
955	Decreased striatal monoaminergic terminals in Huntington disease. 2000 , 54, 1753-9	79
954	Familial aggregation of psychotic symptoms in Huntington's disease. 2000 , 157, 1955-9	50
953	Protein aggregation and pathogenesis of Huntington's disease: mechanisms and correlations. 2000 , 381, 937-42	118
952	Morbus Huntington - a human genetic model disease. 2000 , 91, 90-6	1
951	The human 20-kDa 5'-(CGG)(n)-3'-binding protein is targeted to the nucleus and affects the activity of the FMR1 promoter. 2000 , 275, 6447-52	31

950	Formic acid dissolves aggregates of an N-terminal huntingtin fragment containing an expanded polyglutamine tract: applying to quantification of protein components of the aggregates. 2000 , 277, 386-93	78
949	Characterization of C14orf4, a novel intronless human gene containing a polyglutamine repeat, mapped to the ARVD1 critical region. 2000 , 278, 766-74	42
948	Decrease in striatal enkephalin mRNA in mouse models of Huntington's disease. 2000 , 162, 328-42	105
947	Participation of par-4 in the degeneration of striatal neurons induced by metabolic compromise with 3-nitropropionic acid. 2000 , 165, 1-11	33
946	Ataxin-3 is translocated into the nucleus for the formation of intranuclear inclusions in normal and Machado-Joseph disease brains. 2000 , 165, 248-56	67
945	Deficits in striatal dopamine D(2) receptors and energy metabolism detected by in vivo microPET imaging in a rat model of Huntington's disease. 2000 , 166, 287-97	55
944	Identification and characterization of the miniature pig Huntington's disease gene homolog: evidence for conservation and polymorphism in the CAG triplet repeat. 2000 , 69, 72-85	26
943	Expression of huntingtin-associated protein-1 in neuronal cells implicates a role in neuritic growth. 2000 , 16, 168-83	49
942	Inhibition of Huntington synthesis by antisense oligodeoxynucleotides. 2000 , 16, 313-23	34
941	Genetic mapping of complex traits: promises, problems, and prospects. 2000 , 57, 1-11	28
940	George Huntington (1850-1916) and hereditary chorea. 2000 , 9, 76-89	23
939	Poly-L-glutamine forms cation channels: relevance to the pathogenesis of the polyglutamine diseases. 2000 , 78, 2892-9	75
938	Human huntingtin-associated protein (HAP-1) gene: genomic organisation and an intragenic polymorphism. 2000 , 254, 181-7	4
937	The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. 2000 , 97, 505-19	437
936	Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice. 2000 , 98, 705-13	144
935	Mice transgenic for the human Huntington's disease mutation have reduced sensitivity to kainic acid toxicity. 2000 , 52, 51-9	59
934	Lesch-Nyhan disease and the basal ganglia. 2000 , 32, 449-75	139
933	The age of onset of schizophrenia and the theory of anticipation. 2000 , 93, 125-34	6

932	Neuronal cell death in Huntington's disease: a potential role for dopamine. 2000 , 23, 239-45	149
931	Energetics in the pathogenesis of neurodegenerative diseases. 2000 , 23, 298-304	403
930	Transcriptional dysregulation in Huntington's disease. 2000 , 23, 387-92	354
929	N-myc and c-myc expression in Alzheimer disease, Huntington disease and Parkinson disease. 2000 , 77, 270-6	40
928	What role(s) for TGFalpha in the central nervous system?. 2000 , 62, 443-73	102
927	Tissue transglutaminase: a possible role in neurodegenerative diseases. 2000 , 61, 439-63	143
926	The expanded CAG repeat associated with juvenile Huntington disease shows a common origin of most or all neurons and glia in human cerebrum. 2000 , 286, 203-7	24
925	Impact of genome research on children and their families. 2000 , 15, 207-11	1
924	Huntington's disease: neurological assessment of potential gene carriers presenting for predictive DNA testing. 2000 , 7, 38-41	19
923	Does mRNA translation starting from an alternative initiation site contribute to the pathology of Huntington's disease?. 2000 , 54, 689-90	
922	Genetic analysis for common complex disease. 2000 , 140, S36-44	20
921	Benign hereditary chorea of early onset maps to chromosome 14q. 2000 , 66, 136-42	61
920	Linkage disequilibrium and allele-frequency distributions for 114 single-nucleotide polymorphisms in five populations. 2000 , 66, 216-34	177
919	A recurrent expansion of a maternal allele with 36 CAG repeats causes Huntington disease in two sisters. 2000 , 66, 1145-8	15
918	Bayesian fine-scale mapping of disease loci, by hidden Markov models. 2000 , 67, 155-69	77
917	Predictive testing for Huntington's disease: the calm after the storm. 2000 , 356, 1944-5	40
916	Fetal tissue transplants in animal models of Huntington's disease: the effects on damaged neuronal circuitry and behavioral deficits. 2000 , 61, 313-38	49
915	DMSO and glycerol reduce bacterial death induced by expression of truncated N-terminal huntingtin with expanded polyglutamine tracts. 2000 , 1502, 247-56	12

914	Neural Science. <i>Cell</i> , 2000 , 100, 1-55	56.2	61
913	Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. <i>Cell</i> , 2000 , 101, 57-66	56.2	899
912	Ten years of presymptomatic testing for Huntington's disease: the experience of the UK Huntington's Disease Prediction Consortium. 2000 , 37, 567-71		113
911	Neuroscience: breaking down scientific barriers to the study of brain and mind. 2000 , 290, 1113-20		138
910	The striatum is the most vulnerable region in the brain to mitochondrial energy compromise: a hypothesis to explain its specific vulnerability. 2000 , 17, 251-60		59
909	Characterization of trinucleotide- and tandem repeat-containing transcripts obtained from human spinal cord cDNA library by high-density filter hybridization. 2000 , 19, 265-73		6
908	Challenges Facing Statistical Genetics. 2000 , 95, 319-322		
907	Computational Molecular Biology. 2000 , 95, 322-326		3
906	Genetics of childhood disorders: X. Huntington disease. 2000 , 39, 120-2		1
905	Pathophysiological Considerations in Basal Ganglia Surgery: Role of the Basal Ganglia in Hypokinetic and Hyperkinetic Movement Disorders. 2000 , 15, 31-57		8
904	De novo expansion of a CAG repeat in a Japanese patient with sporadic Huntington's disease. 2000 , 178, 159-62		7
903	Apoptosis in neural development and disease. 2000 , 23, 73-87		266
902	Genome Organization II. 86-124		
901	The emergence of modern neuroscience: some implications for neurology and psychiatry. 2000 , 23, 343-91		84
900	Huntington's disease: a review of the literature on prevalence and treatment of neuropsychiatric phenomena. 2001 , 16, 439-45		68
899	Palliative care for people with late-stage Huntington's disease. 2001 , 19, 849-65		48
898	Genetics of movement disorders: an abbreviated overview. 2001 , 77, 48-60		1
897	Neuropsychiatric aspects of Huntington's disease. 2001 , 71, 310-4		298

896	GABA signalling: therapeutic targets for epilepsy, Parkinson's disease and Huntington's disease. 2001 , 5, 219-39	38
895	Analysis of genetic linkage data for Mendelian traits. 2001 , Chapter 1, Unit 1.4	2
894	Neurobehavioral aspects of movement disorders. 2001 , 19, 535-51, v	13
893	Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. 2001 , 293, 493-8	1044
892	DNA interstrand crosslink formation by mechlorethamine at a cytosine-cytosine mismatch pair: kinetics and sequence dependence. 2001 , 386, 143-53	11
891	Early degenerative changes in transgenic mice expressing mutant huntingtin involve dendritic abnormalities but no impairment of mitochondrial energy production. 2001 , 169, 340-50	154
890	Biochemical analysis of cybrids expressing mitochondrial DNA from Contursi kindred Parkinson's subjects. 2001 , 169, 479-85	38
889	A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease. 2001 , 171, 351-60	87
888	Identification and characterization of a SET/NAP protein encoded by a brain-specific gene, MB20. 2001 , 71, 21-33	17
887	Mutant huntingtin enhances excitotoxic cell death. 2001 , 17, 41-53	158
886	Identification of the full-length huntingtin- interacting protein p231HBP/HYPB as a DNA-binding factor. 2001 , 18, 68-79	22
885	Distinct behavioral and neuropathological abnormalities in transgenic mouse models of HD and DRPLA. 2001 , 8, 405-18	46
884	Neuroprotective effect of a CNTF-expressing lentiviral vector in the quinolinic acid rat model of Huntington's disease. 2001 , 8, 433-46	136
883	Tissue transglutaminase selectively modifies proteins associated with truncated mutant huntingtin in intact cells. 2001 , 8, 391-404	30
882	Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. 2001 , 8, 479-91	237
881	Impaired glutamate uptake in the R6 Huntington's disease transgenic mice. 2001 , 8, 807-21	233
880	The extinction program for Homo sapiens and cloning humans: trinucleotide expansion as a one-way track to extinction. 2001 , 56, 296-301	4
879	Measurement of mutational flow implies both a high new-mutation rate for Huntington disease and substantial underascertainment of late-onset cases. 2001 , 68, 373-85	55

878	Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo. 2001 , 68, 313-24	183
877	Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington's disease. 2001 , 106, 603-12	117
876	Transglutaminase-dependent formation of protein aggregates as possible biochemical mechanism for polyglutamine diseases. 2001 , 56, 169-72	17
875	Cytochrome c oxidase subunit Vb interacts with human androgen receptor: a potential mechanism for neurotoxicity in spinobulbar muscular atrophy. 2001 , 56, 285-97	45
874	Protective effect of chaperones on polyglutamine diseases. 2001 , 56, 165-8	43
873	A survey of trinucleotide/tandem repeat-containing transcripts (TNRTs) isolated from human spinal cord to identify genes containing unstable DNA regions as candidates for disorders of motor function. 2001 , 56, 299-306	2
872	Expression of the Huntington's disease transgene in neural stem cell cultures from R6/2 transgenic mice. 2001 , 56, 307-12	14
871	Polyglutamine tract expansion of the androgen receptor in a motoneuronal model of spinal and bulbar muscular atrophy. 2001 , 56, 215-20	31
870	Anterior cingulate cortical transplantation in transgenic Huntington's disease mice. 2001 , 56, 313-8	53
869	Trinucleotide repeat expansions: do they contribute to bipolar disorder?. 2001 , 56, 243-57	18
868	Identification of alternative splicing of spinocerebellar ataxia type 2 gene. 2001 , 267, 89-93	19
867	RA11 is a novel polyglutamine encoding gene that is deleted in Smith-Magenis syndrome patients. 2001 , 270, 69-76	35
866	A model for the involvement of Okazaki fragments maturation in the expansion of short tandem repeats. 2001 , 276, 153-9	2
865	Characterization of the amphioxus presenilin gene in a high gene-density genomic region illustrates duplication during the vertebrate lineage. 2001 , 279, 157-64	11
864	Anticipation, imprinting, trinucleotide repeat expansions and psychoses. 2001 , 25, 167-92	11
863	The role of cannabinoids in neurodegenerative diseases. 2001 , 25, 743-65	57
862	PGD in the lab for triplet repeat diseases - myotonic dystrophy, Huntington's disease and Fragile-X syndrome. 2001 , 183 Suppl 1, S77-85	64
861	Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model. 2001 , 315, 149-53	143

860	Biological markers and diagnostic accuracy in the genetics of posttraumatic stress disorder. 2001 , 102, 203-15	30
859	Psychiatric symptoms and CAG repeats in neurologically asymptomatic Huntington's disease gene carriers. 2001 , 102, 217-25	53
858	Evaluation of R6/2 HD transgenic mice for therapeutic studies in Huntington's disease: behavioral testing and impact of diabetes mellitus. 2001 , 126, 185-95	109
857	Functional characterization of the human Huntington's disease gene promoter. 2001 , 92, 85-97	14
856	Rethinking genetic strategies to study complex diseases. 2001 , 7, 512-6	17
855	Bilan de dix annès du diagnostic moléculaire de la maladie de Huntington en France. 2001 , 16, 92-95	
854	Androgen induced cell death in SHSY5Y neuroblastoma cells expressing wild-type and spinal bulbar muscular atrophy mutant androgen receptors. 2001 , 1536, 13-20	7
853	Nuclear aggregation of huntingtin is not prevented by deletion of chaperone Hsp104. 2001 , 1537, 158-66	12
852	Aberrant amplification of A2A receptor signaling in striatal cells expressing mutant huntingtin. 2001 , 15, 1245-1247	82
851	Chorea and its disorders. 2001 , 19, 707-22, vii	17
850	Neuroprotective possibilities for Huntington's disease. 2001 , 1, 467-79	8
849	Genetic background for immune-mediated diseases. 2001 , 59, 212-5	2
848	Isolation of 105 microsatellite loci from an ovine genomic library enriched for microsatellites. 2001 , 12, 77-86	8
847	Expanded polyglutamines in <i>Caenorhabditis elegans</i> cause axonal abnormalities and severe dysfunction of PLM mechanosensory neurons without cell death. 2001 , 98, 13318-23	168
846	Evolution of the periodicity and the self-similarity in DNA sequence: a Fourier transform analysis. 2001 , 51, 159-68	9
845	Huntington's Disease. 2001 , 711-725	
844	Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease. 2001 , 21, 9112-23	243
843	Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. 2001 , 86, 2667-77	262

- 842 Identification and characterization of disease-related genes: focus on endocrine neoplasias. **2001**, 28, 20-49
- 841 Tissue-specific proteolysis of Huntingtin (htt) in human brain: evidence of enhanced levels of N- and C-terminal htt fragments in Huntington's disease striatum. **2001**, 21, 1830-7 125
- 840 Huntington's disease. **2001**, 738-740
- 839 Development of ligase-assisted spacer addition for the measurement of microsatellites. **2001**, 31, 96-102, 104-6
- 838 6: Movement disorders II: the hyperkinetic disorders. **2001**, 174, 413-9
- 837 Neurons lacking huntingtin differentially colonize brain and survive in chimeric mice. **2001**, 21, 7608-19 44
- 836 Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease. **2001**, 21, 8772-81 136
- 835 The molecular biology of Huntington's disease. **2001**, 31, 3-14 86
- 834 Longitudinal evaluation of cognitive disorder in Huntington's disease. **2001**, 7, 33-44 83
- 833 Differential processing of tau in corticobasal degeneration (CBD) and supranuclear palsy (PSP): proteolysis as a central mechanism in neurodegenerative diseases. **2001**, 12, A27
- 832 UVB irradiation-induced apoptosis increased in lymphocytes of Huntington's disease patients. **2001**, 12, 1653-6 6
- 831 CAG repeat expansion in the TATA box-binding protein gene causes autosomal dominant cerebellar ataxia. **2001**, 124, 1939-47 119
- 830 Familial frontotemporal dementia with ubiquitin-positive inclusions is linked to chromosome 17q21-22. **2001**, 124, 1948-57 118
- 829 Inheritance of a stable mutation in a family with early-onset disease. **2001**, 87, 340-5 7
- 828 Successful multimodality treatment of severe behavioral disturbance in a patient with advanced Huntington's disease. **2001**, 158, 1966-72 26
- 827 Neurodegenerative disease. **2001**, 44-55 12
- 826 Chaperone suppression of cellular toxicity of huntingtin is independent of polyglutamine aggregation. **2001**, 276, 48417-24 86
- 825 Spinocerebellar ataxia type 1 in China: molecular analysis and genotype-phenotype correlation in 5 families. **2001**, 58, 789-94 18

824	Apoptosis in Huntington disease and animal models. 2001 , 205-223	1
823	Huntington's disease. 2001 , 54, 409-13	67
822	Oculopharyngeal muscular dystrophy in Hispanic New Mexicans. 2001 , 286, 2437-40	56
821	Fluoxetine in the treatment of Huntington's disease. 2001 , 153, 264-6	42
820	Movement-related potentials in Huntington's disease: movement preparation and execution. 2001 , 138, 492-9	21
819	An overview of psychiatric symptoms in Huntington's disease. 2001 , 3, 379-88	38
818	Homozygosity and linkage disequilibrium mapping of autosomal recessive distal myopathy (Nonaka distal myopathy). 2001 , 46, 649-55	6
817	Modelling studies on neurodegenerative disease-causing triplet repeat sequences d(GGC/GCC) _n and d(CAG/CTG) _n . 2001 , 26, 649-65	5
816	Characterization of intracellular aggregates using fluorescently-tagged polyglutamine-expanded androgen receptor. 2001 , 3, 259-75	9
815	Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length. 2001 , 78, 694-703	45
814	EFNS Task Force on Molecular Diagnosis of Neurologic Disorders: guidelines for the molecular diagnosis of inherited neurologic diseases. First of two parts. 2001 , 8, 299-314	17
813	Brain neurotransmitter deficits in mice transgenic for the Huntington's disease mutation. 1999 , 72, 1773-6	72
812	United Kingdom experience with presymptomatic testing of individuals at 25% risk for Huntington's disease. 2000 , 58, 41-9	21
811	The selective vulnerability of nerve cells in Huntington's disease. 2001 , 27, 1-21	114
810	The mitochondrial toxin 3-nitropropionic acid induces differential expression patterns of apoptosis-related markers in rat striatum. 2001 , 27, 68-76	25
809	Altered striatal amino acid neurotransmitter release monitored using microdialysis in R6/1 Huntington transgenic mice. 2001 , 13, 206-10	73
808	Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene. 2001 , 14, 1492-504	117
807	Neuroprotective effect of interleukin-6 and IL6/IL6R chimera in the quinolinic acid rat model of Huntington's syndrome. 2001 , 14, 1753-61	38

806	Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers. 2001 , 41, 329-36	70
805	Nitric oxide and nitric oxide synthase in Huntington's disease. 2001 , 64, 99-107	68
804	Age-dependent and tissue-specific CAG repeat instability occurs in mouse knock-in for a mutant Huntington's disease gene. 2001 , 65, 289-97	63
803	NMDA receptor function in mouse models of Huntington disease. 2001 , 66, 525-39	218
802	Impact of Huntington's disease on quality of life. 2001 , 16, 325-30	75
801	Cervical dystonia in monozygotic twins: case report and review of the literature. 2001 , 16, 714-8	16
800	Juvenile onset Huntington's disease--clinical and research perspectives. 2001 , 7, 153-7	121
799	Role of caspases in neuronal apoptosis. 2001 , 52, 515-533	10
798	Familial influence on age of onset among siblings with Huntington disease*. 2001 , 105, 399-403	75
797	Mitochondria and degenerative disorders. 2001 , 106, 27-36	229
796	Evidence of decreased risk of cancer in individuals with fragile X. 2001 , 103, 226-230	51
795	Using a roster and haplotyping is useful in risk assessment for persons with intermediate and reduced penetrance alleles in Huntington disease. 2001 , 105, 737-44	14
794	A disorder similar to Huntington's disease is associated with a novel CAG repeat expansion. 2001 , 50, 373-380	96
793	A disorder similar to Huntington's disease is associated with a novel CAG repeat expansion. 2001 , 50, 373-80	132
792	Familial dyskinesia and facial myokymia (FDFM): A novel movement disorder. 2001 , 49, 486-492	45
791	Quantitative neuropathological changes in presymptomatic Huntington's disease. 2001 , 49, 29-34	141
790	Association study designs for complex diseases. 2001 , 2, 91-9	1099
789	Population and Family Studies of the CAG Repeats in the IT-15Gene. 2001 , 37, 315-318	

788	Expansion of Trinucleotide Repeats. 2001 , 35, 168-182	16
787	Comparative analysis of superoxide dismutase activity between acute pharmacological models and a transgenic mouse model of Huntington's disease. 2001 , 26, 419-24	50
786	The genetics of cognitive processes: candidate genes in humans and animals. 2001 , 31, 511-31	42
785	Modeling Huntington's disease in cells, flies, and mice. 2001 , 23, 21-51	55
784	Shattuck lecture--neurodegenerative diseases and prions. 2001 , 344, 1516-26	608
783	Ophthalmological findings in patients with spinocerebellar ataxia type 1 are not correlated with neurological anticipation. 2001 , 239, 722-8	8
782	Protein solubility and folding monitored in vivo by structural complementation of a genetic marker protein. 2001 , 19, 131-6	152
781	Epilepsy and all that jazz. 2001 , 7, 1103-5	4
780	Extended polyglutamine selectively interacts with caspase-8 and -10 in nuclear aggregates. 2001 , 8, 377-86	31
779	Isolation of neuronal cells with high processing activity for the Machado-Joseph disease protein. 2001 , 8, 871-3	10
778	Implant-supported denture in a patient with Huntington's disease: interdisciplinary aspects. 2001 , 21, 15-20	17
777	Polar alteration of short tandem repeats (STRs) in mammalian cells. 2001 , 474, 159-68	3
776	Paediatric and adult movement disorders (update). 2001 , 5, 265-8	
775	Huntington's disease. 2001 , 1, 142-152	33
774	Genetic aspects of schizophrenia. 2001 , 1, 158-163	8
773	Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease. 2001 , 98, 4764-9	174
772	Huntington Disease. 2001 ,	2
771	Identities of sequestered proteins in aggregates from cells with induced polyglutamine expression. 2001 , 153, 283-94	178

770	The huntingtin interacting protein HIP1 is a clathrin and alpha-adaptin-binding protein involved in receptor-mediated endocytosis. 2001 , 10, 1807-17	118
769	Abnormalities in the functioning of adipocytes from R6/2 mice that are transgenic for the Huntington's disease mutation. 2001 , 10, 145-52	65
768	Caspases in Huntington's disease. 2001 , 7, 480-9	47
767	Mitochondrial dysfunction in neurodegenerative disorders and ageing. 2001 , 487, 229-51	23
766	New problems in testing for Huntington's disease: the issue of intermediate and reduced penetrance alleles. 2001 , 38, E12	34
765	Assignment of the huntingtin (Hdh) gene, the huntingtin associated protein (Hap1) gene, and the huntingtin interacting protein (Hip1) gene to rat chromosomes 14, 10, and 12 by radiation hybrid mapping and fluorescent in situ hybridization. 2001 , 94, 101-4	
764	Huntingtin's neuroprotective activity occurs via inhibition of procaspase-9 processing. 2001 , 276, 14545-8	109
763	Molecular chaperones and age-related degenerative disorders. 2001 , 7, 131-162	17
762	The coding region of the human DLX6 gene contains a polymorphic CAG/CCG repeat. 2001 , 18, 1293-7	4
761	Isolation of a 40-kDa Huntingtin-associated protein. 2001 , 276, 3188-94	60
760	Tissue transglutaminase does not contribute to the formation of mutant huntingtin aggregates. 2001 , 153, 25-34	118
759	The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: Neuropathologic and genetic evidence for a role in Huntington's disease pathogenesis. 2001 , 98, 1811-1816	142
758	The whole truth and nothing but the truth, but what is the truth?. 2001 , 38, 39-42	11
757	Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. 2001 , 10, 1049-59	344
756	Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9. 2001 , 276, 36337-43	462
755	Juvenile Huntington's disease presenting as progressive myoclonic epilepsy. 2001 , 57, 708-11	55
754	Oligomerization of polyalanine expanded PABPN1 facilitates nuclear protein aggregation that is associated with cell death. 2001 , 10, 2341-51	90
753	Clinical markers of early disease in persons near onset of Huntington's disease. 2001 , 57, 658-62	180

752	The HD mutation causes progressive lethal neurological disease in mice expressing reduced levels of huntingtin. 2001 , 10, 2515-23	86
751	The anatomy of the human genome: a neo-Vesalian basis for medicine in the 21st century. 2001 , 286, 2289-95	42
750	Huntington disease. 2001 , 58, 308-10	4
749	Intracellular aggregation of polypeptides with expanded polyglutamine domain is stimulated by stress-activated kinase MEKK1. 2001 , 153, 851-64	54
748	Histone deacetylase inhibitors reduce polyglutamine toxicity. 2001 , 98, 15179-84	214
747	Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease. 2001 , 10, 1829-45	206
746	Beyond the Qs in the polyglutamine diseases. 2001 , 15, 925-32	138
745	Molecular Genetics and Prenatal Diagnosis. 380-444	
744	Keeping it Together. Axonal Transport to the Synapse and the Effects of Molecular Chaperones in Health and Disease. 2011 , 81-103	
743	Regenerative Medicine in the Central Nervous System: Stem Cell-Based Gene-Therapy. 2011 , 579-604	
742	Applications of fMRI to Neurodegenerative Disease. 2011 , 639-670	
741	Huntington's Disease: Quality of Life and Diet. 2011 , 3199-3208	
740	Gene-Environment Interactions in Neurodegenerative Diseases. 2011 , 191-198	
739	The Present and Future of the Research on Neurological Disorders. 2011 , 16, 52-56	
738	Direct-to-Consumer Genetic Testing. 2011 , 51-84	1
737	Hunting Redundancies in Strings. 2011 , 1-14	1
736	3-Nitropropionic Acid and Other Metabolic Toxin Lesions of the Striatum. 2011 , 71-89	
735	Funciones y disfunciones motoras del sueño. 2011 , 397-435	

- 734 Clinical Overview of Movement Disorders. **2011**, 899-913
- 733 Bewegungsstörungen. **2011**, 955-1054
- 732 Molecular Diagnosis of Neurogenetic Disorders: General Issues, Huntington's Disease, Parkinson's Disease and Dystonias. 51-60
- 731 References. 189-196
- 730 Impaired Dopamine-Glutamate Receptor Interactions in Some Neurological Disorders. **2011**, 227-252
- 729 Mitochondria in Neurodegeneration. **2012**, 885-906
- 728 Inherited Diseases. **2012**, 1239-1292
- 727 Fetal and Neonatal Illnesses Caused or Influenced by Maternal Transplacental IgG and/or Therapeutic Antibodies Applied During Pregnancy. **2012**, 281-333
- 726 Diagnosis and classification in psychiatry. **2012**, 511-519
- 725 Huntington's Disease. **2012**, 142-143
- 724 Dementia due to Huntington's disease. **2012**, 371-375
- 723 Pathophysiology and Molecular Pathology of Tremor, Myoclonus, and Chorea. 26-39
- 722 Huntington Disease and Other Genetic Chorea. 147-174
- 721 Neurological Diseases and Stem Cell Therapy. **2013**, 125-150
- 720 The interplay between the chaperonin TRiC and N-terminal region of Huntingtin mediates Huntington's Disease aggregation and pathogenesis. **2013**, 121-132
- 719 The Aging Male and Impact on Offspring. **2013**, 17-29
- 718 Corea. Enfermedad de Huntington: clínica y tratamiento. **2013**, 131-137
- 717 HTT Evolution and Brain Development. **2013**, 41-55

- 716 Regenerative Medicine in the Central Nervous System: Stem Cell-Based Cell- and Gene-Therapy. **2013**, 695-727
- 715 CHAPTER 15: Role of P2X7 Receptor Signaling in the Treatment of Parkinson's Disease and Other Neurodegenerative Disorders. **2013**, 341-360
- 714 Human Neural Stem Cell-Based Cell- and Gene-Therapy for Neurological Diseases. **2014**, 21-48 ○
- 713 Mechanisms Underlying the Selective Vulnerability of Developing Human White Matter. **2014**, 109-141
- 712 Niezależność jednostki a determinizm genetyczny – decyzje w obliczu możliwości wykonania badań przedobjawowych w chorobie Huntingtona. **2014**,
- 711 Chorea: A Surgical Approach. **2014**, 295-334
- 710 Phosphoinositide-Specific Phospholipase C Enzymes and Cognitive Development and Decline. **2014**, 227-246
- 709 Huntington's Disease: Molecular Pathogenesis and New Therapeutic Perspectives. **2014**, 101-126
- 708 Mitochondrial Dysfunction in Brain and Muscle Pathology of Huntington's Disease. **2014**, 3097-3116
- 707 Stem Cell Therapy for Neurological Disorders: From Bench to Bedside. **2014**, 41-70
- 706 Huntington's Disease: Clinical Phenotypes and Therapeutics. **2014**, 71-99
- 705 PET in Huntington's Disease. **2014**, 655-666
- 704 In Vivo Imaging in Neurodegenerative Diseases. **2014**, 45-80 ○
- 703 Diabetes. **2014**, 115-146
- 702 Molecular dissection of genetic diseases of brain and muscle. **1993**, 159, 52-4
- 701 An Exon Trapping System Providing Size Selection of Spliced Clones and Facilitating Direct Cloning. **1994**, 169-181
- 700 Isolation of Gene Sequences from the BRCA1 Region of Chromosome 17q21 by Exon Amplification. **1994**, 183-198
- 699 Molecular biology of Huntington's disease. **1994**, 4, 1-24

- 698 Direct cDNA Selection Using Human and Mouse cDNAs: Application to Xq13.3 Chromosomal Region. **1994**, 81-90
- 697 What's New?. **1994**, 160, 296-298
- 696 Homologous recombination of monkey alpha-satellite repeats in an in vitro simian virus 40 replication system: possible association of recombination with DNA replication. **1994**, 14, 4173-4182 9
- 695 Non-Alzheimer's degenerative dementias. **1995**, 8, 51-56
- 694 Molecular Basis of Genetic Disorders of the Heart. **1995**, 237-264
- 693 References. **1995**, 707-850
- 692 The Cloning of Tumor Suppressor Genes from the Short Arm of Human Chromosome 3 that Play a Role in the Development of Renal Cell Carcinoma. **1995**, 40-55
- 691 Genetic Diseases in the Tropics. **1995**, 61-123
- 690 Therapeutic Use of Neurotrophic Factors. **1995**, 379-390
- 689 Subcortical Movement Disorders II. **1995**, 312-323
- 688 Systematrophien. **1995**, 174-196 1
- 687 References. **1995**, 381-429
- 686 SPECT-Untersuchungen bei degenerativen Krankheiten des Gehirns. **1995**, 159-173
- 685 Molecular medicine makes its way to the bedside. **1995**, 162, 567-568
- 684 Genetics of Non-insulin-dependent Diabetes Mellitus Among Mexican Americans: Approaches and Perspectives. **1996**, 65-77 1
- 683 Zur Gendiagnostik neurologischer Erkrankungen. **1996**, 21-32
- 682 Higher Psychomotor Functions. **1996**, 1059-1093
- 681 Cell transplantation: Brain. **1996**, 163-173

680 Preconception care. **1996**, 16-33

679 Rapid YAC End Sequencing by Alu-Vector PCR and Biotinylated Primers. **1996**, 227-237

678 Bioethics and the Federal Government. **1996**, 189-218

677 Neuropeptide and Dopamine Receptor Gene Expression in the Human Caudate-Putamen. **1996**, 469-483

676 Positron Emission Tomography Neuroimaging in Dementia. **1996**, 185-222

675 Predictive Testing for Huntington Disease: Lessons for Other Adult Onset Disorders. **1996**, 11-19

674 Biochemical Mechanisms of Neuronal Degeneration and Plasticity. **1996**, 585-599

673 Disease Expression and Gene Expression Can Be Quite Distinct: Modulation of Skeletal Muscle Sodium Channels by the Human Myotonin Dystrophy Protein Kinase (HMPK). **1996**, 95-101

672 Genomanalyse und Gendiagnostik. **1997**, 51-91

671 Ethische Aspekte genetischer Diagnostik und Beratung. **1997**, 57-80

1

670 The Human Genome: Genes and DNA. **1997**, 83-127

669 Direkte Gendiagnostik und Mutationstypen. **1998**, 27-34

2

668 Molecular Diagnostic Testing. **1998**, 83-88

667 Mitochondrial Dysfunction and Neurodegenerative Diseases. **1998**, 265-296

666 Fetal-Tissue Transplantation for Huntington's Disease: Preclinical Studies. **1998**, 77-93

665 Molecular and genetic aspects of fragile X syndrome (Martin-Bell). **1998**, 14, 5-11

664 Gene Therapy of Huntington's Disease. **1998**, 427-443

663 Somatic Gene Transfer and Cell Transplantation Strategies for Neurodegenerative Diseases. **1998**, 303-331

- 662 Extrapiramidal-motorische Syndrome. **1998**, 223-248
- 661 Molecular Mechanisms and Regulating Behavior. **1998**, 979-987
- 660 Fetal Transplantation for Huntington's Disease: Clinical Studies. **1998**, 95-134 1
- 659 Huntington's Disease. **1998**, 891-900
- 658 Locating Genetic Modifiers for Inherited Neurodegenerative Diseases. **1999**, 433-459 1
- 657 Antiglutamate therapies in Huntington's disease. **1999**, 55, 97-102 22
- 656 Bewegungsstörungen. **1999**, 857-953
- 655 Cellular Delivery of Neurotrophic Factors as a Potential Treatment for Huntington's Disease. **1999**, 477-502
- 654 Demenzen bei anderen Hirnkrankheiten. **1999**, 205-223
- 653 Molecular Genetics of Neurologic Diseases. **1999**, 8, 26-32
- 652 Mendelsche Erbgänge und monogene Erkrankungen. **1999**, 97-142
- 651 Genetische Determination häufiger psychischer Störungen. **1999**, 149-194 1
- 650 Exkurs: Therapie der Chorea Huntington. **1999**, 439-445
- 649 Sleep in Neurodegenerative Diseases. **1999**,
- 648 Repetições CAG: candidatos na gênese das psicoses funcionais. **1999**, 21, 23-26 0
- 647 Twisting mice move the dystonia field forward. **2014**, 124, 2848-50 1
- 646 Applications of fMRI to Neurodegenerative Disease. **2015**, 465-504
- 645 Consistent and Widespread Degeneration of the Cerebellum in Huntington's Disease (HD). **2015**, 55-66 1

644 Genetic Risk Factors for Neurodegenerative Diseases. **2015**, 117-134

643 Episodic Learning and Memory in Prodromal Huntington's Disease: The Role of Multimodal Encoding and Selective Reminding. **2015**, 06, 876-886

642 Introduction. **2015**, 1-28

641 Gene Therapy for Huntington's Disease. **2015**, 121-151

640 Using a Suite of Ontologies for Preserving Workflow-Centric Research Objects.

639 Extrapyrmidal Diseases: Huntington's Disease. **2015**, 375-379

638 Nanogold Mediated the Neuroprotection in Mutant Huntingtin Expressing Neuronal Cells. **2015**, 4, 250-253

637 Do Huntington's Disease Patients Benefit From Multidisciplinary Inpatient Rehabilitation?. **2015**, 2, 1-5

636 Introduction of Francis S. Collins. **2015**, 125, 3321-7

635 Altered Neural Synchronies Underlying Cognitive Deficits in a Transgenic Mouse Model of Huntington's Disease. **2016**, 321-335

634 Encyclopedia of Signaling Molecules. **2016**, 1-7

633 Clinical and genetic investigation of a Brazilian family with Huntington's disease. **2016**, 31, 135-42

632 Striatal Mechanisms of Associative Learning and Dysfunction in Neurological Disease. **2016**, 261-287

631 The Life Costs of Living with Rare Genetic Diseases. **2016**, 193-206

630 Regenerative Medicine in the Central Nervous System: Stem Cell-Based Cell- and Gene-Therapy. **2016**, 83-113

629 Review on the Effect of Resveratrol on Central Nervous System Disease. **2016**, 06, 118-123

628 Multimodality Imaging of Huntington's Disease. **2016**, 221-230

627 Huntington Disease. **2016**, 1-9

- 626 The Role of Proteomics in Personalized Medicine. **2016**, 179-218 1
- 625 Predictive Genetic Testing: The Huntington Disease Model. 1-6
- 624 Motivational, proteostatic and transcriptional deficits precede synapse loss, gliosis and neurodegeneration in the B6.HttQ111/+ model of Huntington disease. 0
- 623 Genome-scale transcriptional regulatory network models for the mouse and human striatum predict roles for SMAD3 and other transcription factors in Huntington disease.
- 622 Huntington Disease. **2017**, 115-128 0
- 621 Transglutaminase inhibition: possible therapeutic mechanisms to protect cells from death in neurological disorders'. **2017**, 1, 026-038
- 620 Huntington Disease. **2017**, 195-221 0
- 619 What Are Positive Results of Stem Cell Therapies?. **2017**, 141-161
- 618 RNA toxicity and RAN translation in repeat expansion disorders. **2017**, 150, 165
- 617 Genetics of Movement Disorders. **2017**, 77-92
- 616 Keyword-Based Search of Workflow Fragments and Their Composition. **2017**, 67-90 3
- 615 Huntington Disease. **2017**, 265-274
- 614 Dementia and Psychiatric Disorders. **2017**, 125-147
- 613 An SIMD Algorithm for Wraparound Tandem Alignment. **2017**, 140-149 1
- 612 Huntington Disease and Stem Cells. **2017**, 115-144
- 611 A human huntingtin SNP alters post-translational modification and pathogenic proteolysis of the protein causing Huntington disease. 0
- 610 Protein phosphatase 1 regulates huntingtin exon 1 aggregation and toxicity.
- 609 Early Detection of Apathetic Phenotypes in Huntington Disease Knock-in Mice Using Open Source Tools.

- 608 A putative role for genome-wide epigenetic regulatory mechanisms in Huntington's disease: A computational assessment. **6**, 1888
- 607 Identification of a novel caspase cleavage site in huntingtin that regulates mutant huntingtin clearance.
- 606 Systematic genetic interaction studies identify histone demethylase Utx as potential target for ameliorating Huntington's disease.
- 605 Chorea. **2018**, 1-10
- 604 Proteomics in Personalized Medicine. **2018**, 80-98
- 603 Predicting disease Risk by Transformation Models in the Presence of Unspecified Subgroup Membership. **2017**, 27, 1857-1878 1
- 602 Mitochondrial Function and Neurodegenerative Diseases. **2018**, 369-414 1
- 601 Encyclopedia of Signaling Molecules. **2018**, 1403-1409
- 600 Huntington Disease. **2018**, 93-99 1
- 599 Cellular and Molecular Signalling Mechanisms in Neuronal Injury and Neurodegeneration.
- 598 A Patient-Derived Cellular Model for Huntington's Disease Reveals Phenotypes at Clinically Relevant CAG Lengths. 1
- 597 Characterization of a human-specific tandem repeat associated with bipolar disorder and schizophrenia.
- 596 Robust detection of tandem repeat expansions from long DNA reads. 2
- 595 Expanded CAG/CTG Repeats Resist Gene Silencing Mediated by Targeted Epigenome Editing. 1
- 594 Cortical circuit alterations precede disease onset in Huntington's disease mice.
- 593 MR imaging in extrapyramidal diseases. **2018**, 19, 251-255
- 592 Hypomorphic mutation of the mouse Huntington's disease gene orthologue.
- 591 Pathogenesis of Polyglutamine Diseases. 1-10 0

- 590 To CRUNCH or not to CRUNCH: Task Difficulty Affects Functional Brain Reorganisation during Visuospatial Working Memory Performance in Premanifest Huntington's Disease.
- 589 Design and characterisation of mutant and wild-type huntingtin proteins produced from a toolkit of scalable eukaryotic expression systems. 1
- 588 Expression pattern and alternative splicing of HTT gene in human tissues. **2018**, XII, 26-32
- 587 Neurodegenerative Disorders. **2019**, 195-216
- 586 Huntington's Disease Case Study. **2019**, 305-325
- 585 Metabolic Alterations Amalgamated with Huntington's Disease. **2019**, 163-183
- 584 Neuropathogenesis of Multiple Sclerosis and Huntington's Disease. **2019**, 266-285
- 583 Genetic Epidemiology of Inflammatory Bowel Disease, Early Twin and Family Studies. **2019**, 25-45 0
- 582 Diagnostic Revolution Post-Human Genome Sequence Project: High-Throughput Technologies and Bioinformatics. **2019**, 25-38
- 581 Latent *Toxoplasma gondii* infection increases soluble mutant huntingtin and promotes neurodegeneration in the YAC128 mouse model of Huntington's disease.
- 580 Genomic architecture differences at the HTT locus underlie symptomatic and pre-symptomatic cases of Huntington's disease.. 7, 1757
- 579 Micronutrients for Improved Management of Huntington's Disease. **2019**, 395-422
- 578 El papel de las especies reactivas de oxígeno y nitrógeno en algunas enfermedades neurodegenerativas. **2019**, 62, 6-19 0
- 577 Huntington hastalığına hastalarda ve ailelerinde CAG trinükleotid tekrar sayılarının fragman analizi ile tespiti. **2019**, 44, 1-1
- 576 The Urologic Management of Huntington Chorea. **2020**, 105-115
- 575 Glucose availability impacts proteotoxic stress in *Caenorhabditis elegans*.
- 574 Modulation of dopamine D1 receptors via histamine H3 receptors is a novel therapeutic target for Huntington's disease.
- 573 Phagocytic glia are obligatory intermediates in transmission of mutant huntingtin aggregates across neuronal synapses.

572 Special Kinds and Clinical Manifestation of Voice Disorders. **2020**, 239-347

571 Psychopharmacotherapy in Patients with Tics and Other Motor Disorders. **2020**, 1-31

570 Relatively semi-conservative replication and a folded slippage model for simple sequence repeats.

569 Psychiatric morbidity and poor follow-up underlie suboptimal functional and survival outcomes in Huntington's disease.

568 Synaptic RTP801 Contributes to Motor Learning Dysfunction in Huntington's Disease.

567 Nascent mutant Huntingtin exon 1 chains do not stall on ribosomes during translation but aggregates do recruit machinery involved in ribosome quality control.

566 Inclusion bodies formed by polyglutamine and poly(glycine-alanine) are enriched with distinct proteomes but converge in proteins that are risk factors for disease and involved in protein degradation.

565 A small molecule that binds an RNA repeat expansion stimulates its decay via the exosome complex. ○

564 Impaired Replenishment of Cortico-Striatal Synaptic Glutamate in Huntington's Disease Mouse Model. **2020**, 9, 149-161 ○

563 Circadian rhythm and neurodegenerative disorders. **2020**, 6, 71-80 3

562 An Optimization of AAV-82Q-Delivered Rat Model of Huntington's Disease. **2020**, 63, 579-589 2

561 NEURODEGENERATIVE DISEASES: IMPACT OF PESTICIDES. **2021**, 9, 572-579

560 Metabolism in Huntington's disease: a major contributor to pathology. **2021**, 1 4

559 N-alpha-acetylation of Huntingtin protein increases its propensity to aggregate. **2021**, 297, 101363 ○

558 Huntington's Disease: A Nursing Perspective. **2021**, 31, 18-26

557 In vivo MR spectroscopy reflects synapse density in a Huntington's disease mouse model. ○

556 Time-varying Hazards Model for Incorporating Irregularly Measured, High-Dimensional Biomarkers. **2020**, 30, 1605-1632

555 Huntington's Disease. **2020**, 81-108

- 554 Basal Ganglia. **2020**, 591-667 0
- 553 CRISPR-CAS9 como ferramenta para ediçã do gene IT-15 na Doenã de Huntington. **2020**, 10, 10-15
- 552 Determining the effects of nanoparticulate air pollution on proteostasis in *Caenorhabditis elegans*. **2020**, 15, e0243419 1
- 551 Pharmacodynamic Evaluation: CNS Methodologies. **2020**, 81-94
- 550 Nanoengineering of stem cells for neural regenerative medicine. **2020**, 159-211
- 549 Antisense oligonucleotide drugs for neurological and neuromuscular disease. **2020**, 221-245
- 548 Emotion recognition and inhibitory control in manifest and pre-manifest Huntington's disease: evidence from a new Stroop task. **2020**, 15, 1518-1525 0
- 547 Tandem Duplications, Segmental Duplications and Deletions, and Their Applications. **2020**, 79-102
- 546 Salivary Biomarkers and Neurodegenerative Conditions. **2020**, 263-286
- 545 Chorea. **2020**, 1371-1380
- 544 Longitudinal expression changes are weak correlates of disease progression in Huntington's disease. **2020**, 2, fcaa172 3
- 543 Role of cellular oxidative stress in dementia. **2020**, 147-161
- 542 De-Novo Ligand Design against Mutated Huntington Gene by Ligand-based Pharmacophore Modeling Approach. **2020**, 16, 134-144 0
- 541 Neuron-specific increase in lamin B1 disrupts nuclear function in Huntington's disease.
- 540 Identification of novel therapeutic targets for polyglutamine toxicity disorders that target mitochondrial fragmentation. 2
- 539 Heart Rate Variability during wake and sleep in Huntington's Disease patients. An observational, cross-sectional, cohort study. **2021**,
- 538 Neurodegenerative Diseases and Cholesterol: Seeing the Field Through the Players. **2021**, 13, 766587 2
- 537 Inhibition of HIPK3 by AST487 Ameliorates Mutant HTT-Induced Neurotoxicity and Apoptosis via Enhanced Autophagy. **2021**, 1 0

- 536 Glia: A major player in glutamate-GABA dysregulation-mediated neurodegeneration. **2021**, 99, 3148 o
- 535 Nicotinamide Adenine Dinucleotide Phosphate Oxidases Are Everywhere in Brain Disease, but Not in Huntington's Disease?. **2021**, 13, 736734 1
- 534 Management of altered metabolic activity in model of Huntington's disease by curcumin. **2021**, 15353702211046927
- 533 Imaging gene expression in the brain with peptide nucleic acid (PNA) antisense radiopharmaceuticals and drug targeting technology. **2005**, 10, 169-190
- 532 Investigation of RNA interference to suppress expression of full-length and fragment human huntingtin. **2007**, 9, 145-155
- 531 Insights into the Cellular Trafficking of Prion Proteins. **2005**, 379-405
- 530 Early Behavioral Phenotypes in Mouse Models of Huntington's and Parkinson's Diseases. **2005**, 349-359
- 529 The Ups in Neurodegenerative Diseases and Aging Huntington's Disease. **2006**, 225-235
- 528 Huntington's Disease Animal Models: What Lessons Can Be Learned for Research on Neuroanthocytosis Syndromes?. **2004**, 223-231
- 527 Treatment Options in Huntington's Disease. **2004**, 243-250
- 526 Spinocerebellar Ataxia Type 12 and Huntington's Disease-Like 2: Clues to Pathogenesis. **2006**, 253-276
- 525 Polyglutamine Diseases. **2006**, 199-231
- 524 Huntingtin: Alive and Well and Working in Middle Management. **2003**, 2003, pe48-pe48
- 523 Imaging gene expression in the brain with peptide nucleic acid (PNA) antisense radiopharmaceuticals and drug targeting technology. **2003**, 10, 169-190
- 522 Huntington's Disease. **2006**, 227-239
- 521 Cell-Based Therapy for Huntington's Disease. **2006**, 83-116
- 520 Syndromes of Brain Dysfunction Presenting with Cognitive Impairment or Behavioral Disturbance: Delirium, Dementia, and Mental Disorders Caused by a General Medical Condition. **2008**, 17-37
- 519 Morbus Parkinson und andere extrapyramidale Bewegungsstörungen. **2007**, 211-229

- 518 The paradigm of Huntington's disease: Therapeutic opportunities in neurodegeneration. **2004**, 1, 128-138
- 517 Huntington's disease genetics. **2004**, 1, 255-262
- 516 Using advances in neuroimaging to detect, understand, and monitor disease progression in Huntington's disease. **2004**, 1, 263-272
- 515 Cell therapy in Huntington's disease. **2004**, 1, 394-405
- 514 Somatic CAG expansion in Huntington's disease is dependent on the MLH3 endonuclease domain, which can be excluded via MLH3 splice redirection to suppress expansion.
- 513 CK2 alpha prime and alpha-synuclein pathogenic functional interaction mediates inflammation and transcriptional dysregulation in Huntington's disease. 0
- 512 PET in Huntington's Disease. **2021**, 783-798
- 511 Transposable Element activation promotes neurodegeneration in a *Drosophila* model of Huntington's disease. 1
- 510 Morphine produces better thermal analgesia in young Huntington mice and are associated with less neuroinflammation in spinal cord. **2021**, 84, 73-78
- 509 Genetic Associations with Age at Dementia Onset in the PSEN1 E280A Colombian Kindred.
- 508 Molecular Markers in Anthropological Genetic Studies. 141-186 5
- 507 Genetic counseling. 85-94 1
- 506 Neurogenetics. Triumphs and challenges. **1994**, 161, 242-5
- 505 Genetics of developmental psychiatric disorders: pathways to discovery. **2005**, 30, 349-54 3
- 504 Brain imaging and cognitive dysfunctions in Huntington's disease. **2006**, 31, 21-9 151
- 503 The normal Huntington disease (HD) allele, or a closely linked gene, influences age at onset of HD. **1993**, 53, 125-30 47
- 502 Genetic fatalism and social policy: the implications of behavior genetics research. **1993**, 66, 511-24 32
- 501 Tetrabenazine in the treatment of Huntington's disease. **2007**, 3, 545-51 31

500	Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body. 2008 , 23, 237-50	38
499	Obsessive-Compulsive Disorder Symptoms in Huntington's Disease: A Case Report. 2008 , 37, 644-654	5
498	Huntington disease (chorea) in the middle East. 2009 , 9, 16-23	4
497	Huntington's Disease: From Mutant Huntingtin Protein to Neurotrophic Factor Therapy. 2011 , 7, 89-100	13
496	Huntington's disease: from gene to potential therapy. 2001 , 3, 17-23	1
495	The future of genetic testing for drug response. 2004 , 6, 27-37	5
494	Poly-glutamine expanded huntingtin dramatically alters the genome wide binding of HSF1. 2012 , 1, 33-45	21
493	Update on the Non-Huntington's Disease Choreas with Comments on the Current Nomenclature. 2012 , 2,	1
492	Sleep and circadian dysfunction in neurodegenerative disorders: insights from a mouse model of Huntington's disease. 2012 , 51, 93-106	14
491	Huntington's disease: the past, present, and future search for disease modifiers. 2013 , 86, 217-33	28
490	Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype. 2015 , 4, 17-36	5
489	Support Vector Hazards Machine: A Counting Process Framework for Learning Risk Scores for Censored Outcomes. 2016 , 17,	1
488	New genes for old diseases: the molecular basis of myotonic dystrophy and Huntington's disease. The Lumleian Lecture 1995. 1996 , 30, 221-31	12
487	Huntington's Disease: Calcium Dyshomeostasis and Pathology Models. 2017 , 9, 34-46	10
486	An Exploration of Latent Structure in Observational Huntington's Disease Studies. 2017 , 2017, 92-102	2
485	Worsening Choreoathetosis in Huntington's Disease with Fluoxetine, Lisdexamfetamine, and Melatonin: A Case Report. 2018 , 15, 27-31	1
484	A Novel Therapy for Huntington's Disease. 2018 , 2018,	
483	Models and mechanisms of repeat expansion disorders: a worm's eye view. 2018 , 97, 665-677	3

482	Huntington's chorea, a neurological disorder of all ages - Bioinformatics approach for its precise diagnosis. 2019 , 13, 26-30	
481	Molecular Biology. 1995 , 19, 217-220	1
480	Locus of control in patients with Huntington disease: a cross-sectional study. 2020 , 64, 65-75	
479	Chemical mutagenesis of uncovers genetic modifiers of huntingtin protein aggregation. 2020 , 2020,	1
478	Distribution of the Gene A1 and A2 Haplotypes Worldwide: A Systematic Review. 2020 , 18, 145-152	
477	fMRI biomarker of early neuronal dysfunction in presymptomatic Huntington's Disease. 2004 , 25, 1715-21	166
476	Volumetric MRI-Based Biomarkers in Huntington's Disease: An Evidentiary Review. 2021 , 12, 712555	3
475	Early documentation of inherited disorders through family studies. 2022 , 17-26	
474	Synaptic pathology in Huntington's disease: Beyond the corticostriatal pathway. 2021 , 162, 105574	2
473	Illustrated etiopathogenesis of Huntington's disease. 2022 , 175-214	
472	imaging of fluorescent single-walled carbon nanotubes within nematodes in the near-infrared window.. 2021 , 12, 100175	4
471	DNA Methylation in Huntington's Disease. 2021 , 22,	3
470	Circadian rhythms in neurodegenerative disorders. 2021 ,	10
469	Nuclear and cytoplasmic huntingtin inclusions exhibit distinct biochemical composition, interactome and ultrastructural properties. 2021 , 12, 6579	4
468	A MDS Evidence-Based Review on Treatments for Huntington's Disease. 2021 ,	4
467	The Mutational Dynamics of Short Tandem Repeats in Large, Multigenerational Families.	0
466	Non-Cell Autonomous and Epigenetic Mechanisms of Huntington's Disease. 2021 , 22,	2
465	Myelinosome Organelles in the Retina of R6/1 Huntington Disease (HD) Mice: Ubiquitous Distribution and Possible Role in Disease Spreading. 2021 , 22,	1

- 464 [Disease-modifying treatment approaches in Huntington disease : Past and future]. **2021**, 1 1
- 463 Ginsenoside compound K reduces the progression of Huntington's disease via the inhibition of oxidative stress and overactivation of the ATM/AMPK pathway. **2021**, 1
- 462 Three decades of Cdk5. **2021**, 28, 79 3
- 461 Huntington's Disease Gene Hunters: An Expanding Tale.. **2022**, 9, 330-333
- 460 Stem Cell-Based Therapies: What Interventional Radiologists Need to Know. **2021**, 38, 523-534
- 459 Mono- and bi-allelic effects of coding variants on disease in 176,899 Finns. 2
- 458 Involvement of CRMP2 in Regulation of Mitochondrial Morphology and Motility in Huntington's Disease. **2021**, 10, 0
- 457 Striatal compartmentalization and clustering of different subtypes of astrocytes is altered in the zQ175 Huntington's disease mouse model.
- 456 Intellectual Curiosity and Action Initiation are Subtypes of Apathy Affected in Huntington Disease Gene Expansion Carriers. **2021**, 34, 295-302 0
- 455 Antisense therapies in neurological diseases.. **2021**, 0
- 454 Ethical Issues: Overview in Genomic Analysis and Clinical Context. **2021**, 259-279
- 453 Impact of ER Stress and ER-Mitochondrial Crosstalk in Huntington's Disease.. **2022**, 23, 2
- 452 The protective role of exercise against age-related neurodegeneration.. **2021**, 74, 101543 4
- 451 Pan-neuronal expression of human mutant huntingtin protein in Drosophila impairs immune response of hemocytes.. **2021**, 363, 577801
- 450 Distribution of the HTT Gene A1 and A2 Haplotypes Worldwide: A Systematic Review. **2020**, 18, 145-152
- 449 Application of Nanomaterials in Neurodegenerative Diseases. **2021**, 87-110
- 448 Volumetric MRI-Based Biomarkers in Huntington's Disease: An Evidentiary Review. **2021**, 12, 712555 3
- 447 Linkage Disequilibrium and Association Analysis. **2021**, 182-204

446	Quantitative Phosphoproteomics Reveals Extensive Protein Phosphorylation Dysregulation in the Cerebral Cortex of Huntington's Disease Mice Prior to Onset of Symptoms.. 2022 , 59, 2456	1
445	Understanding the Burdens Associated with Huntington's Disease in Manifest Patients and Care Partners-Comparing to Parkinson's Disease and the General Population.. 2022 , 12,	0
444	Striatal Chloride Dysregulation and Impaired GABAergic Signaling Due to Cation-Chloride Cotransporter Dysfunction in Huntington's Disease.. 2021 , 15, 817013	2
443	"Spazio Huntington": Tracing the Early Motor, Cognitive and Behavioral Profiles of Kids with Proven Pediatric Huntington Disease and Expanded Mutations > 80 CAG Repeats.. 2022 , 12,	0
442	Transposable element activation promotes neurodegeneration in a model of Huntington's disease.. 2022 , 25, 103702	2
441	The three sisters of fate: Genetics, pathophysiology and outcomes of animal models of neurodegenerative diseases.. 2022 , 104541	2
440	Computing the Tandem Duplication Distance is NP-Hard. 2022 , 36, 64-91	
439	Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Protects Striatal Cells and Improves Motor Function in Huntington's Disease Models: Role of PAC1 Receptor.. 2021 , 12, 797541	0
438	More than Just a Brain Disorder: A Five-Point Manifesto for Psychological Care for People with Huntington's Disease.. 2022 , 12,	0
437	Mitochondrial and redox modifications in early stages of Huntington's disease.	0
436	Analysis of LINE1 Retrotransposons in Huntington's Disease.. 2021 , 15, 743797	1
435	Possibilities and challenges of small molecule organic compounds for the treatment of repeat diseases.. 2022 , 98, 30-48	0
434	Inhibition of Polyglutamine Misfolding with D-Enantiomeric Peptides Identified by Mirror Image Phage Display Selection.. 2022 , 12,	0
433	Skeletal muscle regeneration is altered in the R6/2 mouse model of Huntington's disease.	
432	Loss-of-function and gain-of-function studies refute the hypothesis that tau protein is causally involved in the pathogenesis of Huntington's disease.. 2022 ,	0
431	Molecular Mechanisms in Pentanucleotide Repeat Diseases.. 2022 , 11,	0
430	Ocular Motor Findings Aid in Differentiation of Spinocerebellar Ataxia Type 17 from Huntington's Disease.. 2022 , 1	0
429	Small Drugs, Huge Impact: The Extraordinary Impact of Antisense Oligonucleotides in Research and Drug Development.. 2022 , 27,	4

428	A novel and accurate full-length HTT mouse model for Huntington's disease.. 2022 , 11,	0
427	Neurogenetic disorders across the lifespan: from aberrant development to degeneration.. 2022 ,	4
426	Extreme conservation of the poly-glutamine tract in huntingtin is related to neurodevelopmental functions: the "better" may become the "enemy of the good" in the course of evolution.. 2022 ,	
425	PROTAC targeted protein degraders: the past is prologue.. 2022 ,	91
424	The evolutionary history of the polyQ tract in huntingtin sheds light on its functional pro-neural activities.. 2022 ,	1
423	Huntington Disease Gene Expression Signatures in Blood Compared to Brain of YAC128 Mice as Candidates for Monitoring of Pathology.. 2022 , 1	
422	Metabotropic Glutamate Receptor 5 Antagonism Reduces Pathology and Differentially Improves Symptoms in Male and Female Heterozygous zQ175 Huntington's Mice.. 2022 , 15, 801757	1
421	Measuring Movement in Health and Disease.. 2022 ,	0
420	Uninterrupted CAG repeat drives striatum-selective transcriptionopathy and nuclear pathogenesis in human Huntingtin BAC mice.. 2022 ,	2
419	IKK β signaling mediates metabolic changes in the hypothalamus of a Huntington disease mouse model.. 2022 , 25, 103771	2
418	Development of a ligand for in vivo imaging of mutant huntingtin in Huntington's disease.. 2022 , 14, eabm3682	2
417	A novel rhesus macaque model of Huntington's disease recapitulates key neuropathological changes along with progressive motor and cognitive decline.	0
416	Computational strategies to identify new drug candidates against neuroinflammation.. 2022 ,	1
415	Dynamics of huntingtin protein interactions in the striatum identifies candidate modifiers of Huntington disease.. 2022 ,	1
414	Cerebrospinal fluid mutant huntingtin is a biomarker for huntingtin lowering in the striatum of Huntington disease mice.. 2022 , 105652	2
413	Nucleolar stress controls mutant Huntington toxicity and monitors Huntington's disease progression. 2021 , 12, 1139	2
412	Inhibition of Brain GTP Cyclohydrolase I Attenuates 3-Nitropropionic Acid-Induced Striatal Toxicity: Involvement of Mas Receptor/PI3k/Akt/CREB/ BDNF Axis.. 2021 , 12, 740966	4
411	Advances in the discovery of genetic risk factors for complex forms of neurodegenerative disorders: contemporary approaches, success, challenges and prospects. 2018 , 97, 625-648	1

410	Huntington's disease: the coming of age. 2018 , 97, 649-664	12
409	Pionierentwicklungen in der Gentechnik. 2022 , 135-175	
408	Gene Mapping and Human Disease. 2022 , 147-175	
407	Tracking Neurodegeneration: Advancement in Experimental Study Models. 2022 , 25-47	
406	Implications of Poly(A) Tail Processing in Repeat Expansion Diseases.. 2022 , 11,	1
405	Single-cell dissection of the human brain vasculature.. 2022 ,	8
404	MicroRNA editing patterns in Huntington's disease.. 2022 , 12, 3173	0
403	Partners in crime: Proteins implicated in RNA repeat expansion diseases.. 2022 , e1709	0
402	Deletion of the microglial transmembrane immune signaling adaptor TYROBP ameliorates Huntington's disease mouse phenotype.	
401	Defective mitochondrial-lysosomal axis promotes extracellular vesicles release of mitochondrial components in Huntington's Disease.	0
400	A selective inhibitor of the NLRP3 inflammasome as a potential therapeutic approach for neuroprotection in a transgenic mouse model of Huntington's disease.. 2022 , 19, 56	2
399	Huntingtin gene intermediate alleles influence the progression from subjective cognitive decline to mild cognitive impairment: A 14-year follow-up study.. 2022 ,	1
398	-Acetyl-Cysteine: Modulating the Cysteine Redox Proteome in Neurodegenerative Diseases.. 2022 , 11,	3
397	Interaction of Mitochondrial Calcium and ROS in Neurodegeneration.. 2022 , 11,	8
396	Trinucleotide CGG Repeat Diseases: An Expanding Field of Polyglycine Proteins?. 2022 , 13, 843014	2
395	CAG Repeats Within the Non-pathological Range in the HTT Gene Influence Personality Traits in Patients With Subjective Cognitive Decline: A 13-Year Follow-Up Study.. 2022 , 13, 826135	0
394	Altered M2 Cortex - Superior Colliculus visual perception circuit in Huntington's Disease.	1
393	Temporal Phenotypic Changes in Huntington's Disease Models for Preclinical Studies.. 2022 ,	1

392	Uncovering Essential Tremor Genetics: The Promise of Long-Read Sequencing.. 2022 , 13, 821189	2
391	Deciphering therapeutic options for neurodegenerative diseases: insights from SIRT1.. 2022 , 100, 537	0
390	CryoET Reveals Organelle Phenotypes in Huntington Disease Patient iPSC-Derived and Mouse Primary Neurons.	
389	Fluorescence-Based Binding Characterization of Small Molecule Ligands Targeting CUG RNA Repeats.. 2022 , 23,	0
388	Using Big Data in Movement Disorders: Disease States and Progression in Huntington's Disease.. 2022 , 37, 441-443	
387	Progressive Mitochondrial Dysfunction of Striatal Synapses in R6/2 Mouse Model of Huntington's Disease.. 2022 ,	1
386	Comprehensive genetic diagnosis of tandem repeat expansion disorders with programmable targeted nanopore sequencing.. 2022 , 8, eabm5386	4
385	Reactive astrocytes promote proteostasis in Huntington's disease through the JAK2-STAT3 pathway.. 2022 ,	2
384	Neuroimaging Biomarkers for Huntington's Disease.	
383	Structural Plasticity of the Hippocampus in Neurodegenerative Diseases.. 2022 , 23,	3
382	Clinical and genetic characteristics of late-onset Huntington's disease in a large European cohort.. 2022 ,	0
381	Investigation of the Influence of TBP CAG/CAA Repeats in Conjunction with HTT CAG Repeats on Huntington's Disease Age at Onset in a Brazilian Sample.. 2022 , 1	
380	Alterations in the Gut Fungal Community in a Mouse Model of Huntington's Disease.. 2022 , e0219221	3
379	Listener Detection of Objectively Validated Acoustic Features of Speech in Huntington's Disease.. 2021 ,	1
378	Genetic modifiers of Huntington disease differentially influence motor and cognitive domains.. 2022 ,	2
377	Microarray profiling of hypothalamic gene expression changes in Huntington's disease mouse models.	
376	Diminished LC3-Associated Phagocytosis by Huntington's Disease Striatal Astrocytes.. 2022 , 11, 25-33	0
375	Geographic Barriers Drive Disparities in Specialty Center Access for Older Adults with Huntington's Disease.. 2022 , 11, 81-89	

374	An orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusion.. 2022 , 13, 1150	7
373	Polyglutamine Expansion in Huntingtin and Mechanism of DNA Damage Repair Defects in Huntington's Disease.. 2022 , 16, 837576	2
372	Predictive genetic testing for Motor neuron disease: time for a guideline?. 2022 ,	0
371	Exome sequencing of individuals with Huntington's disease implicates FAN1 nuclease activity in slowing CAG expansion and disease onset.. 2022 ,	3
370	The Many Faces of Huntington's Chorea Treatment: The Impact of Sudden Withdrawal of Tiapride after 40 Years of Use and a Systematic Review.. 2022 , 12,	0
369	Smoking, alcohol consumption, and age at onset of Huntington's disease: a Mendelian randomization study.. 2022 , 97, 34-38	0
368	Montreal Cognitive Assessment (MoCA) performance in Huntington's disease patients correlates with cortical and caudate atrophy.. 2022 , 10, e12917	
367	Expression of Huntingtin and TDP-43 Derivatives in Fission Yeast Can Cause Both Beneficial and Toxic Effects.. 2022 , 23,	
366	Development of mAb-based polyglutamine-dependent and polyglutamine length-independent huntingtin quantification assays with cross-site validation.. 2022 , 17, e0266812	0
365	Invited review: Unearthing the mechanisms of age-related neurodegenerative disease using <i>Caenorhabditis elegans</i> .. 2022 , 267, 111166	0
364	Haplotype-specific insertion-deletion variations for allele-specific targeting in Huntington's disease.. 2022 , 25, 84-95	1
363	Metformin to treat Huntington disease: a pleiotropic drug against a multi-system disorder.. 2022 , 111670	1
362	Development of Hippocampus-Associated Cognitive Dysfunction in Huntington's Disease Mouse Model. 2021 , 57, 1449-1460	0
361	Interaction of huntingtin (HTT) with PRMTs and its subsequent arginine methylation affects HTT solubility, phase transition behavior and neuronal toxicity. 2021 ,	0
360	Distinct subcellular autophagy impairments in induced neurons from Huntington's disease patients.. 2021 ,	2
359	Progressive alterations in polysomal architecture in a mouse model of Huntington's disease.	
358	Advancing genomic technologies and clinical awareness accelerates discovery of disease-associated tandem repeat sequences.. 2021 ,	2
357	Identification of Novel Therapeutic Targets for Polyglutamine Diseases That Target Mitochondrial Fragmentation.. 2021 , 22,	0

356	Regulated cell death: discovery, features and implications for neurodegenerative diseases.. 2021 , 19, 120	3
355	Manganese is a Physiologically Relevant TORC1 Activator in Yeast and Mammals.	
354	A PIAS1 Protective Variant S510G Delays polyQ Disease Onset by Modifying Protein Homeostasis.. 2021 ,	2
353	Huntington disease update: new insights into the role of repeat instability in disease pathogenesis. 2022 , 33, 293-300	
352	The molecular pathogenesis of repeat expansion diseases.. 2021 ,	0
351	Microglia Mediate Early Corticostriatal Synapse Loss and Cognitive Dysfunction in Huntington's Disease Through Complement-Dependent Mechanisms.	1
350	Defective linear and circular RNAs biogenesis in Huntington's disease: CAG repeat expansion hijacks neuronal splicing.	0
349	RTP801/REDD1 Is Involved in Neuroinflammation and Modulates Cognitive Dysfunction in Huntington's Disease.. 2021 , 12,	1
348	Friend or Foe? The Varied Faces of Homeostatic Synaptic Plasticity in Neurodegenerative Disease.. 2021 , 15, 782768	1
347	Heat Shock Factor 1 Directly Regulates Postsynaptic Scaffolding PSD-95 in Aging and Huntington's Disease and Influences Striatal Synaptic Density. 2021 , 22,	0
346	The long and the short of Huntington's disease: how the sphingolipid profile is shifted in the caudate of advanced clinical cases.. 2022 , 4, fca303	3
345	Acetylcholine receptor subunit expression in Huntington's disease mouse muscle.. 2021 , 28, 101182	0
344	Anhedonia in Neurodegenerative Diseases.. 2022 , 1	1
343	Nrf2 as a Potential Therapeutic Target for Treatment of Huntington's Disease.	
342	Suppression of Somatic Expansion As a Novel Therapeutic Approach for Huntington Disease and Other Repeat Expansion Disorders. 2022 , 1, 163-175	
341	Environmental stimulation in Huntington disease patients and animal models.. 2022 , 105725	0
340	The Hold me Tight Program for Couples Facing Huntington's Disease.. 2022 ,	
339	Tracing brain genotoxic stress in Parkinson's disease with a novel single-cell genetic sensor.. 2022 , 8, eabd1700	2

- 338 Altered cortical processing of sensory input in Huntington disease mouse models.. **2022**, 105740 0
- 337 Mitochondrial Calcium: Effects of Its Imbalance in Disease. **2022**, 11, 801 2
- 336 Altered Cholesterol Homeostasis in Huntington's Disease.. **2022**, 14, 797220 1
- 335 Cognitive Dysfunction in Repeat Expansion Diseases: A Review.. **2022**, 14, 841711
- 334 Neurodegenerative diseases linked to trinucleotide repeats. 195-208
- 333 Chapter 12. Molecular Modelling and Simulations Applied to Challenging Drug Discovery Targets. 317-348
- 332 Table_1.DOCX. **2020**,
- 331 Data_Sheet_1.pdf. **2020**,
- 330 Data_Sheet_1.PDF. **2018**,
- 329 Table_1.XLS. **2020**,
- 328 Table_2.XLSX. **2020**,
- 327 Image_1.jpeg. **2020**,
- 326 Image_2.jpeg. **2020**,
- 325 Image_3.jpeg. **2020**,
- 324 Image_4.jpeg. **2020**,
- 323 Image_5.jpeg. **2020**,
- 322 Image_1.TIF. **2020**,
- 321 Image_2.TIF. **2020**,

320 Data_Sheet_1.PDF. 2019,

319 Data_Sheet_2.pdf. 2019,

318 Video_1.AVI. 2019,

317 Video_2.AVI. 2019,

316 Video_3.AVI. 2019,

315 Video_4.AVI. 2019,

314 Video_5.AVI. 2019,

313 Data_Sheet_1.xlsx. 2018,

312 Data_Sheet_1.PDF. 2018,

311 Table_1.DOCX. 2020,

310 Data_Sheet_1.PDF. 2020,

309 Table_1.xlsx. 2019,

308 Table_1.DOCX. 2018,

307 Image_1.JPEG. 2019,

306 Image_2.JPEG. 2019,

305 Image_3.JPEG. 2019,

304 Table_1.XLSX. 2019,

303 Table_10.XLSX. 2019,

302 Table_11.XLSX. 2019,

301 Table_2.XLSX. 2019,

300 Table_3.XLSX. 2019,

299 Table_4.XLSX. 2019,

298 Table_5.XLSX. 2019,

297 Table_6.XLSX. 2019,

296 Table_7.XLSX. 2019,

295 Table_8.XLSX. 2019,

294 Table_9.XLSX. 2019,

293 Data_Sheet_1.pdf. 2020,

292 Data_Sheet_1.PDF. 2020,

291 Data_Sheet_2.PDF. 2020,

290 Data_Sheet_3.pdf. 2020,

289 Image_1.TIF. 2019,

288 Image_2.TIF. 2019,

287 Image_3.TIF. 2019,

286 Image_4.TIF. 2019,

285 Image_5.TIF. 2019,

284 Table_1.pdf. **2020**,

283 Table_2.pdf. **2020**,

282 Image_1.JPEG. **2020**,

281 Image_2.JPEG. **2020**,

280 Data_Sheet_1.docx. **2019**,

279 Table_1.docx. **2019**,

278 Metacognitive insight into cognitive performance in Huntington's disease gene carriers.. **2022**, 4, e000268

277 Huntington's Disease Regulatory Science Consortium: Accelerating Medical Product Development.. **2022**,

0

276 The Translational Benefits of Sheep as Large Animal Models of Human Neurological Disorders.. **2022**, 9, 831838

1

275 Moderate Intensity Exercise in Pre-manifest Huntington's Disease: Results of a 6 months Trial.. **2021**, 2, 6-36

274 Rehabilitation outcomes in Huntington disease patients with low body mass index.. **2022**, 22, 79-86

273 DeepRepeat: direct quantification of short tandem repeats on signal data from nanopore sequencing.. **2022**, 23, 108

2

272 Neuroprotective effect of CTK 01512-2 recombinant toxin at the spinal cord in a model of Huntington's disease.. **2022**,

0

271 Expression profile analysis in cells overexpressing DRPLA cDNA to explore the roles of DRPLA as a transcriptional coregulator.

270 Forward Genetics in Apicomplexa Biology: The Host Side of the Story. **2022**, 12,

269 Integration of Protein Structure and Population-Scale DNA Sequence Data for Disease Gene Discovery and Variant Interpretation.. **2022**,

268 Targeting the Type 5 Metabotropic Glutamate Receptor: A Potential Therapeutic Strategy for Neurodegenerative Diseases?. **2022**, 13,

1

267 Genetic and Epigenetic Interplay Define Disease Onset and Severity in Repeat Diseases.. **2022**, 14, 750629

0

- 266 Addressing Peroxisome Proliferator-Activated Receptor-gamma in 3-Nitropropionic Acid-Induced Striatal Neurotoxicity in Rats.. **2022**, 1 0
- 265 A Glimpse of Molecular Biomarkers in Huntington's Disease. **2022**, 23, 5411 1
- 264 Modulation of huntingtin degradation by cAMP-dependent protein kinase A (PKA) phosphorylation of C-HEAT domain Ser2550.
- 263 A CAG repeat-targeting artificial miRNA lowers the mutant huntingtin level in the YAC128 model of Huntington's disease. **2022**, 0
- 262 N-terminal mutant Huntingtin deposition correlates with CAG repeat length and disease onset, but not neuronal loss in Huntington's disease.
- 261 From older to younger generations: Intergenerational transmission of health-related roles in families with Huntington's disease. **2022**, 61, 101027
- 260 Cysteine metabolism and hydrogen sulfide signaling in Huntington's disease.. **2022**, 2
- 259 Rats receiving systemic 3-nitropropionic acid demonstrate impairment of memory in Morris water maze. **1999**, 27, 561-566 1
- 258 The future of genetic testing for drug response. **2004**, 6, 27-37 5
- 257 Metabolic Disorders. **2011**, 383-411
- 256 Disability milestones in Huntington disease. **2017**, 51, 31-35
- 255 Phospholipid Profiles Are Selectively Altered in the Putamen and White Frontal Cortex of Huntington's Disease. **2022**, 14, 2086 0
- 254 Current and Possible Future Therapeutic Options for Huntington's Disease. **2022**, 14, 117957352210925 1
- 253 Novel therapeutics and drug-delivery approaches in the modulation of glioblastoma stem cell resistance. 2
- 252 Proteomic Analysis of Huntington's Disease Medium Spiny Neurons Identifies Alterations in Lipid Droplets.
- 251 Tumor Suppressor p53 Regulates Heat Shock Factor 1 Protein Degradation in Huntington's Disease.
- 250 CRISPR-Based Genome-Editing Tools for Huntington's Disease Research and Therapy.
- 249 Mutant huntingtin exon-1 impaired GTPCH and DHFR expression in plants and mice.

248	Analysis of Huntington's Disease Modifiers Using the Hyperbolic Mapping of the Protein Interaction Network. 2022 , 23, 5853	1
247	Selective observation of semi-rigid residues on the surface of dynamically complex mutant huntingtin protein fibrils.	
246	Potential Therapeutic Benefits of Honey in Neurological Disorders: The Role of Polyphenols. 2022 , 27, 3297	2
245	Critical roles of protein disulfide isomerases in balancing proteostasis in the nervous system. 2022 , 102087	1
244	Acanthocytes Identified in Huntington's Disease. 2022 , 16,	0
243	Hidden brain atrophy in ultra-high field MR images in a transgenic rat model of Huntington's disease. 2022 , 6, 100039	
242	PQBP1: The Key to Intellectual Disability, Neurodegenerative Diseases, and Innate Immunity. 2022 , 23, 6227	
241	Gut Bacteria Regulate the Pathogenesis of Huntington's Disease in Drosophila Model. 2022 , 16,	1
240	CK2 alpha prime and alpha-synuclein pathogenic functional interaction mediates synaptic dysregulation in huntingtin's disease. 2022 , 10,	0
239	Exploring the Role of Posttranslational Modifications in Spinal and Bulbar Muscular Atrophy. 2022 , 15,	
238	The Role of Brain-Derived Neurotrophic Factor Signaling in Central Nervous System Disease Pathogenesis. 16,	1
237	Molecular Pathophysiological Mechanisms in Huntington's Disease. 2022 , 10, 1432	2
236	On Chorea—150 Years of the Beginning of Hope.	
235	Association between sex and Huntington's disease: an updated review on symptomatology and prognosis of neurodegenerative disorders.	1
234	Targeting pathogenic DNA and RNA repeats: a conceptual therapeutic way for repeat expansion diseases.	1
233	A biological classification of Huntington's disease: the Integrated Staging System. 2022 , 21, 632-644	5
232	Chorea, Athetosis, and Ballism. 2022 , 183-228	
231	Neuropathology in Huntington's Disease: A Balancing Act between Neurodegeneration and Aggregates.	

- 230 Oxidation Promotes Distinct Huntingtin Aggregates in the Presence and Absence of Membranes. **2022**, 61, 1517-1530
- 229 Single nuclei RNAseq analysis of HD mouse models and human brain reveals impaired oligodendrocyte maturation and potential role for thiamine metabolism.
- 228 Brain microvascular endothelial cell dysfunction in an isogenic juvenile iPSC model of Huntington disease. **2022**, 19, 1
- 227 Small-Molecule Disruptors of Mutant Huntingtin-Calmodulin Protein-Protein Interaction Attenuate Deleterious Effects of Mutant Huntingtin. 1
- 226 Renin-Angiotensin System in Huntington's Disease: Evidence from Animal Models and Human Patients. **2022**, 23, 7686 0
- 225 Activation of the Mitochondrial Unfolded Protein Response: A New Therapeutic Target?. **2022**, 10, 1611 1
- 224 The use of fibroblasts as a valuable strategy for studying mitochondrial impairment in neurological disorders. **2022**, 11, 1
- 223 An exploration of the genetics of the mutant Huntingtin (mHtt) gene in a cohort of patients with chorea from different tribes in 6 sub-Saharan African countries.
- 222 A probable cis-acting genetic modifier of Huntington disease frequent in individuals with African ancestry. **2022**, 100130 0
- 221 Differential Cellular Balance of Olfactory and Vomeronasal Epithelia in a Transgenic BACHD Rat Model of Huntington Disease. **2022**, 23, 7625
- 220 Exosomes, autophagy and ER stress pathways in human diseases: Cross-regulation and therapeutic approaches. **2022**, 1868, 166484 1
- 219 TRANSPLANTATION OF FETAL TISSUES. **1996**, 16, 333-359
- 218 Mutant Huntingtin Derails Cysteine Metabolism in Huntington Disease at Both Transcriptional and Post-Translational Levels. **2022**, 11, 1470
- 217 Alternatively Spliced Isoforms of the P2X7 Receptor: Structure, Function and Disease Associations. **2022**, 23, 8174 0
- 216 HAP40 is a conserved central regulator of Huntingtin and a potential modulator of Huntington disease pathogenesis. **2022**, 18, e1010302 0
- 215 Anti-Huntington Effect of Rosiridin via Oxidative Stress/AChE Inhibition and Modulation of Succinate Dehydrogenase, Nitrite, and BDNF Levels against 3-Nitropropionic Acid in Rodents. **2022**, 12, 1023 1
- 214 Principles and correction of 5 splice site selection. **2022**, 19, 943-960 2
- 213 GWAS to Identify SNPs Associated with Common Diseases and Individual Risk: Genome Wide Association Studies (GWAS) to Identify SNPs Associated with Common Diseases and Individual Risk. **2022**, 51-76

212 Autophagy and Huntington's disease. **2022**, 245-259

211 Emerging Role of NLRP3 Inflammasome/Pyroptosis in Huntington's Disease. **2022**, 23, 8363

1

210 Manganese is a physiologically relevant TORC1 activator in yeast and mammals. 11,

0

209 Alternative processing of human HTT mRNA with implications for Huntington's disease therapeutics.

1

208 Galectin-3, a rising star in modulating microglia activation under conditions of neurodegeneration. **2022**, 13,

0

207 Synaptic and functional alterations in the development of mutant huntingtin expressing hiPSC-derived neurons. 9,

206 Huntingtin turnover: modulation of huntingtin degradation by cAMP-dependent protein kinase A (PKA) phosphorylation of C-HEAT domain Ser2550.

205 Integrated transcriptome analysis of Huntington's disease iPSC-derived and mouse astrocytes implicates dysregulated synaptogenesis, actin, and astrocyte maturation.

204 Protein Kinase CK2 and Its Potential Role as a Therapeutic Target in Huntington's Disease. **2022**, 10, 1979

203 Beyond the CAG triplet number: exploring potential predictors of delayed age of onset in Huntington's disease.

0

202 Identification of a HTT-specific binding motif in DNAJB1 essential for suppression and disaggregation of HTT. **2022**, 13,

201 PAM-altering SNP-based allele-specific CRISPR-Cas9 therapeutic strategies for Huntington's disease. **2022**,

200 Therapeutic Strategies in Huntington's Disease: From Genetic Defect to Gene Therapy. **2022**, 10, 1895

0

199 The Significance of NLRP Inflammasome in Neuropsychiatric Disorders. **2022**, 12, 1057

0

198 The Role of a Gut Microbial-Derived Metabolite, Trimethylamine N-Oxide (TMAO), in Neurological Disorders.

0

197 CAG Repeat Instability in the Peripheral and Central Nervous System of Transgenic Huntington's Disease Monkeys. **2022**, 10, 1863

196 The role of the glycerol transporter channel Fps1p in cellular proteostasis during enhanced proteotoxic stress.

0

195 HTT-OMNI: A Web-based Platform for Huntingtin Interaction Exploration and Multi-omics Data Integration. **2022**, 100275

194	Mitochondrial organization and structure are compromised in fibroblasts from patients with Huntington's disease. 1-14	1
193	TRAX Provides Neuroprotection for Huntington's Disease Via Modulating a Novel Subset of MicroRNAs.	1
192	Cerebral blood flow is associated with markers of neurodegeneration in Huntington's disease. 2022 , 102, 79-85	
191	Glutamyl cyclases, the potential targets of cancer and neurodegenerative diseases. 2022 , 931, 175178	
190	Postnatal Foxp2 regulates early psychiatric-like phenotypes and associated molecular alterations in the R6/1 transgenic mouse model of Huntington's disease. 2022 , 173, 105854	1
189	Mitochondrial and redox modifications in early stages of Huntington's disease. 2022 , 56, 102424	2
188	The Use of MicroPET for the Development of Neural Repair Therapeutics: Studies in Epilepsy and Lesion Models. 2001 , 41,	1
187	Oxytocin in Huntington's disease and the spectrum of amyotrophic lateral sclerosis-frontotemporal dementia. 15,	2
186	Apathy and Depression in Huntington's Disease: Distinct Longitudinal Trajectories and Clinical Correlates.	1
185	Huntington's disease: Mortality and risk factors in an Australian cohort. 2022 , 442, 120437	0
184	The effects of antidepressants on depressive symptoms in manifest Huntington's disease. 2022 , 162, 111023	0
183	Pathogenesis and potential therapeutic application of stem cells transplantation in Huntington's disease. 2022 , 21, 406-412	0
182	Epigenetics, Stem Cells, Cellular Differentiation, and Associated Neurological Disorders and Brain Cancer. 2023 , 381-401	0
181	Neurotoxicity in Huntington Disease. 2022 , 1-17	0
180	Adenosine. 2022 , 45-71	0
179	Distinct Binding Interactions Trigger Opposite Conformational Modulations on Pathogenic and Wildtype Huntingtin Exon 1 Proteins.	0
178	Endocytosis of GABA receptor: Signaling in nervous system. 2022 ,	0
177	Small Molecules Targeting Repeat Sequences Causing Neurological Disorders. 2022 , 1-31	0

176	Mitochondrial Dysregulation and the Influence in Neurodegenerative Diseases. 2022 , 109-118	0
175	Mismatch repair is a double-edged sword in the battle against microsatellite instability. 2022 , 24,	0
174	Allele-specific silencing of the gain-of-function mutation in Huntington's disease using CRISPR-Cas9.	0
173	Huntington's disease phenotypes are improved via mTORC1 modulation by small molecule therapy. 2022 , 17, e0273710	0
172	Huntington's Disease: A Clinical Review. 2022 ,	0
171	Neuroprotective Effects of α R/TMEM97 Receptor Modulators in the Neuronal Model of Huntington's Disease. 2022 , 13, 2852-2862	1
170	Longitudinal assessment of water-reaching reveals altered cortical activity and fine motor coordination defects in a Huntington Disease model.	0
169	Resveratrol: A potential therapeutic natural polyphenol for neurodegenerative diseases associated with mitochondrial dysfunction. 13,	3
168	Huntington's disease phenocopy syndromes revisited: a clinical comparison and next-generation sequencing exploration.	0
167	Haplotyping SNPs for allele-specific gene editing of the expanded huntingtin allele using long-read sequencing. 2022 , 100146	1
166	Global proteome metastability response in isogenic animals to missense mutations and polyglutamine expansions in aging.	0
165	Lipid-lowering drug targets and Parkinson's disease: A sex-specific Mendelian randomization study. 13,	0
164	Calabria as a Genetic Isolate: A Model for the Study of Neurodegenerative Diseases. 2022 , 10, 2288	0
163	Neuropathology of Huntington's Disease.	0
162	Rat cortico-striatal sagittal organotypic slice cultures as ex vivo excitotoxic striatal lesion models. 2022 , 8, e10819	0
161	Impaired XK recycling for importing manganese underlies striatal vulnerability in Huntington's disease. 2022 , 221,	1
160	Huntingtin Over-Expression Does Not Alter Overall Survival in Murine Cancer Models.	0
159	Thermodynamics and Conformations of Single Polyalanine, Polyserine, and Polyglutamine Chains within the PRIME20 Model. 2022 , 126, 7286-7297	0

158	Distinct histological alterations of cortical interneuron types in mouse models of Huntington's disease. 16,	0
157	Integrated multi-omic analysis of Huntington disease and yeast model delineates pathways modulating protein aggregation.	2
156	A survey of protein interactions and posttranslational modifications that influence the polyglutamine diseases. 15,	0
155	Roles of Siglecs in neurodegenerative diseases. 2022 , 101141	0
154	Kynurenine 3-Monooxygenase Interacts with Huntingtin at the Outer Mitochondrial Membrane. 2022 , 10, 2294	1
153	A Review on Neurodegenerative Diseases with their Suitable Animal Models. 2022 , 19, 579-587	0
152	Cannabinoid signaling and risk in Huntington's disease. 16,	0
151	A case of Huntington disease-like 2 in a patient of African ancestry: the everlasting support of clinical examination in the molecular era. 2022 , 10,	0
150	Complexities in Genetic Counseling and Testing of Huntington's Disease: A Perspective from India. 2022 , 70, 2141	0
149	The microbiota-gut-brain axis in Huntington's disease. 2022 ,	0
148	Autonomic changes in Huntington's disease correlate with altered central autonomic network connectivity. 2022 , 4,	0
147	Automated and objective analysis of speech in premanifest and early-stage Huntington's disease.	0
146	Longitudinal evaluation of proton magnetic resonance spectroscopy metabolites as biomarkers in Huntington's disease.	0
145	Reproductive choices and intrafamilial communication in neurogenetic diseases with different self-estimated severities. jmedgenet-2022-108477	0
144	Exosomes as CNS Drug Delivery Tools and Their Applications. 2022 , 14, 2252	1
143	Defective mitochondria-lysosomal axis enhances the release of extracellular vesicles containing mitochondrial DNA and proteins in Huntington's disease. 2022 , 1,	1
142	A plant-based mutant huntingtin model-driven discovery of impaired expression of GTPCH and DHFR. 2022 , 79,	0
141	Description of the First Registered Case of LopesMacielRodan Syndrome in Russia. 2022 , 23, 12437	0

- 140 Insights into White Matter Defect in Huntington's Disease. **2022**, 11, 3381 1
- 139 Huntingtin expression influences spontaneous seizure disorder susceptibility in FVN/B mice. 0
- 138 Role of SUMOylation in Neurodegenerative Diseases. **2022**, 11, 3395 1
- 137 Neurochemical correlates of synapse density in a Huntington's disease mouse model. 0
- 136 Lumbar puncture safety and tolerability in premanifest and manifest Huntington's disease: a multi-analysis cross-sectional study. **2022**, 12, 0
- 135 Microarray profiling of hypothalamic gene expression changes in Huntington's disease mouse models. 16, 0
- 134 Longitudinal Clinical and Biological Characteristics in Juvenile-Onset Huntington's Disease. 0
- 133 Calcium imaging: A versatile tool to examine Huntington's disease mechanisms and progression. 16, 0
- 132 Current Diagnostic Methods and Non-Coding RNAs as Possible Biomarkers in Huntington's Disease. **2022**, 13, 2017 0
- 131 N-terminal mutant huntingtin deposition correlates with CAG repeat length and symptom onset, but not neuronal loss in Huntington's disease. **2022**, 174, 105884 0
- 130 miR-196a enhances polymerization of neuronal microfilaments through suppressing IMP3 and upregulating IGF2 in Huntington's disease. **2022**, 30, 286-299 0
- 129 Myelinosome organelles in pathological retinas: ubiquitous presence and dual role in ocular proteostasis maintenance. **2023**, 18, 1009 0
- 128 Hypogonadismus, Infertilität und sexuelle Dysfunktion bei systemischen Erkrankungen. **2021**, 1-43 0
- 127 Psychopharmacotherapy in Patients with Tics and Other Motor Disorders. **2022**, 4271-4301 0
- 126 Aggression in Huntington's Disease. **2022**, 1-22 0
- 125 Different depression: motivational anhedonia governs antidepressant efficacy in Huntington's disease. 1
- 124 Huntingtin exon 1 deletion does not alter the subcellular distribution of huntingtin and gene transcription in mice. 16, 0
- 123 Genome-wide contribution of common short-tandem repeats to Parkinson's disease genetic risk. 0

- 122 VarSCAT: A computational tool for sequence context annotations of genomic variants. ○
- 121 Fragment-based virtual screening identifies a first-in-class preclinical drug candidate for Huntington's disease. **2022**, 12, ○
- 120 An alternative splicing modulator decreases mutant HTT and improves the molecular fingerprint in Huntington's disease patient neurons. **2022**, 13, ○
- 119 Selective observation of semi-rigid non-core residues in dynamically complex mutant huntingtin protein fibrils. **2022**, 100077 ○
- 118 Psychotropic medication use in Huntington's disease: A retrospective cohort study. **2022**, 105, 69-74 ○
- 117 HSF1 and Its Role in Huntington's Disease Pathology. **2022**, ○
- 116 Longitudinal spatial mapping of lipid metabolites reveals pre-symptomatic changes in the hippocampi of Huntington's disease transgenic mice. **2023**, 176, 105933 ○
- 115 Detection and modulation of neurodegenerative processes using graphene-based nanomaterials: Nanoarchitectonics and applications. **2023**, 311, 102824 ○
- 114 The contribution of an imbalanced redox signalling to neurological and neurodegenerative conditions. **2023**, 194, 71-83 ○
- 113 Single-nuclei transcriptome analysis of Huntington disease iPSC and mouse astrocytes implicates maturation and functional deficits. **2023**, 26, 105732 ○
- 112 Resting-State fMRI reveals Longitudinal Alterations in Brain Network Connectivity in a Mouse Model of Huntington's Disease. ○
- 111 Expanding the Huntington's disease research toolbox; validated subdomain protein constructs for biochemical and structural investigation of huntingtin. ○
- 110 BDNF and TRiC-inspired Reagents Rescue Cortical Synaptic Deficits in a Mouse Model of Huntington's Disease. ○
- 109 Evidences for Mutant Huntingtin Inducing Musculoskeletal and Brain Growth Impairments via Disturbing Testosterone Biosynthesis in Male Huntington Disease Animals. **2022**, 11, 3779 ○
- 108 A perspective on Drosophila genetics and its insight into human neurodegenerative disease. 9, ○
- 107 Dual role of brain-derived extracellular vesicles in dementia-related neurodegenerative disorders: cargo of disease spreading signals and diagnostic-therapeutic molecules. **2022**, 11, 1
- 106 Cerebrospinal fluid biomarkers for assessing Huntington disease onset and severity. **2022**, 4, ○
- 105 Phosphoproteomic dysregulation in Huntington's disease mice is rescued by environmental enrichment. **2022**, 4, ○

104	Cannabinoid CB2 Receptors in Neurodegenerative Proteinopathies: New Insights and Therapeutic Potential. 2022 , 10, 3000	0
103	Psychosocial Impact of Huntington's Disease and Incentives to Improve Care for Affected Families in the Underserved Region of the Slovak Republic. 2022 , 12, 1941	0
102	clusterMLD: An Efficient Hierarchical Clustering Method for Multivariate Longitudinal Data. 1-36	0
101	Huntingtin regulates calcium fluxes in skeletal muscle. 2023 , 155,	0
100	Huntington disease oligodendrocyte maturation deficits revealed by single-nucleus RNAseq are rescued by thiamine-biotin supplementation. 2022 , 13,	1
99	Genetically transitional disease: a new concept in genomic medicine. 2022 ,	0
98	Extracellular vesicles improve GABAergic transmission in Huntington's disease iPSC-derived neurons.	0
97	Unraveling the role of relative telomere length and CAG expansion on initial symptoms of juvenile Huntington disease.	0
96	Global Repeat Map (GRM) Application: Finding All DNA Tandem Repeat Units. 2022 , 15, 458	0
95	AAV5-miHTT-mediated huntingtin lowering improves brain health in a Huntington's disease mouse model.	0
94	Alteration of Autophagy and Glial Activity in Nilotinib-Treated Huntington's Disease Patients. 2022 , 12, 1225	0
93	Reduced D2 / D3 Receptor Binding and Glucose Metabolism in a Macaque Model of Huntington's Disease.	0
92	The Role of Lipid Domains and Physical Properties of Membranes in the Development of Age-Related Neurodegenerative Diseases. 2022 , 16, 268-281	0
91	Therapeutic modulation of JAK-STAT, mTOR, and PPAR- β signaling in neurological dysfunctions.	0
90	The mutational dynamics of short tandem repeats in large, multigenerational families. 2022 , 23,	0
89	Longevity-Associated Variant of BPIFB4 Confers Neuroprotection in the STHdh Cell Model of Huntington Disease. 2022 , 23, 15313	1
88	Juvenile-Onset Huntington's Disease in Peru: A Case Series of 32 Patients.	0
87	An altered extracellular matrix-integrin interface contributes to Huntington's disease-associated CNS dysfunction in glial and vascular cells.	0

- 86 Huntingtin Overexpression Does Not Alter Overall Survival in Murine Cancer Models. **2022**, 11, 383-389 ○
- 85 Neuroinflammation in Huntington's disease: From animal models to clinical therapeutics. 13, ○
- 84 Brain modulation by the gut microbiota: From disease to therapy. **2022**, 1 ○
- 83 Should we rethink neurodegeneration?. **2022**, 75-82 ○
- 82 FLUORESCENCE HYBRIDIZATION IMAGING OF NEUROLOGICAL DISEASE MESSENGER RNAs. **2023**, 345-372 ○
- 81 Novel Small Molecule Positive Allosteric Modulator SPAM1 Triggers the Nuclear Translocation of PAC1-R to Exert Neuroprotective Effects through Neuron-Restrictive Silencer Factor. **2022**, 23, 15996 ○
- 80 Mechanism Action of Iron Regulatory Protein 1 (IRP1/ACO1) in Disease. **2022**, 12, 11662-11668 ○
- 79 Huntington's Disease and Neurodegeneration. **2022**, 1765-1787 ○
- 78 Promising Molecular Targets in Pharmacological Therapy for Neuronal Damage in Brain Injury. **2023**, 12, 118 ○
- 77 PQBP5/NOL10 maintains and anchors the nucleolus under physiological and osmotic stress conditions. **2023**, 14, ○
- 76 Animal toxins: As an alternative therapeutic target following ischemic stroke condition. **2023**, 121365 ○
- 75 Water-Reaching Platform for Longitudinal Assessment of Cortical Activity and Fine Motor Coordination Defects in a Huntington Disease Mouse Model. **2023**, 10, ENEURO.0452-22.2022 ○
- 74 Neuronal and astrocytic contributions to Huntington's disease dissected with zinc finger protein transcriptional repressors. **2023**, 42, 111953 1
- 73 Resting-State fMRI reveals Longitudinal Alterations in Brain Network Connectivity in the zQ175DN mouse Model of Huntington's Disease. ○
- 72 NanoSTR: A method for detection of target short tandem repeats based on nanopore sequencing data. 10, ○
- 71 Nucleic acid drug vectors for diagnosis and treatment of brain diseases. **2023**, 8, ○
- 70 Circulating miRNA Signatures in Early-Stage Huntington's Disease. ○
- 69 The Antifungal Antibiotic Filipin as a Diagnostic Tool of Cholesterol Alterations in Lysosomal Storage Diseases and Neurodegenerative Disorders. **2023**, 12, 122 ○

- 68 Combating the Sustained Inflammation Involved in Aging and Neurodegenerative Diseases with Probiotics. **2023**, 193-213 ○
- 67 Applications of Extracellular Vesicles in Nervous System Disorders: An Overview of Recent Advances. **2023**, 10, 51 ○
- 66 The length of uninterrupted CAG repeats in stem regions of repeat disease associated hairpins determines the amount of short CAG oligonucleotides that are toxic to cells through RNA interference. **2022**, 13, ○
- 65 Coexisting amyotrophic lateral sclerosis and chorea: A case report and literature review. **2022**, 101, e32452 ○
- 64 Reduction in PA28 β activation in HD mouse brain correlates to increased mHTT aggregation in cell models. **2022**, 17, e0278130 ○
- 63 The Comprehensive Analysis of Motor and Neuropsychiatric Symptoms in Patients with Huntington's Disease from China: A Cross-Sectional Study. **2023**, 12, 206 ○
- 62 Animal Models for Huntington's Disease. **2011**, 214-229 ○
- 61 What we don't need to prove but need to do in multidisciplinary treatment and care in Huntington's disease: a position paper. **2023**, 18, ○
- 60 Mono- and biallelic variant effects on disease at biobank scale. **2023**, 613, 519-525 ○
- 59 Alternations of Lipoprotein Profiles in the Plasma as Biomarkers of Huntington's Disease. **2023**, 12, 385 ○
- 58 G-Quadruplexes in Repeat Expansion Disorders. **2023**, 24, 2375 ○
- 57 Epigenetics of aging. **2023**, 213-234 ○
- 56 COVID-19: The Ethno-Geographic Perspective of Differential Immunity. **2023**, 11, 319 ○
- 55 Stem Cell-Based Therapeutic Approaches in Genetic Diseases. **2023**, ○
- 54 Importance of mitochondrial quality control and its role in pathophysiology. **2023**, 6, 8-13 ○
- 53 Charge transport properties of ideal and natural DNA segments, as mutation detectors. ○
- 52 The updated development of blood-based biomarkers for Huntington's disease. ○
- 51 CryoET reveals organelle phenotypes in huntington disease patient iPSC-derived and mouse primary neurons. **2023**, 14, ○

- 50 Peripheral Biomarkers in Manifest and Premanifest Huntington's Disease. **2023**, 24, 6051 ○
- 49 ALOX5-mediated ferroptosis acts as a distinct cell death pathway upon oxidative stress in Huntington's disease. **2023**, 37, 204-217 ○
- 48 Protocol Optimization for Direct Reprogramming of Primary Human Fibroblast into Induced Striatal Neurons. **2023**, 24, 6799 ○
- 47 miR-34a-5p as molecular hub of pathomechanisms in Huntington's disease. **2023**, 29, ○
- 46 RPTRF: A rapid perfect tandem repeat finder tool for DNA sequences. **2023**, 226, 104869 ○
- 45 Understanding the role of the hematopoietic niche in Huntington's disease's phenotypic expression: in vivo evidence using a parabiosis model. **2023**, 180, 106091 ○
- 44 Resting-state fMRI reveals longitudinal alterations in brain network connectivity in the zQ175DN mouse model of Huntington's disease. **2023**, 181, 106095 ○
- 43 Cyclodextrin based nano gene delivery using pharmaceutical applications to treat Wolfram syndrome. **2022**, 13, 449-462 1
- 42 Neurotoxicity in Huntington Disease. **2022**, 1747-1763 ○
- 41 Validation of the ACMG/AMP guidelines-based seven-category variant classification system. ○
- 40 Necroptosis in CNS diseases: Focus on astrocytes. 14, ○
- 39 3-Nitropropionic Acid Enhances Ferroptotic Cell Death & NOX2-Mediated ROS Generation in STHdhQ111 Striatal Cells Carrying Mutant Huntingtin. **2023**, 46, 177-186 ○
- 38 Neuroprotectant Effects of Hibiscetin in 3-Nitropropionic Acid-Induced Huntington's Disease via Subsiding Oxidative Stress and Modulating Monoamine Neurotransmitters in Rats Brain. **2023**, 28, 1402 ○
- 37 Editorial: New insight into Huntington's disease: From neuropathology to possible therapeutic targets. 17, ○
- 36 Chemical Modifications and Design Influence the Potency of Huntingtin Anti-Gene Oligonucleotides. **2023**, 33, 117-131 ○
- 35 Speech biomarkers in Huntington's disease: A cross-sectional study in pre-symptomatic, prodromal and early manifest stages. **2023**, 30, 1262-1271 ○
- 34 An Overview of the Pathophysiological Mechanisms of 3-Nitropropionic Acid (3-NPA) as a Neurotoxin in a Huntington's Disease Model and Its Relevance to Drug Discovery and Development. **2023**, 48, 1631-1647 ○
- 33 Ubiquitin-modifying enzymes in Huntington's disease. 10, ○

- 32 Disentangling the neurobiological bases of temporal impulsivity in Huntington's disease. 0
- 31 AAV vectors applied to the treatment of CNS disorders: Clinical status and challenges. **2023**, 355, 458-473 2
- 30 Modulation of Synaptic Plasticity Genes Associated to DNA Damage in a Model of Huntington's Disease. 0
- 29 Role of Gut Microbiota in Neurological Disorders and Its Therapeutic Significance. **2023**, 12, 1650 0
- 28 Beneficial behavioral effects of chronic cerebral dopamine neurotrophic factor (CDNF) infusion in the N171-82Q transgenic model of Huntington's disease. **2023**, 13, 0
- 27 Oxidative Stress and Antioxidants in Neurodegenerative Disorders. **2023**, 12, 517 2
- 26 Nanoparticulate air pollution disrupts proteostasis in *Caenorhabditis elegans*. **2023**, 18, e0275137 0
- 25 FPR1 is essential for rapamycin-induced lifespan extension in *Saccharomyces cerevisiae*. **2023**, 653, 76-82 0
- 24 Neuroprotective effects of hepatoma-derived growth factor in models of Huntington's disease. 0
- 23 Cell Rearrangement and Oxidant/Antioxidant Imbalance in Huntington's Disease. **2023**, 12, 571 0
- 22 Astrocytic contributions to Huntington's disease pathophysiology. **2023**, 1522, 42-59 0
- 21 Tumor suppressor p53 regulates heat shock factor 1 protein degradation in Huntington's disease. **2023**, 42, 112198 0
- 20 Oligomerization enhances huntingtin membrane activity but is suppressed by covalent crosslinking. 0
- 19 Cell Encapsulation and 3D Bioprinting for Therapeutic Cell Transplantation. **2023**, 9, 1862-1890 1
- 18 *Caenorhabditis elegans* as a Model System to Study Human Neurodegenerative Disorders. **2023**, 13, 478 0
- 17 Advances of H₂S in Regulating Neurodegenerative Diseases by Preserving Mitochondria Function. **2023**, 12, 652 0
- 16 Mutant huntingtin expression in the hypothalamus promotes ventral striatal neuropathology. 0
- 15 Zfp106 binds to G-quadruplex RNAs and inhibits RAN translation and formation of RNA foci caused by G4C2 repeats. 0

- 14 Sphingolipids and impaired hypoxic stress responses in Huntington disease. **2023**, 90, 101224
- 13 Pyrrole-Imidazole Polyamides –A Frontrunner in Nucleic Acid-Based Small Molecule Drugs.
- 12 Neurodegeneration, Mitochondria, and Antibiotics. **2023**, 13, 416
- 11 NAADP-Evoked Ca²⁺ Signaling Leads to Mutant Huntingtin Aggregation and Autophagy Impairment in Murine Astrocytes. **2023**, 24, 5593
- 10 Native functions of short tandem repeats. 12,
- 9 Proteomic Analysis of Huntington’s Disease Medium Spiny Neurons Identifies Alterations in Lipid Droplets. **2023**, 100534
- 8 Iron Oxide Nanoparticle-Mediated siRNA Delivery System for Huntington’s Disease Treatment. **2023**, 6, 5106-5116
- 7 Hunting out the repeat expansion in Huntington’s pigs.
- 6 Contribution of Glial Cells to Polyglutamine Diseases: Observations from Patients and Mouse Models. **2023**, 20, 48-66
- 5 Naïve Huntington’s disease microglia mount a normal response to inflammatory stimuli but display impaired development of innate immune tolerance that can be counteracted by ganglioside GM1.
- 4 Health Benefits of Mushrooms: An Appraisal. **2023**, 179-226
- 3 Comparative molecular dynamics simulations of pathogenic and non-pathogenic huntingtin protein monomers and dimers. 10,
- 2 Vector enabled CRISPR gene editing –A revolutionary strategy for targeting the diversity of brain pathologies. **2023**, 487, 215172
- 1 Defining Clinical Meaningfulness in Huntington’s Disease.